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Understanding the underlying molecular events in human early 
embryonic development has been a major challenge for addressing the cause 
of human-specific embryo implantation disorders and infertility problems. To 
address this, an in vitro system has been developed with the use of human 
embryonic stem cells differentiated towards the syncytiotrophoblast lineage. I 
argue this model recapitulates the formation of the primitive syncytium, a 
conceptus-derived cell type present at the earliest stages of maternal-embryo 
interactions. With this model, I address some outstanding questions with 
respect to the evolution and development of human embryo implantation and 
early placenta formation. By applying mRNA-seq and ChIP-seq of important 
transcription factors and epigenetic marks of these cells, I have identified 
molecular mechanisms contributing to primate-specific trophoblast biology.  
I found within the primitive syncytium protein coding transcriptome, 
novel primate-specific features arising from positive selection and co-option 
of endogenous retroviral (ERV) genes. Extensive regulatory change altering 
gene expression was also identified. These regulatory novelties arose both 
through apparent accumulation of single nucleotide mutations creating new 
transcription factor binding sites and the co-option of ERV long terminal 
repeats (LTRs). The LTRs contributed to both new promoter/first exons and 
solely as distal enhancer elements driving new trophoblast-specific expression 
of genes. 
LTRs contribute extensively to the emergence of novel functions in 
primate early implantation and placenta formation. I found three additional 
LTR-mediated mechanism of trophoblast synthesis of estrogen (E2) from a 
DHEA substrate. Thus, the primate- and trophoblast-specific expression of the 
four biochemical step pathway from DHEA-S to E2 production has been 
influenced by historical retroviral infection. Functionality of this pathway has 
been validated in our primitive syncytium model with the use of specific 
inhibitors of the enzymes and simultaneous stimulation with DHEA to 
recapitulate the in vivo scenario of a working model of primate placental E2 
 IX	  
biosynthesis.  
This work has provided mechanistic insights into the evolutionary events, 
which is involved in the emergence of novel features/phenotypes of early 
human embryo implantation and placental development; these findings will 
help to design better regimes of therapies for increasing the success rate of 
pregnancies in IVF clinics. Another contribution of these findings is to help to 
understand the root of human-specific reproductive complications such as 
preeclampsia and IUGR for developing novel approaches to tackle these 
human-specific complications. 	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Chapter 1: Introduction 
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1.1. Embryo implantation and placentation in mammals  
 
Mammalian embryo implantation starts with the attachment of the 
outer layer of the embryo to the uterus. This outer layer, the trophectoderm 
(TE), is derived from the first cell lineage decision in the developing embryo 
arising from outer cells of the morula after compaction. Inner cells of the 
morula subsequently become inner cell mass (ICM) and TE makes the extra-
embryonic tissues and contributes to the formation of the placenta. This will 
be followed by the second lineage decision, which is the segregation of 
epiblast (EPI) from primitive endoderm (PE). This EPI will give rise to the 
fetus and PE will form the visceral endoderm and contribute to yolk sac. 
(Cockburn and Rossant, 2010). Although there are morphological similarities 
in the blastocyst stage across mammals but however there are fundamental 
molecular differences between species in terms of molecular events at the 
early stage of trophectoderm segregation from ICM. One of the differences 
between mice and human is the timing of the expression of CDX2 in embryo. 
This transcription factor is the first transcription factor which is expressed in 
the subset of cells at morula stage of the mouse embryo which later these cells 
will form the first lineage of trophectoderm cells in mouse (Red-horse et al., 
2004). On the other hand, human CDX2 is only expressed at the very late 
stage of blastocyst formation in a subset of trophoblast cells at very low level, 
which is shown by immunofluorescence (Niakan and Eggan, 2013).  Analysis 
of the human embryo by RNA-seq also verifies the expression of this 
transcription factor at very low level in the blastocyst stage (Yan et al., 2013). 
Another difference between human and mouse is the fact that early 
trophoblast in mouse is proliferative. This proliferation capacity might be the 
reason for successful derivation of mouse trophoblast stem (TS) cells from 
mouse embryo outgrowth. In the human embryo on the other, the early 
trophectoderm is invasive and has syncytial features (James et al., 2012), 
which is possibly the reason for not being able to derive human trophoblast 
stem cells from the human embryo at this stage. All of these differences 
indicate that human and mouse systems in terms of early events of trophoblast 
formation are fundamentally different at the cellular and molecular level. The 
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underlying molecular differences between human and mouse with respect to 
embryo preimplantation events are not extensively explored in the literature. 
However, recently comparing transcriptome of ICM and embryo across 
species provides new insights in the differences between molecular regulations 
of pluripotency gene regulatory network between these species (Kuijk et al., 
2014; Xie et al., 2010).  
The inaccessibility of human implantation and post-implantation 
embryo material resulted in a paucity of knowledge regarding these stages of 
human embryonic development. Although from histopathological studies, it is 
clear that there are morphological difference between the human and mouse 
embryo implantation and early post-implantation (Wang and Dey, 2006), but 
at the molecular level there is no study to address these molecular differences. 
The importance of these early events of TE formation is that 75% of all human 
pregnancy loss is at this early stage of embryo implantation and post-
implantation (Norwitz et al., 2001). These cases are not likely to be diagnosed 
in the clinic and all are categorized under the generic term infertility (Cha et 
al., 2012), therefore understanding this early stage of development at the 
molecular level will improve our understanding of the pathways, which is 
involved in these early events.  
For understanding the primate-specific features of implantation, post-
implantation and placental formation and their mechanisms at the molecular 
level, the following questions need to be addressed: 
 
1. What is the extent of differences between species in TE formation and 
placentation? 
2. When did this variability arise in the evolutionary context leading to 
primate-specific features? 
 
By understanding the primate-specific features of TE formation and 
placentation, we will be able to apply our basic findings to improve human 
reproductive complications and infertility problems. In the following section, I 
provide the background and rationale for identifying differences between 
species in placentation with a focus on the primate-specific features of human 
early implantation events. 
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1.2. Diversity in placentation across mammals  	  
There are different types of placentation across placental mammals. 
Morphologically there are four different types of placentation including 
cotyledonary (e.g. cow, sheep), diffuse (e.g. horse), zonary (e.g. canine) and 
discoid (e.g. primates) (Figure 1.1.). Based on the trophoblast accessibility to 
maternal tissues, the placenta is also categorized to epitheliochorial, 
synepitheliochorial, endotheliochorial, and haemochorial placentation. In 
epitheliochorial placentation there is no invasion of the trophoblast to the 
maternal epithelium (e.g. pangolin, pigs and camel). In synepitheliochorial 
placentation in ruminants (e.g. ovine and bovine) there is fusion of binucleated 
trophoblastic cells to the uterine epithelium allowing the embryo to develop on 
the uterine wall. In endotheliochorial placentation (e.g. canine and feline) 
trophoblast migrates through the maternal epithelial layer and has direct 
contact with endothelial cells of maternal vessels. The deepest contact 
between fetus and mother is in haemochorial placentation where trophoblast 
cells penetrate to the maternal stromal layer and have direct contact with 
maternal blood. However, there are controversies for the timing of emergence 
and diversification of haemochorial mammals (Carter, 2001). 
	  
Figure 1.1. Different types of placentation in mammals. Placenta is categorized based on (a) 
morphological features and (b) fetus accessibility to mother in different species, modified 
from (Moffett and Loke, 2006) 
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These morphological and histological differences in placentation 
across species are implying the different molecular mechanism of controlling 
species-specific features of these events. Not much known about the details of 
the molecular mechanism of primate-specific features of early pregnancy and 
placentation. In this study I will discuss the unique features of human embryo 
implantation and placentation from different aspects including: cellular, 
hormonal, signaling and molecular perspective and then, I will describe a 
model system which I will be using to address these unique aspects at 
transcriptome level and transcriptional regulation.  
 
1.3. Unique features of primate embryo implantation and placentation 
 
1.3.1. Cellular components of primate embryo implantation and 
placentation  
 
There are two unique known cellular events at the window of 
implantation, which are only present in the primates with haemochorial 
placentation: 1) spontaneous decidualization (Figure1.2.c) (Emera et al., 2012) 
and 2) formation of the primitive syncytium (Figure1.2.a). Spontaneous 
decidualization, involving hormonal modulation and signaling events at the 
window of implantation, influences the way the embryo implants and is 
subsequently maintained at the earliest stages of post-implantation. 
Spontaneous decidualization (versus embryo-induced decidualization found in 
all other mammals) has been suggested to have evolutionary advantages and 
selective pressure in human for two reasons. (Emera et al., 2012): first, to 
minimize the conflict between the embryo and mother for nutrients in which 
decidualization makes the endometrium thick enough for the invasive embryo 
to implant. The second reason is to reject impaired aneuploidy embryos at the 
earliest stage of development (Fig.1.2.b). Aneuploidy is very high (10-fold) in 
human embryos relative to the mouse (Lucas et al., 2013). Estrogen (E2) and 
progesterone (P4) are systematic regulators of the early events in the window 
of implantation to prepare the endometrium for the implanting embryo 
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especially the spontaneous decidualization that only happens at the window of 
implantation. (Wang and Dey, 2006) 
 
Figure 1.2. Unique features of primate embryo implantation. (a) Presence of primitive 
syncytium in different primate including human, baboon and marmoset. (b) Window of 
implantation in the human, which shows the synchrony between spontaneous decidualization 
and attachment of the embryo. (c) The highlighted area in red shows those species with 
menstruation in the primate lineage. 
	  
 
In accordance to this spontaneous decidualization, human embryos 
need to embed very quickly into the endometrium as it is within 2 to 3 days 
that menstruation will begin. If menstruation occurs, the embryo would indeed 
be lost. Therefore, this quality control step needs to be implemented 
immediately. The cell that has the capacity to drive the embryo to the maternal 
tissue is an early syncytium which is referred to as the primitive syncytium in 
the literature, this distinct cell population has been identified by studies that 
have investigated the ultrastructural properties of implantation events in the 
primate and human ((Bentin-Ley et al., 2000; Lindenberg et al., 1986) and 
also the histopathological studies of primate embryo implantation as shown in 
Fig.1.2.a. 
The extensive embedment of the human embryo into the stromal layer 
is a unique feature of human placentation, which leads to full embedding of 
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the human embryo into the maternal stromal layer in 10 days. This is in 
contrast to the superficial attachment in more distal primates (Rhesus, Baboon, 
and Marmoset) where the embryo remains in the uterine lumen. Another 
unique morphological feature of human placentation, occurring later in 
development and providing more extensive contact between the embryo and 
the mother, is the villous structure of the human placenta (Wulff et al., 2003). 
This enables direct contact of villous syncytiotrophoblast layer to the decidua 
parietalis on the maternal side. 
This extensive contact between fetus and mother has been speculated 
to be related to bipedalism in primates and have a direct correlation to brain 
size in humans (Rockwell et al., 2003). These unique features of human 
placentation in terms of depth of embedment of embryo in the stromal layer 
and villous structure of syncytiotrophoblast layer fulfill the high requirement 
of the human embryo for nutrients and gas exchange throughout the entire 
pregnancy. As this highly regulated and deep contact between the human 
embryo and mother imposes a high investment of mother for the fetus. 
(Weisbecker and Goswami, 2010) Any condition which result in incomplete 
contact between fetus and mother such as low proliferation of trophoblast cells 
or low angiogenesis capacity of the trophoblast will lead to the human 
placental-specific complication such as preeclampsia and intrauterine growth 
restriction (IUGR) (Chaline, 2003). 
The central role of the trophoblast in the establishment of pregnancy in 
placental mammals is the capacity to produce an essential signal that will be 
transmitted to the endometrium. This signal activates the maternal recognition 
systems, which leads to the maintenance of the corpus luteum and 
subsequently P4 secretion, which maintains the endometrium (and the 
pregnancy). These signals are very diverse across mammals: in rodents release 
of prolactin from the pituitary after mating is the first luteotrophic signal, in 
ruminants interferon tau (INFT) is the first luteotrophic signal from the 
conceptus, in pigs estrogen and prolactin from the conceptus provide this 
initial luteotrophic effect, in primates the primitive syncytium produces 
chorionic gonadotrophin (CG) which signals to the corpus luteum for 
maintenance of pregnancy through secretion of P4 from corpus luteum. Since 
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this primitive syncytium is at the forefront of contact between mother and 
fetus, understanding its specific features and molecular regulation is important 
in understanding the unique features of human embryo implantation.  
In this work, I first describe the features of molecular events that 
govern these cells to the state that is known from the published data, then I 
will describe a valuable, as access to the in vivo populations is virtually 
impossible,  in vitro model for the generation of these cells. Finally, I will 
describe the molecular approach for studying these cells with the use of 
genomic tools applied to understand the transcriptome and transcriptional 
regulation. These data will provide the insights for being able to understand 
the biology and physiology of these cells. The insights from this work will be 
very useful for addressing fundamental questions in reproductive medicine 
and in addressing human-specific reproductive complications and disorders. 
 
1.3.2. Molecular characteristics of primate embryo implantation and 
placentation 
 
There are some attempts at identifying the molecular signature of 
human-specific early events at the window of implantation by sampling and 
profiling of gene expression from endometrium during different phases of the 
menstrual cycle. Moreover, some more recent studies from gene expression of 
pre-implanting human embryo (Bai et al., 2012) provide information on the 
gene expression at this early stage. The results from these studies remain 
inconclusive in identifying important biomarkers of receptive endometrium 
(Aghajanova et al., 2008) moreover, these approaches are not able to provide a 
mechanistic view of the dynamics of molecular events in transcriptional 
regulation at this early stage of human embryonic development. Most of our 
functional information and molecular insights from this developmental stage 
comes from the mouse model (Wang and Dey, 2006). There is a lack of 
functional knowledge and mechanistic view of the primate-specific features of 
early human embryonic developmental events at the window of implantation. 
The reason for this lack of knowledge mainly is difficulty in accessing clinical 
samples until fifth weeks of pregnancy, which is the earliest time one can have 
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access to these samples. Moreover, the limitation for recapitulating the early 
events as the samples are either mid-gestation or end-term which are not 
mimicking the actual events. 
In this work with the use of a stem cell model of primitive syncytium, 
this challenge will be addressed and molecular mechanistic events, which have 
led to the formation of this novel cell type in the evolutionary context of 
primates, will be addressed.  
Molecular changes creating evolutionary novelty can include change 
within coding sequence or change altering cis-regulatory elements (Carroll, 
2005). Following are more details of the three possible mechanisms of 
emergence of a new function in placenta as an evolving organ, which will be 
the focus of this work.  
 
(1) Emergence of new coding gene through gene duplication ((Louis, 
2007), and positive selection through non-synonymous point mutation. 
(2) ERV contribution in the divergence and formation of species-specific 
features of placenta development in mammals through novel cis-regulatory 
elements and new coding sequences (Rawn and Cross, 2008).  
(3) Emergence of new cis-regulatory events through point mutation 
 
1.3.2.1. Gene duplication and positive selection 
 
There is clear evidence that gene duplication has been a primary driver 
of speciation and emergence of the new function in different species in the 
course of evolution (Taylor et al., 2001). With respect to placenta-specific 
genes which has been under gene duplication there are a few examples which 
has species-specific duplication, (Rawn and Cross, 2008) e.g the CGB family 
of genes in primates; the CGB locus is a result of duplication from the 
luteinizing hormone beta polypeptide gene (LHB). Multiple duplication events 
in primates has led to the human having six members of the CGB family 
consisting of CGB, CGB1, CGB2, CGB5, CGB7, CGB8. The molecular 
mechanism of transcriptional regulation of these hormones is not completely 
known. These genes are encoding beta peptide of human chorionic 
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gonadotropin (hCG), which is the first signal from the human embryo to ovary 
for maintaining the corpus luteum; this signal is essential for the maintenance 
of pregnancy. There are other families like LGALS (13, 14 and 16), which has 
been duplicated in the primate lineage and are involved in early events of 
embryo implantation and immune modulation (Than et al., 2009). These 
families have been described with respect to the evolution of placental 
function in the primates. There is no comprehensive work to measure and 
quantify gene duplication in the primate lineage with respect to evolution and 
function of the placenta. In this study, we will explore the extent of gene 
duplication contribution in placenta evolution and function with the use of our 
human embryonic stem cell model. Moreover, also in this work I will explore 
the extent of positive selection in primates through non-synonymous point 
mutation of those genes, which are expressed in the primitive syncytium. This 
combination of evolutionary changes in the coding sequence through gene 
duplication and positive selection will provide insights into the primate-
specific coding genes which eventually altered functional features of the 
ancestral cells leading to the emergence of primitive syncytium. 
 
1.3.2.2. ERV contribution to coding genes and cis-regulatory elements in 
the evolution of the primate placenta  
 
1.3.2.2.1. Transposons as drivers of evolution  
 
A large proportion of mammalian genomes composed of sequences 
derived from the activity of transposable elements. In the human genome, 
sequences directly derived from transposable elements comprise 45% of the 
genome, DNA transposons account for 3% and retrotransposons 42%. 
Retrotransposons, based on the presence or absence of long terminal repeats 
(LTRs), are categorized into two groups, 1) LTR retrotransposon, accounting 
for 8.3% of the human genome, are derived from endogenous retroviral 
elements and, 2) non-LTR retrotransposon which make up the remainder of 
retrotransposons, the two major ones being LINE-1 and Alu elements 
representing 16.9% and 10.6%, respectively (Cordaux and Batzer, 2009). 
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There is substantial evidence showing the contribution of transposable 
elements to being a potential driving force of evolution (Feschotte and Gilbert, 
2012; Feschotte and Pritham, 2007; Lisch, 2013). With respect to the placental 
mammals evolution, a comparative genomic analysis between eutheria and 
metatherian showed that 20% of the non-coding sequences are conserved 
between eutherians revealing the importance of these regulatory elements. 
Transposable elements comprise a substantial proportion, (16%), of these 
conserved non-coding elements (Mikkelsen et al., 2007). Such evidence 
suggests the significant contribution of TEs in the evolution of the regulatory 
network of transcription regulation by acting as cis-regulatory elements in 
driving new functions. Moreover, there is evidence of the emergence of new 
genes and transcription factors as a product of transposases, which can exert 
emergence of new signaling pathways and ultimately new functions in 
evolving tissues (Feschotte, 2008; Cordaux et al., 2006). 
Different genomes have been exposed to exogenous retroviral elements 
throughout evolution. The contribution of endogenous retrovirus elements 
(ERVs) to human genome evolution has been shown in various studies 
(Bannert and Kurth, 2006; Jern and Coffin, 2008). These retroviruses, after 
integrating their genome into the host genome and endogenization process in 
germ cells, can be inherited in a Mendelian manner (V Blikstada, 2008). 
Human genome sequencing showed 8.3% of the human genome is reminiscent 
of these retroviral elements (Lander et al., 2001). The most recent of these 
ERV elements have an ORF similar to the original exogenous retroviral 
particle. They contain gag, pol, pro and end, with a long terminal repeat (LTR) 
at the 5´and 3´ ends. There are several loci with relatively full ORF of HERV-
K (recent integrated ERV) (Barbulescu et al., 1999), which is detected, in the 
human genome and all are thought to be inactive because of mutations or a 
premature stop codon in their sequence. There are indications of functional 
activity of ERVs in driving primate-specific features: A recent genome-wide 
comparison study between mouse and human revealed how the LTR from 
these ERV elements rewired transcriptional regulatory networks of 
pluripotency in human embryonic stem cells compared to mouse embryonic 
stem cells (Kunarso et al., 2010). This study suggests; significant differences 
in transcription factor binding sites (TFBS) of pluripotency related 
 12	  
transcription factors in pre-implantation embryos of different species could be 
affected by the presence of these LTRs at different evolutionary stages.  
1.3.2.2.2. ERV contribution to placenta biology 
 
  Placenta is the only organ where an ERV-derived protein-coding gene 
has been co-opted by the host genome and has become functionally essential. 
These are the so-called syncytins, envelope (ENV) proteins of ERVs 
(Fig.3.a.). which mediate fusion and, in some cases, immunosuppression in 
syncytiotrophoblast cells. Multiple syncytins in various mammalian species 
have been independently co-opted from different ERV families (Fig.3.e.). In 
the mouse the knockout of syncytins (A and B) is lethal due to a defect in the 
formation of syncytial layer of labyrinth.  (Bawa et al., 2009). In humans, 
Syncytin-I and syncytin II, which are the envelope proteins of ERV-W (Mi et 
al., 2000) and ERV-FRD (Villesen et al., 2004), respectively, have been 
shown to have a role in the formation of syncytiotrophoblast and have 
immunosuppressive effect on the maternal immune system (Bouallaga et al., 
2007). Low expression of these envelope proteins in human placenta has a 
direct effect in pregnancy outcome by causing intrauterine growth restriction 
(IUGR), leading to prenatal morbidity and mortality (Ruebner et al., 2010). 
An additional intriguing aspect of ERV expression in the placenta is 
evidence pointing towards the presence of entire intact viral particles, in some 
cases infectious, in the mammalian placenta. Ultrastructural studies by 
electron microscopy revealed the presence of intact virion particles in both 
human (Imamura et al., 1976) and sheep placentas (Palmarini, 2004). In 
ruminants, activity of these viral particles is important for conceptus 
elongation and trophectoderm growth and development. Potential for re-
infectivity of these particles has been shown in cross-species embryo transfer 
experiments in ruminants (Black et al., 2010). However, the source of these 
endogenous viral particles in sheep is the endometrium. There are several loci 
with relatively intact ORFs of HERV-K (Barbulescu et al., 1999) in the human 
genome, but all are inactive because of mutations leading to premature stop 
codons (Boller et al., 2008). While it remains unclear whether an active ERV 
still exists in the human genome, the most recent integrated ERV (ERV-K113) 
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can be re-activated with only a few point mutation modifications. (Lee and 
Bieniasz, 2007) Moreover, integration of this reconstituted retrovirus genome 
in gene active marks (Brady et al., 2009) emphasize the change driving 
capability of these elements in the context of evolution. Although the reverse 
transcriptase activity of HERV-K in the primate placenta (Simpson et al., 
1996) raises the possibility of an intact, infectious virion, none has yet been 
characterized in the human placenta. Nonetheless, it is clear there has been 
recent ERV activity in many mammalian species implying continued 
contribution genomic and evolutionary change. 
Another ERV component that has been known to be co-opted by host 
mammalian genomes for use in the placenta are LTRs that provide new 
regulatory elements. The human genome contains thousands of LTRs, mostly 
single LTRs that are formed by excision of internal proviral structures by 
homologous recombination between the two proviral LTRs (Benachenhou et 
al., 2009). LTRs contain regulatory sequences (Fig.1.3.a), such as 
transcription start site, splicing donor (SD), promoters, polyadenylation 
signals, and enhancers, which can act as regulatory elements to change the 
expression of neighboring genes (Cohen et al., 2009). In the placenta a group 
of genes in which these LTRs act as primary and alternative promoters 
include: CYP19A1 (aromatase) (Fig.3.b,c,d)., IL2RB (interleukin-2 receptor 
B), NOS3 (nitric oxide synthase 3) and PTN (pleiotrophin), HSD17B1 
hydroxysteroid 17-beta dehydrogenase 1), INSL4 (insulin-like 4) and 
PAPPA2 (pappalysin 2) (Cohen et al., 2009). As much of these placenta-
specific LTRs are a result of relatively recent integration events, each is not 
deeply conserved across mammals. Thus, such elements can be a significant 
contributor to variation among mammals such as in the evolution of primate-
specific features of the embryo implantation and placenta formation. 
Therefore in one part of my attempt I will attempt to identify all the elements, 
which has been contributed by ERV in the primate-specific features of 




Figure 1.3. Contribution of ERVs in the mammalian placenta. (a) Structure of ERV genome 
containing two LTRs, gag, pro, pol and env with two possible mRNA transcripts (b) LTR 
based promoter of placenta CYP19A1 (c) UCSC track which shows conservation of LTR of 
CYP19A1 in primates. (d) Mouse placenta of transgenic mice carrying human CYP19A1-
LTR-fused to hGH which radiolabeled with antisense cRNA probe of hGH. (e) Independent 
integration of syncytin genes in different species of placental mammals.   
1.3.2.3. Novel cis-regulatory elements in transcriptional regulation of 
trophoblast lineage in the primate placenta through point mutation 
 
The focus of my study is the identification of primate-specific features 
of human implantation using in vitro human ES-derived primitive syncytium. 
A significant proportion of evolutionary change is expected to be at the level 
of transcriptional regulation. Therefore, it is crucial to understand 
transcriptional regulatory network of primitive syncytium that is unique in 
early primates embryo implantation. For understanding this developmental 
stage, it is necessary to identify important transcription factor, which is likely 
to be a master regulator of the primitive syncytium formation in the primate. 
Although the formation of syncytiotrophoblast is at different development 
stages in mouse compared to primate but the knowledge from genetic studies 
in the mouse is useful for identification of the master regulator of syncytium 
formation. In the mouse, the first syncytiotrophoblast forms at day 8.5 of 
embryonic development following contact between the chorion and allantois. 
The small clusters of cells in the mouse chorioallantois express GCM1, the 
expression of this transcription factor leads to cellular fusion and formation of 
the syncytiotrophoblast (Anson-Cartwright et al., 2000). In the primate 
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(baboon) embryo, the syncytium has been observed by electron microscopy, to 
form at the blastocyst stage (Enders et al., 1997). GCM1 in human also has 
been shown to be involved in the formation of syncytiotrophoblast (Baczyk et 
al., 2004).  Moreover, also based on our analysis of expression data from the 
human embryo (Zhang et al., 2009), GCM1 is expressed at high level in the 
blastocyst stage of the human embryo. This drastic difference between primate 
and mouse in terms of formation of syncytiotrophoblast under the regulation 
of same transcription factor, GCM1 as being the primary known driver of 
syncytiotrophoblast formation, makes GCM1 a prime candidate of interest for 
this study of primate-specific transcriptional regulation of primitive 
syncytium. A second transcription factor of interest that was identified from 
my literature search is TFAP2A; this transcription factor has been shown to 
regulate primate-specific markers of the syncytiotrophoblast such as CGB5, 
which encode CGB peptide of hCG hormone (Johnson et al., 1997). The 
argument here was that if one primate-specific gene (CBG5) is being regulated 
by TFAP2A, there is possibility that other primate-specific genes might also 
have same transcriptional regulation. 
Therefore, in my thesis I have focused on these two transcription 
factors (GCM1 and TFAP2A), to identify their primate-specific transcriptional 
regulation events in the early primitive syncytium formation. This will be 
done through identification of their targets with ChIP-seq experiments in 
human ES-derived primitive syncytium. This would allow me to be able to 
identify the primate-specific transcriptional regulatory network of primitive 
syncytium formation, which is contributed to the emergence of primitive 
syncytium formation in primates. 
 
1.3.2.3.1. GCM1 Biology 
 
GCM1 (glial cell missing 1) is a transcription factor consisting of 436 
amino acids with a conserved DNA-binding domain (DBD) of 150 amino 
acids at the N-terminus (Akiyama et al., 1996). GCM1 is rather unique as its 
DBD cannot be classified into any of the much larger transcription factor gene 
families; it is thought to be a product of a transposase with a unique DNA 
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binding domain (WRKY-GCM1) (Babu et al., 2006) . The emergence of this 
WRKY-GCM1 new DNA binding domain family in plants provided new 
functions in the activation of a new signaling pathway in light sensing (Lin et 
al., 2007). In Drosophila, GCM1 is involved in the differentiation of neural 
precursor cells to glial cells, in mammals, it has been shown that both Gcm1 
and Gcm2 are contributing to the formation of neural stem cells and the double 
knockout of Gcm1 and Gcm2 resulted in the lack of formation of neural stem 
cells (Hitoshi et al., 2011) . Although, the knockout of Gcm1 alone did not 
show neural phenotype defects in mice but however there are reports of 
GCM1 having a role in the glial cells development in mammals (Nait-
Oumesmar et al., 2002). The mouse knockout of GCM1 is lethal between days 
9.5 and 10 of gestation due to the failure of placenta formation (Figure 1.4.c). 
This knockout mouse lacks the ability to form the labyrinthine layer, 
necessary for nutrient exchange between the fetus and decidua, and 
specifically lacking syncytiotrophoblast (Anson-Cartwright et al., 2000; 
Schreiber et al., 2000). The mechanism by which this conserved domain has 
changed its function through evolution is not clear but perhaps can be 
explained by evolution of tissue-specific cofactors that interact with GCM1. 
This phenomenon is shown in the evolution of function of other classes of 
transcription factors in new organs (Gunter et al., 2005; Carroll, 2008). GCM1 
expression in mouse is first detected at day 7.5 embryonic development within 
trophoblast cells of the chorion in the labyrinth layer and expression persists 
until day 17.5 (Basyuk et al., 1999) (Figure 1.4.d). GCM1 was considered to 
have a similar expression pattern in human embryonic development (Baczyk 
et al., 2004; Baczyk et al., 2009) where it clearly is expressed and involved in 
the formation of the villous syncytiotrophoblast in the mature placenta. 
However, surprisingly we found that this transcription factor is also expressed 
much earlier in the human, within the blastocyst.  
 17	  
	  
Figure 1.4. Syncytiotrophoblast formation and GCM1 expression pattern in human and 
mouse. (a) Human embryo (Barnes embryo) at day 11-12th, primitive syncytium starts to form 
around the implantation site. (b) Surface view of the implantation site of Barnes embryo. (c) 
Phenotype of GCM1 knockout mouse that shows a lack of labyrinth (I) at day 11.5; 
d(decidua), (s) spongiotrophoblast. (d) a- Stepwise formation of  chorioallantoic placenta  and 
location of the labyrinth layer. (b-f)- mRNA expression of GCM1 at day 8.5 in wild-type 
mouse by in situ hybridization 
 
This finding reveals a significant difference in expression patterns 
between mouse and human, possibly reflecting the major differences in the 
initial appearance of the syncytiotrophoblast in the primate. High expression 
of GCM1 mRNA in the human blastocyst (day 5) provides molecular support 
for histological findings of syncytiotrophoblast formation at this early stage of 
the human embryo  (Hamilton and Boyd, 1960). (Figure 1.4.a,b). 
1.3.2.3.2. TFAP2A Biology: 
 
Transcription factor AP-2 (activating enhancer binding protein 2) 
alpha, TFAP2A, has been shown to be involved in differentiation of human 
trophoblast cells to syncytiotrophoblast (Cheng and Handwerger, 2005). 
TFAP2A has also been shown to regulate primate-specific syncytiotrophoblast 
genes in the placenta such as CGA and CGBs (Johnson et al., 1997), 
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HSD17B1 (Leivonen et al., 1999), and CYP11A1 (Wada and Chou, 1993). 
TFAP2A has been shown to be highly expressed in the trophectoderm of the 
human embryo. In the mouse system, on the other hand, Tfap2c but not 
Tfap2a has been shown to have a role in the maintenance of trophoblast stem 
cells. Tfap2c knockout mice indicate a clear placental defect but the Tfap2a 
knockout mice did not show phenotype in extraembryonic tissues although the 
mouse dies at day 9 to 9.5, this remain to be investigated in more detail for the 
involvement of Tfap2a in extraembryonic tissues and placenta formation in 
mice (Schorle et al., 1996; Kuckenberg et al., 2012).  The lack of a placental 
defect in the Tfap2a null mouse and the observation human TFAP2A is 
regulating essential primate-specific genes expressed in the 
syncytiotrophoblast (and possibly as early as the blastocyst stage) makes 
TFAP2A a second strong candidate to pursue investigations on primate-
specific control of the syncytiotrophoblast.  
 
In my thesis, both GCM1 and TFAP2A were selected for performing 
chromatin immunoprecipitation to identify primate-specific regulatory 
elements driving gene expression in the human ES-derived primitive 
syncytium. 
1.4. Establishment of in vitro models of trophoblast lineage 
1.4.1. Differentiation of human embryonic stem cells to the trophoblast 
lineage 
 
While studying different animals, allow us to have a comprehensive 
view of the molecular and cellular events of early embryo implantation in an 
evolutionary context. (Bazer et al., 2009) This comparison may miss important 
mechanisms that are species-specific; because, as stated earlier, of all tissues, 
the placenta is the most diverse mammalian organ. Since human peri-
implantation and early post-implantation embryonic development is virtually 
inaccessible, in vivo, establishing a human-based model primitive syncytium is 
essential. Currently, the most prevalent models which have been used are term 
placenta and trophoblast-derived cancer cell lines (Hannan et al., 2010). Term 
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placenta, 200+ days post-fertilization, is not a good representative for studying 
early molecular events in the trophoblast lineage. In addition, the placenta 
consists of mixed population of cells at the end-differentiated stage. Therefore, 
cancerous choriocarcinoma cell lines are preferred for investigations into the 
developmental and molecular control of human trophoblast in most 
laboratories. However, it should be noted that abnormality in cancerous cell 
lines might lead to misinterpretation of the pathways and their transcriptional 
regulatory networks (Ferretti et al., 2007). For this reason, in addition to the 
ethical and practical reason for obtaining human blastocysts, it is invaluable to 
have a human-based in vitro model to investigate molecular events of early 
human embryo implantation. A major challenge in establishing this in vitro 
model is the lack of a human trophoblast stem cell line. With such a cell line, 
one would be able to produce an in vitro biological counterpart of the 
trophoblast lineage and recapitulate early developmental events to test 
outstanding questions in the field of human reproductive medicine. The 
advantages of using human ES cells as a model for trophoblast differentiation 
has been stated by others  (Schulz et al., 2008; Douglas et al., 2009; Golos et 
al., 2010) but the existing differentiation protocols from human embryonic 
stem cell toward trophoblast contain cellular heterogeneity and lack a clear 
cellular identity for the end differentiated products. 
 While the body of evidence supports the ability of human ES cell 
differentiation towards the trophoblast lineage, there remains a counter view in 
the literature that human ES cells lack the capacity to form trophoblast. Their 
argument is that since human ES cells are similar to mouse epiblast stem cells 
(EpiSC), which is derived from post-implantation embryo, therefore, lacks the 
facilities to differentiate to trophoblast. This argument is based on two 
reasons: (1) morphological similarities between human ES cells and EpiSC 
and (2) the fact that the growth factor requirement for maintaining human 
embryonic stem cells is similar to that of EpiSC cells (Brons et al., 2007).  
Further work from one of the groups that initially derived the mouse EpiSC 
showed that human embryonic stem cells induction with BMP4 produced a 
mixed population of cells predominantly mesendoderm lineage (Bernardo et 
al., 2011). This report was a clear contradiction to the substantial body of 
evidence in the field that shows BMP4 can induce differentiation of human ES 
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cells to trophoblast-like cells (Xu et al., 2002). The discrepancy between 
Bernardo et al, and the number of groups that do claim successful BMP4-
mediated trophoblast differentiation has been speculated to be influenced by 
artifacts in the maintenance or differentiation medium by Bernardo et al, 
(Amita et al., 2013) or it may represent cell line-specific artifacts since 
Bernardo et al only used one human embryonic cell line (H9) in their studies.  
 There are new works, which indicate a combinatorial treatment of 
BMP4 with FGF inhibitor and TGF-beta inhibitors (Sudheer et al., 2012; 
Amita et al., 2013) improves differentiation of human ES cells to the 
trophoblast lineage. The use of these inhibitors in the differentiation cocktail 
has been proposed to reduce the possibility of differentiation of cells to other 
lineages (Amita et al., 2013) and also since both FGF and TGF-beta pathways 
play important roles in the maintenance of pluripotency (Vallier et al., 2005), 
by inhibiting these pathways the efficiency of differentiation will be improved. 
This combinatorial treatment also prevents the possibility of BMP4 working 
with endogenous FGFs on Brachyury (T) promoter to direct the cell to 
mesendoderm lineage (Yu et al., 2011). In all the current differentiation 
protocols of human ES-derived trophoblast, the identity of the end-stage cells 
are not clear and is only referred to as a trophoblast-like cell type. Therefore, 
to address the questions in this study I aimed to develop a differentiation 
protocol to direct the cells to syncytiotrophoblast lineage.  
For having a biological counterpart of the human primitive syncytium 
for evolutionary comparisons, I developed an in vitro system using mouse 
trophoblast stem (TS) cells differentiated toward the syncytiotrophoblast. This 
is discussed further in the Results section.	  
In the following chapters, I will present my practical approach for 
identifying the unique primate-specific features of primitive syncytium at the 
molecular level on a genome-wide scale with the use of an in vitro stem cell-
based model. Each chapter in the result section will address one of the 
following questions with a focus on primate-specific features. 
 
1-Establishment of in vitro system to recapitulate the syncytiotrophoblast 
formation of the human and mouse with the use of stem cell. 
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2-Uncovering the primate-specific features of human embryo implantation and 
placentation with the use of genome-wide approaches on in vitro models. 
3-Finding the biological implication of the genomic changes, which have 
contributed to the major phenotypic differences between primate embryo 
implantation compared to other species. 
1.5. Significance of the Project: 
 
Identification of primate-specific features of early embryonic 
development and placenta formation will bring new insights into our basic 
knowledge in the field of human reproductive medicine. The findings from 
this work will provide mechanistic insights into the evolutionary events 
involved in the emergence of novel features of early human embryo 
implantation and placental development. These findings will help to design 
better regimes of therapies for increasing the success rate of pregnancies in 
IVF clinics in addition to natural pregnancies. Another contribution of these 
findings is a further understanding of the root of human-specific reproductive 
complications such as preeclampsia and IUGR. This may aid in the 
development of novel approaches to tackle these complications. In addition to 
this clinical relevance, these investigations will provide insight into the 
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The commonly used and NIH-approved human embryonic stem (ES) 
cell lines H1, H7 and HES3 were maintained in mTeSR1 medium (Stem Cell 
Technologies) on Matrigel (BD Bioscience) coated plates. The medium was 
changed every day, and cells were passaged once a week with Dispase (Stem 
Cell Technologies). A ROCK inhibitor (3-5µM) was included in the media at 
the time of passage for the subsequent 24 hours (Watanabe et al., 2007), this is 
known to help increase the survival rate of human ES cells over the first 24 
hours after passage where there is known to be a lot of cell death. This 
consideration is crucial in experiments requiring large numbers of 
differentiated cells to syncytiotrophoblast for the ChIP assay, however for the 
routine maintenance of human ES cell the ROCK inhibitor may not be 
necessarily required. 
 
For the differentiation of human ES cells to the trophoblast lineage, I 
began the differentiation program 3-4 days after passage. This depended on 
the growth of the colonies at the time; Figure 2.1 is an example of a good 
starting condition at day 0 and further differentiation time point at day 2, 4 and 
6. Before starting the differentiation, the cells were washed three times with 
DMEM/F12. These washing steps help to remove all the residual growth 
factors used to maintain the undifferentiated state of human ES cells such as 
bFGF and TGF-beta, both of which are present in the mTSR1 media. Trace 




Figure 2.1. Light microscopy image (200X) of human ES differentiation to 
syncytiotrophoblast at day 0, 2, 4 and 6 with the use of established protocol containing BMP4 
(100ng/ml) + SU5402 (20uM) + SB431542 (10uM) + cAMP (150uM) in this work with 
KOSR basal medium.  
 
In this study the three basal medium KOSR, N2B27 and STEMdiff™ 
APEL™ Medium (Stem Cell Technologies Inc.) were used to optimize the 
best basal condition for differentiation. KOSR medium contains DMEM/F12, 
knockout serum replacement (KOSR) 20%, L-Glutamine (2mM), NEAA 
(0.1mM) and penicillin-streptomycin (1X). N2B27 medium contains, 
DMEM/F12, BSA (0.5mg/ml), L-Glutamine (2mM), NEAA (0.1mM), N2 
supplement (1X), B27 supplement (1X) and penicillin-streptomycin (1X). 
STEMdiff™ APEL™ Medium (Stem Cell Technologies Inc.) is a 
commercially available serum-free medium. 
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The growth factors and inhibitors used in either/or the differentiation 
of human ES cells and mouse TS cells are: BMP4 (Cat. No: 314-BP-050, 
R&D) and Activin (Cat. No: 338-AC-010, R&D), SU5402  (Cat. No: 572630-
1MGCN, Merck), SB431542 (Cat. No: S4317-5MG, Sigma-Aldrich), cAMP 
(Cat. No: 203800-10MGCN, Merck) and CHIR 99021 (Cat. No: 4423, 
Tocris). All these compounds were prepared based on the suggested methods 
from the manufacturer. To ensure uniformity in the experiments, preparation 
of these materials was done in bulk and the stocks frozen down at -80oC for 
future use. The stock (100 µg/ml) for BMP4 and activin was prepared in PBS 
containing 1% BSA fraction V (Cat. No: 15260-037, Life Technologies). 
Stock for SU5402 and SB431542 (100 mM) was prepared in DMSO. cAMP 
stock was prepared (1 mM ) in water.  
The following differentiation cocktails have been used for 
differentiation of human ES cells to the trophoblast lineage, and the following 
abbreviations are used throughout the thesis for referring to these 
differentiation cocktails. 
SB consists of: BMP4 (100ng/ml) + SU5402 (20µM); SSB consists of: 
BMP4 (100ng/ml) + SU5402 (20µM) + SB431542 (10µM); SSBC150 
consists of: BMP4 (100ng/ml) + SU5402 (20µM) + SB431542 (10µM) + 
cAMP (150µM) and SSBC500 consists of: BMP4 (100ng/ml) + SU5402 
(20µM) + SB431542 (10µM) + cAMP (500µM).  
 
2.2. Mouse trophoblast stem (TS) cell maintenance and differentiation 
protocol: 
 
Mouse TS cells from the Rossant lab (Tanaka et al., 1998) were 
maintained by using a standard protocol. Briefly, conditioned medium was 
prepared from mouse embryonic fibroblasts (MEF) with the following 
medium: RPMI1960, FBS (ES grade) 20%, sodium pyruvate 1mM, beta-
Mercaptoethanol 55mM, and then addition of FGF4 (25 ng/ml) after 
conditioning. Mouse TS cells were maintained on gelatin-coated plates, and 




Since in my project I was interested in differentiation of TS to 
syncytiotrophoblast lineages, I realized that the cells did not differentiate 
effectively to the syncytiotrophoblast without coating the plate with Matrigel. 
Instead, for the syncytiotrophoblast differentiation protocol, cells were 
cultured on Matrigel coated plates for three passages before initiation of 
differentiation. The differentiation was started 24 hours after passage. The 
basal medium for differentiation contained no conditioning and no FGF4.   
 
The following differentiation cocktails have been used for the 
differentiation of mouse TS cells to the syncytiotrophoblast lineage, and the 
following abbreviations are used throughout the thesis:  A consists of: activin 
(20ng/ml); AS consists of: Activin (20ng/ml) + SU5402 (20µM), AB consists 
of: Activin (20ng/ml)+ SB431542 (10µM); ASB consists of: Activin + 
SU5402 (20µM) + SB431542 (10µM) 
 
2.3. Maintenance of the human choriocarcinoma cell lines, JEG3 and 
BEWO. 
 
Choriocarcinoma cell lines were maintained under the suggested 
conditions as follow, BEWO cells were maintained in DMEM-F12K with 
10% FBS and passaged every 8-10 days. JEG3 cells were maintained in MEM 
medium with 10% FBS and passaged every 4-5 days. 
 
2.4. Generation of the V5 tagged GCM1 stable cell line 
 
For the generation of the GCM1-V5 tagged stable human ES cell line, 
the GCM1-V5 construct was obtained from DNASU Plasmid Repository. This 
lentiviral construct was then packaged using the ViraPower™ Lentiviral 
Packaging Mix (Invitrogen) using 293FT cells following the instruction 
provided in the kit. The virus from the supernatant of these cells was 
concentrated with Amicon Ultra-15 Centrifugal Filter Units (Merck 
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Millipore). Undifferentiated human ES cells were infected with this GCM1-
V5 lentivirus as follows: human ES cells at day 4 after passage were fed with 
culture medium containing Polybrene (6µg/ml) for 15 minutes and then viral 
particles were added to the cells. Next day, media were removed and again fed 
with culture medium containing polybrene (6µg/ml) for 15 minutes and 
subsequently three times the initial amount of the viral particle was added. For 
the next five days, the cells were fed with medium containing Blasticidin (10 
mg/ml) for selection of GCM-V1 positive clones. The cells were passaged and 
maintained on the mTeSR1 containing Blasticidin until the time of 
differentiation. Blasticidin was removed in the same passage of initiation of 
differentiation. 
 
2.5. Optimization of the ChIP-seq protocol 
 
The ChIP protocol was performed as follow: briefly, after harvesting 
and fixation of the cells with 1% paraformaldehyde (EM BioScience), the 
cells were lysed with the lysis buffer containing Tris-HCl (10mM, pH8.0), 
TritonX-100 (0.25%) , EDTA (10mM,  pH8.0), NaCl ( 0.1M). Chromatin was 
extracted with the use of nuclear lysis buffer containing HEPES-KOH (50mM, 
pH7.5), NaCl (150mM), EDTA (2mM), TritonX-100 (1%), NaDOC (0.1%),  
SDS(1%). The sonication was done with the Biorupter sonicator for 20 pulse 
(30 second on/ 30 second off) and then after centrifugation, pre-clearing of 
chromatin was done with Dynabeads for 2 hours. For Immunoprecipitation 
(IP) antibodies were conjugated with Daynabeads for 4 hours before 
incubation with chromatin and then the IP was done with Daynabeads-
antibody conjugate overnight; All the incubation steps was done in reduced 
SDS buffer (rSDS) containing HEPES-KOH (50mM, pH7.5), NaCl (150mM), 
EDTA (2mM), TritonX-100 (1%), NaDOC (0.1%), SDS (0.1%). Then the 
washing step was done to remove all the nonspecific binding: three times with 
reduced SDS buffer and once with rSDS ( 0.35mM NaCl) and one time with 
NP40 wash buffer containing Tris-HC (10 mM l pH 8), EDTA (1 mM), LiCl 
(0.25 M), NP40 (0.5 %), 0.5 NaDOC (0.5 %), then another three times of 
washing with TE buffer. (All the IP steps were done at 4oC and protease 
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inhibitor was included in all the buffers after extraction of the chromatin). 
After the IP step, proteinase K treatment was done for 4 hours at 45oC and de-
crosslinking was done at 67oC for 6 hours. Then RNAse treatment was done 
for 1 hour at 37oC and the DNA was purified with a standard 
phenol/chloroform extraction protocol, and then the size distribution of 
fragments was checked by agarose gel electrophoresis. Finally, after 
measurement of the DNA concentration with Quant-iT kit (Life Technologies) 
qPCR was performed on the target and control regions.   
 
Figure 2.2. Schematic of different steps of ChIP-seq approach (a) described from Park et al 
(2009) (Park, 2009) different stage of optimization in the ChIP-seq protocol for histone 
modification mark and TFs. (b) Distribution of sonicated DNA for 3 of the samples in this 
thesis, showing enrichment between 100bp to 350bp.  
 
In a ChIP-seq experiment, there are four crucial steps, which need to 
have independent optimization in each experiment. Figure 2.2.a shows the 
schematic representation of these optimization steps: after selection of the 
desired cell type, in this case human ES cell differentiated to the trophoblast 
lineage for six days with the SSBC150 protocol. Then the following technical 
considerations include: (1) Identification of the best cross-linking time and 
sonication cycles to have good resolution of the positive signal to noise ratio 
after sequencing. (2) The identification of a specific antibody, which can 
recognize the desired protein (TFs or histone modification marks), works with 
cross-linked chromatin. (3) The identification of appropriate target genes and 
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the design of specific primers around these known binding sites to show 
enrichment by qPCR for validation of ChIP before proceeding to sequencing. 
 
For the ChIP assay on human ES-derived primitive syncytium, 
chromatin fixation was done with paraformaldehyde for 10 min (1% in the 
medium). After quenching with glycine for 5 min (0.125M in the medium), 
the cells were collected in the cold room in cold PBS. Cells were lysed, and 
chromatin was extracted, and sheared in a water bath sonicator ( 20 cycle 30 
second On/Off). Targeted fragment range from sonication was 100bp to 400bp 
(Figure 2.2.b). The immunoprecipitation was done with the following 
antibodies for histone modification marks and transcription factors: H3K27ac 
(Cat. No: 39133, Active Motif), H3K4me3 (Cat. No: 39159, Active Motif), 
TFAP2A (ab52222, Abcam), and the V5 epitope antibody (Invitrogen, R960-
25). 
Frequently during the optimization steps, there was a relatively low 
amount of chromatin following the pull down. This, despite the need to first 
confirms the ChIP quality by ChIP-qPCR before preparing libraries for 
sequencing. To address this, I developed a protocol for use in ChIP 
experiments yielding low input amounts of material.  In this protocol, a pre-
amplification step was included before qPCR to increase the amount of DNA 
available for analysis of targets. With this, as little as 0.1 ng of IP material 
before pre-amplification is sufficient. 
This ChIP-preamplification protocol was validated using an OCT4 
ChIP-seq and antibody from Kunarso et al. (2010). As the OCT4 antibody and 
the target genes in human ES cells are very well-known from previous ChIP 
experiments, this system provided a good validation for ChIP-preamplification 
protocol with a small amount of IP materials. 
 
2.6. Validation of ChIP with qPCR before library preparation for 
sequencing  
 
Using the above-mentioned ChIP-qPCR pre-amplification method, the 
following are the validation of the control targets, which have been studied in 
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my thesis including H3K27ac, H3K4me3, H3K27me3, H3K9me3, TFAP2A 
and GCM1-V5 in two human ES cell lines (H1 and HES3). The result of the 
fold enrichment can be seen in Figure 2.3, the primer used for these targets 
these targets are listed in Supplementary Table 2.1. 
 
	  
Figure 2.3. ChIP-qPCR validation of histone modification marks (H3K27ac and H3K4me3) 
and TFs (GCM1 and TFAP2A) target and control sites in the human ES-derived primitive 





2.7. ChIP-seq library preparation for sequencing  
 
ChIP-seq libraries were prepared with the use of Illumina DNA paired-
end multiplexing library preparation kit (Catalog # PE-930-1002). This kit is 
originally recommended for use with a minimum of 5µg of genomic DNA and 
since in the ChIP experiments, DNA yields are less than 10ng materials; some 
modifications was done to the main protocol for the library preparation of 
ChIP materials. First, DNA from ChIP material went through an end repair 
step leaving the DNA adenylated at 3´end. Next, adaptors were ligated to the 
DNA fragments using a concentration of adaptors adjusted based on the 
amount of starting material (0.25µM of annealed adaptors for 10ng of starting 
materials). This step ends with a PCR amplification step using Platinum® Pfx 
DNA Polymerase (Invitrogen) (Pfx). Note, in my hands the Phusion enzyme 
from the Illumina kit and similar products from other companies did not 
perform well, (Phusion and similar products in this family are considered the 
third generation of Taq enzymes). I found this enzyme had a bias toward the 
amplicon size of 200bp (Figure 2.4.a,c)  whereas the original pattern of 
distribution of starting material was ranging from 100bp to 400bp (Figure 
2.2.b) Instead, using the Pfx enzyme I found the PCR products better 
represented the original input material, notwithstanding the addition of ~70 
bp, a size increase the result of adaptors ligation. With the Pfx enzyme, there 
is a 150bp to 550bp size range of amplified materials (Figure 2.4.b,d). From 
the Bioanalyzer analysis, the peak height from this is determined to be 300bp, 
which is the ideal size for sequencing. In contrast, the profile using the 
Phusion enzyme is 200bp at the height of the peak similar to what we see in 
the gel (Figure 2.4.a,c).  All the size selection and purification step in this 




Figure 2.4. Optimization of the type of enzymes in the amplification step of library 
construction in this study. (a, b) distribution of amplified materials with two different enzymes 
used in this study (a) Phusion and (b) pfx. (c) The Agilent bioanalyzer profile of Phusion 
amplified product with the peak at 200bp and (d) The Agilent bioanalyzer profile of pfx 
amplified products with peak at 300bp. 
	  
The multiplexed libraries for both TFs and histone marks were 
submitted to the GIS sequencing core facility for running with 1x50base reads 
on the HighSeq sequencer. Before submission, quality control (QC) steps were 
done on each submitted sample. This includes size fragment distribution 
measurement using High Sensitivity DNA kit on the Bioanalyzer and a qPCR 
QC step to make sure the DNA fragments contained the appropriately ligated 
sequencing adaptors.  
 33	  
All ChIP experiments were prepared in two cell lines (H1 and HES3) 
to provide biological replicates. One of the libraries, GCM1-V5 in the H1 cell 
line, failed during the library preparation. This was likely a result of the 
limited chromatin materials from these GCM1-V5 ChIPs compared to the 
other preps. All the ChIP-seq libraries were multiplexed for sequencing run. 
 
 
2.8. RNA extraction  
 
RNA from all the experiment in this work was extracted using the 
Tryzol method (Nolan et al., 2006). After final DNAse treatment, the purified 
material was subsequently column purified with a QIAGEN column. Then 
RNA was processed for different application in this study such as qPCR, 
microarray, and RNA-seq. 
 
2.9. mRNA-seq library preparation  
 
mRNA-seq libraries were constructed using True-seq kit from Illumina 
by following the protocol provided from the kit. Briefly as follow: polyA 
RNA was isolated from total RNA using Daynabeads poly(dT). Then the 
polyA RNA was purified, and the first and second strand cDNA was 
synthesized. Then the cDNA was end repaired and a 3' A base was added to 
the fragments. TrueSeq adapters were incorporated to the cDNA fragments, 
and then adapter-ligated DNA was amplified by PCR. All the size selection 
and purification steps were done with AMPure XP beads (Beckman Coulter 
Genomics, Danvers, MA) 
The output of this protocol for both human and mouse samples were 
submitted to the GIS sequencing core facility for running 2x100 base reads on 
a HighSeq sequencer. Prior to submission, QC on samples including checking 
the fragment size distribution check with the DNA 1000 kit on the 
Bioanalyzer and a PCR QC step to make sure the DNA fragments contained 
the appropriately ligated sequencing adaptors. All the libraries were prepared 
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in two biological replicates. The mRNA-seq libraries were multiplexed of six 
libraries in each lane of sequencing.  
A summary of sequencing reads of RNA-seq for both human ES-
derived primitive syncytium samples and mouse TS-derived 
syncytiotrophoblast samples has been provided in Supplementary Table 2.4. 
 
2.10. qPCR Protocol (Conventional and High-throughput ) 
 
qPCR was done by following a standard protocol (Schmittgen and 
Livak, 2008).Briefly cDNA was prepared (up to 1µg of RNA) from different 
samples by use of Superscript III kit (Invitrogen) with random primers. 
Briefly, the protocol is as follow: in the first step, RNA were incubated with 
random primers and dNTP at 65oC for 5 min and then in the next step 5X 
buffer, Superscript III enzyme enzyme, RNAse inhibitor (RNAse OUT) and 
DTT were added to the reaction and incubated for 50 min at 42oC. The 
inactivation of the enzyme was done at 85oC for 5 min. Then the cDNA used 
in the conventional qPCR with concentration of equivalent to 10ng of original 
RNA in each well of 384 well plates. In the High-throughput qPCR, the 
protocol from Fluidigm was followed; briefly, after cDNA synthesis, a pre-
amplification step (Specific Target Amplification (STA)) was performed with 
the 0.2X diluted TaqMan assays and the Taqman preamplification kit (ABI).  
The pre-amplified samples were then analyzed following Fluidigm’s standard 
protocol for running STA samples (Guo et al., 2010). The data analysis for the 
conventional qPCR was done with Vii7 software provided by ABI and for the 
high-throughput qPCR, the analysis was performed with Fluidigm qPCR data 
analysis software. In the data analysis the fold change of delta delta Ct values 
against control sample and housekeeping gene (ACTB and GAPDH) were 
calculated in all the comparisons. The qPCR was done with the following 




2.11. Microarray protocol and data analysis 
 
RNA (1ug) from different samples of human ES differentiation system 
(H1, H7 and HES3) at different time points was subjected to total cRNA 
preparation kit (Ambion), briefly RNA was reverse transcribed with Oligo(dT) 
T7 primer to synthesize the first cDNA and then double strand cDNA was 
synthesized, then the cDNA was purified to remove primers, salts and RNAs 
from the reaction.  The purified sample was subjected to in vitro transcription 
to synthesize cRNA. The cRNA (750ng) were hybridized directly on the 
BeadChip (HumanHT-12_V4) in a shaker incubator, after the washing steps 
the BeadChips were scanned using Illumina BeadArray Reader. The values 
are exported to Genome Studio for normalization. After normalization step, 
the values were exported to Partek Suite Genome analysis software for 
visualization of the all expressed genes in PCA and hierarchical clustering in 
which the values are standardized (shift genes to mean of zero and scale to 
standard deviation of one). 
 
2.12. Hormone measurement assay methods 
 
Hormone measurements was done in 24-well format plate, one well of 
a 6-well plate, which is around 3-4 million cells was passaged into one 24-
well plate as the initial condition for differentiation in all the hormone 
measurement assays and then the cells were differentiated toward the 
trophoblast lineage with different differentiation cocktails for HCG and for E2 
measurement with the protocol established in this work. 
For the E2 measurement of inhibitor assay of the pathway, human ES 
cells were differentiated to primitive syncytium until day 6 with the protocol 
established in this work (SSBC150). Then the inhibitor tested in this work 
including HSD3B1 (Trilestone, Sigma-Aldrich), HSD17B1 (CC-115, not 
commercially available, a generous gift from Dr. Poirier) (Poirier, 2010) and 
CYP19A1 (Letrozole, Sigma-Aldrich). The inhibitors were added to the 
culture condition with 20µM concentration for 30 minutes before addition of 
DHEA (Sigma-Aldrich) at 10µM concentrations. After 12 hours the 
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supernatant from the cells were collected for E2 measurement. All the 
measurements were done in triplicate. 
For HCG measurement, different cocktail of differentiation was added 
to human ES cells which is ready for differentiation (day 3-4) and then the 
supernatant was collected at different days of differentiation at day 0, 4 and 6, 
all the measurements were done in triplicate.  
All the hormone measurements were done at NUH with Beckman 
Coulter Unicell DXI 800 instrument. The principles for the test are as follow: 
For E2, the assay principle is chemiluminescent immunoassay (Competitive 
Binding) and for BHCGT the assay principle is the Chemiluminescence 
Immunoassay (Sandwich) (WHO 5th International Standard for Chorionic 
Gonadotropin). Since the values for samples at day 6 of differentiation were 
higher than the high end of the measurement of the assay by the instrument, 
the samples were diluted 100 times for E2 and 150 times for BHCG to be able 
to measure the concentration of the samples. 
	   
 
2.13. Knockdown of GCM1: 
 
GCM1 shRNA knockdown was performed with lentiviral vectors using 
unverified Mission shRNA clones from Sigma-Aldrich. A JEG-3 cell line was 
used for the initial screening of the unverified shRNA clones to identify the 
validated shRNA clones. The experimental procedure is as follow, JEG3 cells 
were passaged at 70-80% confluency into a 24-well culture dish, 24h later 
cells were fed with culture medium containing polybrene (6 µg/ml) for 15 
minutes and then cells were given the viral particles (10 µl of 1x106 TU/ml 
viral particles for each well). Next day, media were removed and again fed 
with culture medium containing polybrene (6 µg/ml) for 15 minutes and then 
three times the initial amount of the viral particle was added to each well. For 
the next four days, the cells were fed with medium containing one µg/ml 
puromycin for selection of resistance colon. At day six, cells were collected, 
and RNA was extracted for qPCR analysis. 
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The initial plan for the knockdown was to check the target of GCM1 in 
human ES cells differentiated to primitive syncytium by establishing stable 
knockdown of GCM1 line with the verified clones and, then identifying the 
functional effect of knockdown of GCM1 on differentiation of human ES cells 
to trophoblast lineage. However, the result of knock down of GCM1 in the 
differentiated stable line was not convincing and the cells did not have a good 
viability, although the progression of differentiation morphologically seemed 
to be similar to the normal cells. Therefore, the JEG3 shRNA knockdown 
result, at this point, was considered to be used as validation for target of 
GCM1 ChIP-seq. 
 
2.14. Luciferase assay  
 
As a part of the validation of a true functional binding sites of TFs 
(GCM1, TFAP2A), and also the LTRs which act as trophoblast-specific 
promoter and enhancer are the analysis of their transcriptional activity by 
luciferase assays. The workflow for dual luciferase assay is shown in Figure 
2.5.  Supplementary Table 2.3 shows all the elements and their primer, which 
are tested by luciferase assay in this study. BAC clones for amplification of 
the LTRs was obtained from BACPAC resources (Children’s Hospital 
Oakland). The short olio’s of binding site of TFAP2A and GCM1 (wild-type 
and mutated version) were synthesized through a service provided by IDT. To 
determine the functional activity of these elements, the elements were cloned 
in either PGL4.11 or PGL4.24, and then these constructs were transfected into 
JEG-3 and BEWO cells, human choriocarcinoma cell lines used to study 
human trophoblast transcriptional regulation. We assume these cells express 
all the transcriptional machinery required for regulation of these regulatory 
regions. Signal from the Firefly luciferase was normalized to Renilla signal 
from pGL4.74. Moreover, then the fold change of luciferase activity of these 
elements was compared to the luciferase signal from the basic construct for 




Figure 2.5. Workflow of the validation of the cis-regulatory elements (LTRs and TFBS) by 
dual luciferase assay (1) The cis-regulatory elements were clone in either PGL4.24 or 
PGL4.11 plasmid (2) Two choriocarcinoma cell lines (JEG3 and Bewo) were transfected with 
these plasmid and a PGL.74 plasmid as a control (3) The measurement was done with the dual 
luciferase assay from Promega. 
 
2.15. Western blotting 
 
Cells were collected and washed two times with cold PBS plus 
protease inhibitor, then cell were lysed with RIPA buffer (Sigma-Aldrich) at 
4oC. Total protein was measured with Pierce BCA protein assay kit (Thermo 
Scientific. Cat No: 23225). The samples were denatured with NuPAGE® LDS 
Sample Buffer in 70oC for 10 min. Then the samples were loaded on LDS 
NuPAGE® Bis-Tris Precast Gels 12%, the gel was run with XCell 
SureLock™ Mini-Cell Electrophoresis System and buffers. Transfer of 
proteins to (Polyvinylidene fluoride (PVDF) membrane was done with the use 
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of XCell II™ Blot Module and buffers. After washing the membrane, 
blocking was done with blocking reagent (PBS 5% non-fat dry milk) for 1 
hour at room temperature. The incubation with the first antibody was done 
overnight in the blocking reagent at 4oC, after washing steps the secondary 
staining was done for 2 hours at room temperature in the blocking reagent. 
Detection was done with ECL Plus Western Blotting Detection Reagents (GE 
Healthcare). Following are the antibodies, which is used for western blotting 
in this study. First antibodies: TFAP2A (ab52222, Abcam), and the V5 
epitope antibody (Invitrogen, R960-25), GCM1 (Santa Cruz, sc-98719) Actin 
(Santa Cruz, sc-1616), GAPDH (Millipore, MAB374). Secondary antibodies: 
HRP donkey anti-goat Ig-G (Santa Cruz, sc-2020), HRP donkey anti-rabbit Ig-
G (Millipore, AP182P), Mouse ExactaCruz E, HRP (Santa Cruz, sc-45042) 
 
	  
2.16. Bioinformatics method and data analysis 
 
2.16.1. RNA-seq data analysis and calculation of differentially expressed 
genes 
RNA-seq reads for each library were mapped independently using 
TopHat (Trapnell et al., 2009) against the human genome build hg19 and 
mouse genome build mm9, and the expression count for each gene was 
obtained using Cufflinks (Trapnell et al., 2013) against the Ensemble 
annotation for hg19 and mm9. EdgeR (Robinson et al., 2010) was applied to 
perform significant analysis by comparing different groups (day 0 vs. day 4; 
day 4 vs. day 6) of human ES cell differentiation and (day 0 mTS vs. day 2 
activin, day 0 mTS vs. day 2 activin + SU5402) . The genes with P-value < 
0.01, logCPM>2 and at least two-fold change from edgeR result (logCPM 
means log-transformed gene count per million reads) were defined as 
significant differential expressed genes. 
 
2.16.2. Peak calling and motif discovery in ChIP-seq data  
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Sequence reads were aligned to the human genome (hg19) using 
bowtie (Langmead et al., 2009) (v0.12.9) and the settings ‘–best –y –m 500 –p 
2 –nomaqround’. Peaks discovery was performed using first Dfilter (Kumar et 
al., 2013) using the settings ‘-bs=50 –ks=20 –refine –nonzero –std=5’ for the 
GCM1 ChIP-seq. For the AP2A peaks a very relaxed significance level ‘-
std=3’ was used to collect the initial superset of peaks. Then Manorm (Shao et 
al., 2012) was used to merge replicate peaks and only peaks with an abs(M) < 
1.0 and A > 2.0 were kept. Peaks were ranked by either their enrichment score 
from Dfilter or by their ‘A’ from Manorm. Motif discovery was performed 
using HOMER (Heinz et al., 2010) and all other bioinformatics analysis was 
performed using glbase (Hutchins et al., 2014). For H2K27ac and H3K4me3 
zero-mean filter of width 6kbp and 10kbp were used respectively. For 
clustering H3K27ac peaks only those peaks were used which had P-value less 
than 1E-5 and fold enrichment of at least 4, as provided by DFilter. Enhancers 
were defined as those H3K27ac peaks, which were not within 2.5kbp of TSS 
of UCSC Known genes and RefSeq genes. Initial enhancers and promoters 
clustering was performed using Chip-seq data from 5 cell lines which 
provided the set of enhancers unique to trophoblast cells.	  	  	   
 
 
2.16.3. Repeat (LTR) finding in RNA-seq and ChIP-seq data 
 
Repeat coordinates were downloaded from the UCSC genome browser 
for hg19 (repeatMasker). Only LTR repeats were used for the analysis. 
Overlapping or nearby regions (within 20bp) that belong to the same repeat 
(repName) were merged prior to the analysis. Gene annotations were 
downloaded from Ensemble (gtf, v69) and exons, introns and transcription 
start sites (TSS) were extracted from that file. Read counting, normalization, 
and estimation of differential expression was done using DESeq2 (Love et al., 
2014). Only repeats that had at least an average read count of 5 for at least one 
group (D0, D6) were retained Differential expression of repeat classes was 
done using a paired t-test and a paired Wilcoxon test on the mean normalized 
expression values for D0 and D6. 
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2.16.4. Finding positively selected genes and calculation of non-
synonymous to synonymous substitution for CGA  
 
To identify those genes under positive selection in the primitive 
syncytium in the primate lineage, primitive syncytium gene-set was 
overlapped with a published data set of positively selected genes in six 
mammalian species (Kosiol et al., 2008). With this method a very strict list 
presented in Table 3.4 was identified which contains those genes, which 
passed at least one test after multiple corrections. One of the interesting genes 
in this list is CGA. The rate of non-synonymous to synonymous substitution 
rate (dN/dS ratio, omega) for CGA gene was calculated by employing a 























Chapter 3: Results - 
 








3.1. Establishing a model for human primitive syncytium formation  
 
From a comparison of all published human ES cell differentiation 
protocols directed towards the trophoblast lineage, I realized there was no 
explicit comparison of these to the in vivo equivalent trophoblast cell type. 
The general terms ‘trophoblast-like’ and ‘trophoblast lineage’ have been used 
for describing the product of these differentiation systems. As the purpose of 
my study was to perform downstream functional studies on primate-specific 
features of human primitive syncytium, my initial aim was to establish an in 
vitro model that recapitulated primitive syncytium formation. I did this by 
using growth factors and inhibitors characterized in the earlier studies in 
addition to including two chemical compounds that I chose myself to be used 
in the context of human ES cells differentiation toward syncytiotrophoblast 
lineage. Since, to date, there has been no success at maintaining human 
trophoblast stem cells for extended in vitro culture, this ruled out the 
possibility of beginning my differentiation from such cells. Instead, I resorted 
to human ES cells to establish a dynamic cellular differentiation system to 
primitive syncytium.  
I reasoned this protocol had to be in two steps to recapitulate what 
occurs in vivo: the first step directing the cells to a trophoblast progenitor-like 
state and then in step two, directing these trophoblast progenitor-like cells to 
primitive syncytium. Published protocols clearly indicate by using BMP4 and 
a combination of FGF and TGF-beta inhibitors (Amita et al., 2013) (Sudheer 
et al., 2012) human ES cells can be differentiated to the trophoblast lineage 
within four days of treatment. I hypothesized that, if exposed to the 
appropriate signal, these ‘trophoblast progenitors’ would be able to 
differentiate further to the syncytiotrophoblast lineage. 
From the body of literature on directing choriocarcinoma cells to form 
syncytiotrophoblast there is evidence that the cAMP (Muroi et al., 2009) and 
WNT (Matsuura et al., 2011) pathways are involved. I sought to confirm this 
in my hands and therefore set up an experiment using two different human 
choriocarcinoma cell lines (JEG3 and BEWO) to measure their responsiveness 
to cAMP and CHIR99021 (a WNT agonist functioning through inhibition of 
the GSK3 pathway). Induction of syncytiotrophoblast was measured by the 
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expression (real-time PCR) of classic markers of this lineage. 
 
 
Figure 3.1.Induction of syncytiotrophoblast markers by cAMP and the Wnt agonist CHIR. 
RT-qPCR of indicated trophoblast markers in JEG3 and BEWO cells after stimulation with 
CHIR and cAMP. The values are fold change of delta delta CT normalized to GAPDH and 
control (untreated) samples. 
 
In this experiment, I selected two concentrations of CHIR99021 (low, 
3 µM and high 10 µM) to test, and a single concentration of cAMP (500 µM) 
as was chosen based on the earlier works on the effect of cAMP on 
trophoblast differentiation(Ogura et al., 2000). 
 
Surprisingly, I observed the WNT agonist (CHIR) did not induce an 
increase in expression of syncytiotrophoblast markers as compared to the 
untreated control in both the JEG3 and BEWO cell lines (Figure 3.1). This 
observation was in contrast to the result of Matsuura et al., which showed the 




















Condition A B C D E F G H
CHIR 3uM - + - - - + - -
CHIR 10uM - - + - - - + -
cAMP 500uM - - - + - - - +
Cell line Bewo JEG3
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2011). cAMP however showed strong induction of all syncytiotrophoblast 
markers (CGA, GCM1, PGF, HSD3B1, and HERV-FRD) tested in both JEG3 
and BEWO cell lines (Figure 3.1). Rather than pursuing the discrepancy I saw 
with the WNT agonist between my data and that in the literature, I chose to 
next test the ability of cAMP to induce syncytiotrophoblast in human ES cell-
derived progenitors since here I had confirmed its ability to robustly do this in 
JEG3 and BEWO choriocarcinoma cell lines. 
Prior to treatment of human ES cell-derived trophoblast progenitors 
with cAMP, I first established the protocol to derived these progenitors from 
undifferentiated human ES cells following published works (Amita et al., 
2013; Sudheer et al., 2012) with modification in the concentration of BMP4. I 
used 100 ng/ml BMP4, 20µM FGF inhibitor, and 10µM TGF-beta inhibitor 
for the first step of differentiation. 
To determine the length of treatment for induction with cAMP, four 
days of treatment with cAMP was performed, as shown in Figure 3.2, 
syncytiotrophoblast markers such as PGF, CYP19A1 and CYP11A1 are 
stimulated to the highest level after 48 hours of initial induction with cAMP 
and remain constant or down-regulated until day 8. However, there are some 
markers, specifically the transcription factors GCM1 and GATA3, with highest 
expression at day 5 with a subsequent decline by day 6. This suggests that 
these TFs are transiently required for syncytial formation, perhaps not required 
for maintaining syncytiotrophoblast but required to initiate the formation of 
these cells. On the other hand, there are some markers like CGA and HSD3B1, 
which continuously increase in expression until day 7. Collectively, from all 
the above markers and the morphological observation I decided to select day 6 
as the final day of syncytiotrophoblast differentiation, the first four days with 
BMP4 in combination with two inhibitors (FGF inhibitor and TGF-beta 
inhibitor) and the last 48 hours with cAMP included (Figure 3.2).  
Subsequently, the measurement of hCG secreted into the media combined 
with the dynamic expression of the CGB genes (detected by microarray) 
confirmed that day 6 is indeed producing a functional syncytiotrophoblast.	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Figure 3.2.Time-course of differentiation of human ES cell to syncytiotrophoblast with 
combinatory treatment of BMP4, FGF inhibitor, and TGF-beta inhibitor until day 4 and then 
addition of   cAMP until day 8. Expression of different trophoblast marker was measured by 
RT-qPCR, the values are fold change of delta delta Ct normalized to GAPDH and control 
(human ES cells at day 0). 
  
 
Next was to determine the minimum concentration of cAMP for this 
syncytiotrophoblast induction in the context of human ES cell differentiation, 
concentrations of cAMP described in the literature range from 150µM and 
500µM (Ogura et al., 2000), I chose the minimum and maximum of this range 
to test in my differentiation system. As shown in Figure 3.3 both 
concentrations are stimulating equivalent expression of important markers 
such as CGA, GCM1, PGF, HSD3B1, HERV-FRD, HSD17B1, and CYP19A1, 









































































































































































Figure 3.3. Effect of two concentrations of cAMP on human ES cells differentiation to 
syncytiotrophoblast. Expression of trophoblast markers was measured by RT-qPCR at day 6 
of differentiation in two concentrations of cAMP (150uM and 500uM) for 48 hours. The 




One of the important factors in all differentiation protocols is to 
identify the best condition of basal medium for differentiation, in this work 
three different basal medium were tested: KOSR, N2B27, and APEL. As 
shown in Figure 3.4 with the use of above mentioned differentiation cocktail 
(cAMP plus two inhibitors (FGF and TFG-beta) and BMP4) for important 
markers, KOSR showed the best performance among the three basal medium 
across two human ES cell lines (H1 and HES3) with respect to differentiation 














































Figure 3.4. Optimization of basal medium for differentiation of human ES cells to the 
syncytiotrophoblast . Detection of expression of trophoblast markers by RT-qPCR at day 6 
with three basal mediums, APEL, KOSR and N2B27. The values are fold change of delta 
delta CT normalized to GAPDH and control (human ES cells at day 0) 




To directly compare the current differentiation protocol with other 
published protocols directing human ES cells to the trophoblast lineage, three 
cocktails of differentiation medium were tested as follow to be checked by 
qPCR for important trophoblast markers: BMP4 + SU5402 (Sudheer et al., 
2012), BMP4 + SU5402 + SB (Amita et al., 2013) and BMP4 + SU5402 + SB 
+ cAMP (this work). As shown in Figure 3.5 markers of the trophoblast 
lineage including GCM1, PGF, CYP19A1 and HSD3B1 at day 6 of 
differentiation (after 48h of induction with cAMP) have higher expression in 
















































































































Figure 3.5.	  Comparison of different differentiation protocols  from human embryonic 
stem cell to trophoblast lineage. [(A) Sudheer et al., 2012 (B) Amita et al., 2013 and 
(C) this work]. Expression of trophoblast markers was measured by RT-qPCR during 
the course of differentiation from day 2 to day 8. The values are fold change of delta 
delta Ct normalized to GAPDH and control (human ES cells at day 0)	  	  
The data in Figure 3.5, indicates the protocol which is established in 
this work generally stimulates higher level of expression of the 
syncytiotrophoblast markers compared to the other two methods, this is most 
notable from day 4 (the point of inclusion of cAMP) onwards. GCM1 
considered a driver of syncytiotrophoblast formation is most notably activated 
within 24 hours of cAMP stimulation, and subsequently decreasing while 
other syncytiotrophoblast markers, some known GCM1 targets, increase from 
day 5 to day 6 of differentiation. To check the extent of functionality of the 
cells at day 6, hCG as one of the important markers of a functional 
syncytiotrophoblast has been measured. As shown in Figure 3.6.c., there is a 
significant increase in the hCG secretion in the protocol established in this 
work compared to other published protocol. This secretion is notable only 
after day 4 of differentiation; secretion of hCG from the cells shows 
functionality of the end-differentiated cells and also the efficiency of the 
Compound/Condition A B C
BMP4(100 ng/ml) + + +
SU5402(20uM) + + +
SB431542(10uM) - + +
















































































protocol. Raw signal from a microarray time course experiment (Figure 3.6.a.) 
also confirms a significant increase from day 5 to day 6 transition in 
expression of the CGB genes (CGB, CGB1, CGB5, CGB8) and CGA after 
induction with cAMP. Moreover, this increase in CGB expression from day 4 
to day 6 in the in vitro differentiation is similar to CGA and CGBs up-
regulation found in the morula to blastocyst transition in the human embryo 
(Figure 3.6.b). 	  
	  
Figure 3.6. Expression of CGA and CGBs and secretion of HCG in the primitive syncytium 
and human embryo.(a) Expression of CGA and CGB genes at transcriptome level from 
microarray data of human ES-derived primitive syncytium at different days of differentiation. 
(b) Expression of CGA and CGB genes at transcriptome level from microarray data of human 
embryo [extracted from Zhang et al, 2009] (c) measurement of HCG from supernatant of 
culture conditions of different differentiation protocols: BMP4 (Xu et al., 2002); BMP4 + 
FGF inhibitor (SU) (Sudheer et al., 2012); BMP4 + FGF inhibitor (SU) + TGF-beta 
inhibitor (SB) (Amita et al., 2013); BMP4 + FGF inhibitor (SU) + TGF-beta inhibitor (SB) + 
cAMP ( this work). 
To test if this differentiation protocol is replicable and efficient across 
different lines of human ES cells, microarray data was generated by three 
human ES cell lines (H1, H7 and HES3) differentiated with this protocol at 4 
time points (day 0, 4, 5 and 6). The PCA clustering of microarray data in 
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Figure 3.7.a shows all three cell lines are behaving in the same pathway of 
differentiation. Moreover, hierarchical clustering of these cells at day 0, 4 and 
6 (Figure 3.7.b) confirms this pattern of gene expression with a significant 
changes from day 4 to day 6 of differentiation.	  
	  
Figure 3.7.	   Consistent trophoblast differentiation across three independent human ES cell 
lines. Microarray data was generated from three human ES cell lines (H1, HES3 and H7) at 
four time points time (0,4,5,6) of differentiation towards the syncytiotrophoblast lineage. (a) 
Represented is a PCA plot, generated using the Partek genomic suite software with all 
expressed genes. (b) Hierarchical clustering of three time points, days (0,4,6) of differentiation 
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towards the trophoblast lineage. Hierarchical clustering plot, generated using the Partek 
genomic suite software with all expressed genes with raw signal value of more than 100 
For the validation of this microarray data, the following markers in 
Figure 3.8 were checked by qPCR in two of the cell lines (H1 and HES3). The 
result from qPCR confirms the microarray expression data. 
	  
Figure 3. 8. Validation of important markers of trophoblast across two human ES cell lines by 
RT-qPCR. Expression of trophoblast markers by RT-qPCR was measured with the established 
protocol in this work over the course of 6 days of differentiation. The values are fold change 
of delta delta Ct normalized to GAPDH and control (human ES cells at day 0). 
 
The ultrastructure of these syncytiotrophoblast cells, as determined by  
transmission electron microscopy (TEM), shows similarity of the in vitro 
syncytiotrophoblast (Figure 3.9.c) to primitive syncytium in the polar 
trophectoderm of the primate embryo (Figure 3.9.a)  Moreover, in contrast to 
the undifferentiated human ES cells (Figure 3.9.b). Light microscopy also 



































































































































































































































of syncytial formation, cells are ranging from one to up to ten nuclei can be 
seen in the dissociated cells (Figure 3.9.d). 
	  
Figure 3.9. Ultra-structural similarity between primate primitive syncytium and human ES-
derived primitive syncytium. (a) Micrograph of preimplantation baboon embryo at blastocyst 
stage. The syncytial trophoblast (str) is distinguished by multiple nuclei and large vacuoles, 
from Enders et al (Enders et al., 1997) (b) Micrograph of human ES cell with compact nucleus 
and cytoplasm. (c) Micrograph of human ES-derived syncytium with multiple nuclei and large 
vacuoles. (d) Syncytiotrophoblast at different stage of syncytium formation with different 
number of nuclei from dissociated samples at day 6 of differentiation. 
 
Overall the data from qPCR, microarray and hormone measurements 
have suggested that day 6 of this differentiation represents a cell population in 
the process of forming an actual syncytiotrophoblast state representing 
primitive syncytium. It is at this stage that I chose to analyze cells for further 
downstream functional analysis.  
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Figure 3.10.	   Schematic representation of human ES differentiation to syncytiotrophoblast 
lineage, a model for recapitulation primitive syncytium formation 
 
 
For the downstream functional studies, KOSR was selected as the basal 
medium of choice with the combinatorial treatment of BMP4 plus two 
inhibitors (FGF and TFG-beta inhibitor) for four days and then addition of 
cAMP for another 2 days. This two-step differentiation protocol as shown 
schematically in Figure 3.10 is recapitulating in vivo formation of primitive 
syncytium. The cells first commit to a trophoblast progenitor-state and then 
after induction with cAMP the cells are pushed toward the syncytiotrophoblast 
lineage. This system is a good model for addressing biological questions of 




Figure 3.11. Hierarchical clustering of differentially expressed genes from mRNA-seq of 
human ES-derived syncytiotrophoblast. Differentially expressed genes from human ES-
derived syncytiotrophoblast from different time points of differentiation in two human ES 
lines (H1 and HES3) was calculated by edgeR for each pair of samples (described in the 
method). The hierarchical clustering is generated from differentially expressed gene of pairs 
of samples as follow, day 0 vs. day 4, day 0 vs. day 6, and day 4 vs. day 6. Plots were 
generated with Partek genomic suite software. 
 
 
For a comprehensive characterization of the transcriptome of these 
cells and addressing the central questions of the project related to molecular 
evolution of primitive syncytium, in the first step, I generated mRNA-seq data 
on day 0, 4, and 6 of this differentiation system in two human ES cell lines 
(H1 and HES3). The hierarchical clustering of the data from microarray data  
(Figure 3.11) indicates similarity between the two cell lines at each of the 
three stages. It also provides evidence that both cells lines are responding 
robustly to the differentiation protocol with hundreds of differentially 
expressed genes. Looking at important pluripotency, primitive streak, 
ectoderm, endoderm and mesoderm markers from the RNA-seq data 
(Fig.3.12.a) shows there in no expression of these markers at day 4 and 6 of 
differentiation while many key trophoblast markers are significantly up-
regulated over the same period (Fig.3.12.b). Some of these non-trophoblast 
makers, including T and EOMES, have been shown to be expressed in BPM4-
induced human ES cell differentiation by others (Bernardo et al, 2011) but in 
my differentiation system, which includes three human ES lines, I did not find 
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any expression of any of these markers. This confirms there is no mixed 
population of other cell types in the differentiation system I developed. 
 
 
Figure 3.12.	   FPKM values from RNA-seq data of human ES differentiation to primitive 
syncytium at day 0, day 4 and day 6 of differentiation (a) FPKM values of pluripotency, 
primitive streak and three germ layers (ecto/meso/endoderm) at day 0, day 4 and day 6 of 
differentiation. (b) FPKM values of syncytiotrophoblast markers at day 0, day 4 and day 6 of 
differentiation. 
One of the challenges in studying human trophoblast biology is the 
lack of availability of a human trophoblast stem cell-derived from the in vivo 
source and maintained in vitro. The main challenge comes from the fact that 
there is no clear and verified marker for purifying of these stem cells from in 
vivo or in vitro sources. As described earlier my differentiation system has a 
dynamic transition from trophoblast progenitor-like cells (day 4) to a 
syncytiotrophoblast state (day 6), therefore one of the questions which can be 
addressed immediately by this system is finding potential markers of the 
human trophoblast stem cells and also human primitive syncytium markers. 
Identification of these markers will improve our understanding of the markers 
for isolation of the true cell populations from in vivo material for further 
functional studies. 
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3.3. Identification of human trophoblast stem (TS) cells markers 
 
For identification of trophoblast stem cell markers, I considered the 
following criteria: the gene should not have any expression at day 0 (human 
ES cells), the gene should be significantly expressed at day 4 (fold change 
more than 2 and P.value >0.05), and upon induction with cAMP until day 6 
there should either be no change (constant) or a decrease in expression 
compared to day 4. Applying the above-mentioned filter to the mRNA-seq 
data of human ES differentiation system, I have generated a gene list I believe 
would be enriched in human trophoblast stem cell markers (Supplementary 
Table 3.1).  
 
One of the questions not yet addressed is how cAMP is working as a 
signaling molecule to induce the formation of primitive syncytium in vivo in 
the context of embryo implantation. Since our syncytiotrophoblast model is a 
dynamic model, we can ask what might be a player(s) in this syncytialization 
event from establishing primitive syncytium to maintenance of this 
syncytiotrophoblast structure. 
 
Figure 3.13. Proposed model of formation primitive syncytium and maintenance syncytium. 
(a) Intersection of human trophoblast stem cell (TS) markers with GPCR family members 
(Paavola and Hall, 2012) (b) Expression pattern of CCKBR and GAST in human ES-
derived primitive syncytium at different days of differentiation. The Venn diagrams are 
generated by Venny (Oliveros, J.C., 2007). 
 
One of the gene families implicated in regulating cAMP levels inside 
the cell is the GPCR family members (Paavola and Hall, 2012). Several 
members of this 7 span membrane protein family are expressed in primitive 
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syncytium, However if we are about to identify only those GPCRs family 
members which might be involved in the syncytialization of human 
trophoblast stem cells and early formation of primitive syncytium, CCKBR is 
the only candidate GPCR which is expressed at this stage (Figure 3.13.a). The 
importance of this GPCR is that, the endogenous signaling ligand for CCKBR, 
gastrin (GAST), is shown to be expressed in the receptive endometrium during 
the window of implantation (Giudice, 2006; Altmäe et al., 2012). This raises 
the possibility that GAST from the endometrium in the in vivo condition of 
human embryo implantation is the endogenous signal that initiates the 
formation of primitive syncytium. Since syncytialization is a continuous 
process throughout pregnancy, as the syncytial layer needs constant 
contributions to replace loss into maternal blood by syncytial knotting, it is 
interesting to note that GAST is also expressed in the primitive syncytium 
(Figure 3.13.b). Thus, a hypothesis that would be interesting to follow up from 
my work is this GAST-CCKBR signaling access as the syncytialization signal. 
The initial inductive signal, to induce the initial syncytialization within the 
blastocyst, coming from the endometrium at implantation, and subsequent to 
this the GAST inductive signal then originates from the syncytiotrophoblast 
itself.  
3.4. Identification of human primitive syncytium (Pr.synT) markers 
 
For the identification of primitive syncytium markers all genes which 
are differentially expressed at day 4 to day 6 transition with minimum FPKM 
value of 10 at day 6 for both cell lines, genes within this list, entitled 
‘primitive syncytium gene-set’, are the focus in the following sections for 
analysis on the evolution of coding sequence and transcriptional regulation. 
The entire list with the associated expression (i.e. FPKM) values for both the 




3.5. Establishment of mouse trophoblast differentiation to 
syncytiotrophoblast 
 
For having a biological counterpart of the human syncytiotrophoblast 
in the mouse for evolutionary comparisons at transcriptome level, mouse 
trophoblast stem (TS) cells were used for establishing a differentiation 
protocol to the syncytiotrophoblast lineage. Activin has been used for the 
induction of mouse TS cells to syncytiotrophoblast (Natale et al., 2009), 
however replication of this protocol in my hands indicated the main markers 
of mouse syncytiotrophoblast, namely Gcm1 and Synb, were not significantly 
expressed. I also attempted to reproduce other differentiation protocols from 
mouse ES cells with the use of an HDAC inhibitor (Maltepe et al., 2005) but 
was unsuccessful; the cells were unable to survive under the reported 
conditions. 
Therefore, there was a need to develop a differentiation protocol that 
led to significant expression of syncytiotrophoblast markers in a mouse in 
vitro system. My focus was on identifying a mouse TS cell to 
syncytiotrophoblast system, as TS cells are the in vitro equivalent of the E6.5 
extraembryonic ectoderm and the cells of the extraembryonic ectoderm 
subsequently give rise to Gcm1 and Synb-positive syncytiotrophoblast by E9.0 
(Basyuk et al., 1999). As a known inducer of TS cell differentiation, I used 
activin but also included an FGF inhibitor, SU5402. As FGF signaling is key 
to the maintenance of the undifferentiated TS cell (TS cells are maintained in 
FGF4 supplemented MEF condition medium), I reasoned that inhibiting this 
pathway would contribute to TS cell differentiation. To test this hypothesis, I 
compared trophoblast marker gene expression in activin versus 
activin/SU5402 treated TS cells over five days of culture.  
Indeed, a combination of activin and SU5402 on TS cells led to 
significant differentiation and, specifically an increase in the induction of 
syncytiotrophoblast markers (Figure 3.14) after two days of treatment, Gcm1 
and Synb expression was highest in this combinatorial treatment compared 
with activin alone. Interestingly, this Gcm1 and Synb induction is transient as 
by day three these syncytiotrophoblast markers are down again. It remains 
unexplained why these cells down-regulate syncytiotrophoblast markers. The 
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TS cell markers Cdx2 and Eomes are down-regulated more rapidly in the 
activin/SU5402 compared to the activin alone, being completely down 
regulated within two days, indicating this system is leading to robust 
differentiation. 
 The data from this experiment suggests activin through the TGF-beta 
pathway combined with inhibition of FGF pathway drives the cells toward the 
syncytiotrophoblast. As shown in Figure 3.14, day 2 of combinatorial 
treatment of activin and FGF inhibitor shows the highest expression of 
syncytiotrophoblast markers (Gcm1 and Synb) and the lowest expression of 
TS cell markers (Cdx2, Eomes). Therefore, day 2 (versus day 0) was selected 
to generate mRNA-seq expression data. 
	  
Figure 3.14.	   Differentiation of mTS to syncytiotrophoblast with the use of activin and FGF 
inhibitor. The result shows RT-qPCR of trophoblast markers from mouse TS differentiated to 
syncytiotrophoblast with combinatorial treatments during the course of 5 days of 
differentiation. The values are fold change of delta delta CT normalized to GAPDH and 
control (untreated) samples at day 0. 
mRNA-seq was prepared on two biological replicates of these cells 
from different passages. There are three conditions: mouse undifferentiated TS 
cells (day 0) and two sets of day two samples, one differentiated with activin 


































































































































































Condition D0 A-D2 AS-D2 A-D3 AS-D3 A-D4 AS-D4 A-D5 AS-D5
Day D0
Activin(20 ng/ml) - + + + + + + + +
SU5402(20uM) - - + - + - + - +
D2 D3 D4 D5
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replicates in each of the three samples behave similarly in response to the 
treatment (Figure 3.15.). As was evident from the earlier qPCR data, the 
RNA-seq data also confirmed that combinatorial treatment of activin with 
FGF inhibitor is more efficient at driving the cells toward the 
syncytiotrophoblast compared with activin alone. Expression of a large set of 
genes (including many classic mouse syncytiotrophoblast markers) is much 
higher in the activin/FGF inhibitor compared to the activin alone.  
	  
Figure 3.15. Hierarchical clustering of differentially expressed genes from RNA-seq data of 
mouse TS differentiation to syncytiotrophoblast. The Hierarchical clustering is from the 
samples of, day 0 mTS, day 2 (activin) and day 2 (activin plus SU5402). The plots is 
generated with Partek genomic suite software from differentially expressed genes between 
pairs of samples calculated by edgeR(described in the method) from two biological replicates 
of mTS (with 10 passage difference) for different treatment. 
 
	  
Figure 3.16.	  FPKM values from RNA-seq data of mouse TS to syncytiotrophoblast at day 0, 
day 2 (activin) and day 2 ( activin + FGF inhibitor) for selected markers. (a) Expression of 
syncytiotrophoblast markers. (b) Expression of mouse TS and other lineage markers of mouse 
trophoblast including spongiotrophoblast markers. 
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The hierarchical clustering of the data from RNA-seq data (Figure 
3.15) indicates similarity between two cell lines which provides evidence that 
both cells lines are responding robustly to the differentiation protocol with 
hundreds of differentially expressed genes. Looking at important mouse TS 
markers and spongiotrophoblast markers (Fig.3.16.b) shows there in no 
expression of these markers at day 2 of differentiation with Activin/SU5402, 
while key mouse syncytiotrophoblast markers are significantly up-regulated 
over the same period (Fig.3.16.a).  
 
	  
Figure 3.17.	   Validation of selected markers of mTS cells and mTS-derived 
syncytiotrophoblast. The result shows RT-qPCR of trophoblast markers from mouse TS 
differentiation with combinatorial treatment during the course of 2 days of differentiation to 
syncytiotrophoblast. The values are fold change of delta delta CT normalized to GAPDH and 
control samples (untreated) at day 0. 
 
Validation by RT-qPCR of a few of the markers genes is shown in 
Figure 3.17. As can be seen, syncytiotrophoblast markers (Gcm1 and Synb) 
have the highest expression at day 2 with the combinatorial treatment whereas 
mTS cell markers (Cdx2, Eomes, Esrrb) are at their lowest. The lack of 
expression of Pl1 indicates these cells are not in the direction of producing 






































































































































Genes that are significantly up-regulated upon differentiation include 
important markers of mouse syncytiotrophoblast (m.SynT), these are listed in 
Supplementary Table 3.3. Genes that are significantly down-regulated upon 
differentiation include markers of mouse TS cells; these are listed in 
Supplementary Table 3.4. I will subsequently use these gene lists for 
comparisons between human and mouse trophoblast. Particularly useful is this 
mouse system provides me with a Gcm1-positive syncytiotrophoblast in which 
to compare to my human GCM1-positive syncytiotrophoblast. 
3.6. Comparing Human ES-derived primitive syncytium with human 
trophectoderm (TE) and mouse trophectoderm (TE) 
 
 
Human primitive syncytium forms as early as the blastocyst stage, 
based on the data from the gene expression of the human embryo (Bai et al., 
2011; Zhang et al., 2009) and also histological studies from the early primate 
embryo (Enders et al., 1997). To understand how the human ES cell-derived 
primitive syncytium from my work is similar to the trophoblast within the 
human early embryo (i.e. the blastocyst stage), a global comparison was 
performed between these two cells type. To identify the human trophectoderm 
( Human TE) markers, those genes with two-fold change gene expression 
from morula to blastocyst stage (microarray data from Zhang et al, 2009) were 
selected as the trophectoderm markers. To make sure these early trophoblast 
markers are truly expressed in the human trophectoderm, these genes were 
also crosschecked with the data from Bai et al., 2011, where they performed 
microarray on the microdissected trophectoderm from the human blastocyst. 
The primitive syncytium gene-set (Pr.synT) in this comparison is from 
Supplementary Table 3.2, which was described in the earlier section. 
The mouse pre-implantation embryo expression data set was generated 
by RNA-seq (RPKM value) (Lili SUN, Guoji Guo and Wishva Herath in the 
Robson lab) and represents the fold up-regulation from the 8-cell embryo to 
the blastocyst (d3.75). 
 This comparison of human TE, mouse TE and the primitive syncytium 
gene-set (Pr.synT) are shown in Figure 3.18. This shows there are significant 
 64	  
similarities between the trophoblast within the blastocyst and human ES-
derived primitive syncytium. This comparison also indicates that there are 
significant differences between human and mouse systems, genes shown in 
gray in Figure 3.18 are absent in the mouse at this developmental stage.  
The observation of this significant difference between human and 
mouse trophoblast of blastocyst stage was the first indication that I might be 
comparing different developmental stages of syncytiotrophoblast between 
these species. Syncytiotrophoblast in the mouse does not form until E8.5, 
within the placental labyrinth and long after the blastocyst stage, 4 days after 
implantation and 2 days after gastrulation. To differentiate between 
syncytiotrophoblast genes shared between mice and human from those that are 
unique to human, I used the following strategy. First, I identified all genes 
shared between human primitive syncytium and human TE but not present in 
the mouse TE (Figure 3.19.a). This results in a list of 136 genes, which I 
define as primate-specific primitive syncytium (Ps.Pr.synT) (Supplementary 
Table 3.5). This list would exclude any gene shared between human and 
mouse TE but contain primate-specific genes that are expressed in primitive 
syncytium. The next filter aimed to identify genes that are shared between 
human and mouse syncytiotrophoblast. For this the Ps.Pr.synT gene list was 
compared to m.synT (Figure 3.19.f). This comparison revealed 15 genes 
(Figure 3.19.g) shared between human primitive syncytium and mouse 
syncytiotrophoblast, and this enriched in transcription factors (GCM1, TEAD3, 
VGLL1, DLX3, CDKN1C, CEBPB). This provides an explanation for the early 
appearance of syncytialization in the human TE lineage - the early expression 
of these transcription factors would lead to early expression of hundreds of 
genes through these TF’s downstream regulatory networks. This drastic 
change in the regulatory network of early human TE can install a new gene 
regulatory network, resulting in the formation of the primitive syncytium in 
the primates, which in effect will change the characteristic of early primate 







Figure 3.18.	   Heatmap comparing expression data from human TE, mouse TE and hES-
derived primitive syncytium (Pr.synT.). The human embryo data is from the microarray data 
from Zhang et al, 2009, genes with two-fold change gene expression from morula to 
blastocyst stage (microarray data from Zhang et al, 2009) were selected as the human TE 
markers and crosschecked with the data from Bai et al., 2011, where they performed 
microarray on the micro-dissected trophectoderm from the human blastocyst. The primitive 
syncytium gene-set (Pr.synT) in this comparison is from Supplementary Table 3.2, which was 
described in the earlier section.. Mouse data set is the fold change of RNA-seq data (RPKM 
value) (Lili SUN, Guoji Guo and Wishva Herath) from mouse blastocyst (d3.75) over 8 cells 
stage. All fold changes were first compiled across the different datasets for each individual 
genes, sorted by the human TE genes form most up-regulated genes. Hierarchical clustering 
was done using Cluster® and visualized by Treeview®. In the graph gray means the gene is 























































































3.7. Comparing Human ES-derived primitive syncytium with villous 
trophoblast and mouse syncytiotrophoblast  	  
The next question is how this primitive syncytium is similar to 
definitive syncytium found in the chorionic villi of the mature human 
placenta, the so-called villous syncytiotrophoblast (VT). To address this 
question Ps.Pr.synT was compared with human TE and villous trophoblast 
(VT), the VT data was extracted from the Apps et al (Apps et al., 2011). As 
can be seen in the Ps.Pr.synT gene list, there are 23 genes that are not present 
in VT, but present in human TE and human ES-derived primitive syncytium 
(Figure 3.19.c). The expressions of some of these markers are shown in Figure 
3.19.d and Figure 3.19.e. As can be seen the human ES-derived primitive 
syncytium markers like PRR9, MRGPRX1 and FOXO6 show high expression 
only in primitive syncytium and human TE and not in VT and morula. On the 
other hand some of the markers are shared between primitive syncytium and 
VT such as GCM1, HSD3B1, and ERVWE1, indicating these as more 
universal markers of trophoblast syncytialization. 
 
This comparison emphasizes the similarity of the human ES cell-
derived primitive syncytium to the TE from the human blastocyst. The TE  
data, while not actually primitive syncytium as this forms just as the blastocyst 
begins to implant, is the closest in vivo data available for comparison as it 
would be virtually impossible to collect human implanting embryos for data 
generation. While not a precise comparison, it represents the closest 




Figure 3.19.	   Human ES-derived primitive syncytium is similar to early human trophoblast 
and not villous trophoblast. (a) Generation of primate-specific primitive syncytium gene list 
(Ps.Pr.synT) by intersection of human primitive syncytium markers with human TE markers 
and excluding mouse TE markers  (b, c) Generation of the gene list that is shared between 
human primitive syncytium and human TE but not human VT. (f) Generation of gene list that 
is shared between human primitive syncytium and mouse syncytiotrophoblast. (d,e) Stage-
specific markers of human ES (D0), primitive syncytium, human morula, human TE and 
human VT. The Venn diagrams are generated by Venny (Oliveros, J.C., 2007). 
Up to this stage I developed two novel differentiation protocols, one 
from human ES cells to primitive syncytium and the other from mouse TS 
cells to mouse syncytiotrophoblast. Further in-depth analysis of these cells 
with respect to functional and biological differences between human and 
mouse syncytiotrophoblast will be explored in the following chapters.  The 
primitive syncytium is a unique cell type in the body as they are in the 
forefront of the contact between mother and fetus and involved in early 
implantation events; therefore the insight from this evolutionary comparison 
will be useful to have a clear understanding of the evolutionary transition 
between species and also species-specific features of these cells. A gene-set of 
primitive syncytium markers (shown in Supplementary Table 3.2) 
representing up-regulated genes between day 4 to day 6 has been generated. 
This list represents the core set of primitive syncytium genes that will be used 















Chapter 4: Results - 
Identification of primate-specific features of 
















As described in the Introduction, the molecular mechanisms involved 
in the emergence of the new function in a tissue can be categorized into two 
major themes:  
1) Emergence of new coding sequence and, 2) the alteration of expression, 
leading to an old gene being expressed in the new tissue through changes in 
cis-regulatory elements or a associated transcriptional machinery (i.e 
regulatory change).  
The approaches I used for identifying such primate-specific changes 
altering human primitive syncytium biology, and the results from these 
approaches, are presented in this chapter.  The approaches include the analysis 
of the mRNA-seq generated from human ES-derived primitive syncytium, 
specifically focusing on the primitive syncytium gene-set and ChIP-seq on 
important transcription factors and histone modification marks performed on 
these cells. I will highlight specific examples of each regulatory module 
leading to primate-specific gene expression and functional changes within the 
primitive syncytium gene-set. 
 
4.1. Novelty through emergence of new coding sequence:  
 
New protein coding sequence can emerge through gene duplication, 
through the alteration of existing protein-coding genes (i.e. positive selection 
on amino acid residues), and through the co-option of coding sequence from 
another genome (i.e. horizontal transfer), co-option of viral envelope proteins 
has repeatedly occurred in the mammalian placenta. Here, I analyze the 
primitive syncytium gene-set with respect to protein coding sequence changes 
in light of these three mechanisms. 
4.1.1. Gene duplication  
 
There are two well-known cases where gene families have been 
expanded through duplication leading to primate-specific placental function. 
These are the CGB and LGALS families, and both are dynamically up- 
regulated in human ES-derived primitive syncytium model. 
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 The human CGB family consists of 6 members CGB, CGB1, CGB2, 
CGB5, CGB7, and CGB8. These formed through an initial duplication of LHB 
approximately 40 mya and continued to expand further with duplications 
thought to have occurred most recently as 5 million years ago (mya) (Maston 
and Ruvolo, 2002). The encoded protein forms the beta peptide (the alpha 
peptide is from CGA) for human chorionic gonadotropin (HCG), a hormone 
expressed in the primitive syncytium that is absolutely essential for the 
establishment and maintenance of primate pregnancy beyond the first week of 
post-implantation development. HCG is first expressed in the peri-
implantation blastocyst (Butler et al., 2013) and is detectable in maternal 
blood and urine within days after implantation providing the foundation for 
the pregnancy test.  
I have already shown the production of HCG in the human ES-derived 
primitive syncytium (Figure 3.6.c), with the mRNA-seq data the dynamics and 
gene-specific expression within the CGB locus can be explored (Table 4.1). 
As can be seen, the expression of all the CGB family members at the RNA 
level can be detected only after stimulation with cAMP. In terms of the 
individual CGB gene expression, there are six, the mRNA-seq data indicates 
that CGB5 with FPKM value of 3050.9 has the highest expression in these 
family, the reads from the LHB locus is around 10 FPKM which is likely a 
result of homologous reads generated from the CGB loci mapping to this gene 
rather than any indication that LHB is expressed, and the reason for this 
argument is that, there is no expression of exon one of LHB, this reason may 
apply to CGB1 and CGB2 as there is no expression of exon one for these two 
genes although in total we have a report of expression based on exon 2 and 3 
(Figure 4.1) As can be seen all of the CGB family have similar expression 
pattern, which suggest they are similarly regulated at the transcriptional level. 
 
Figure 4.1. Expression of GGB genes in human ES-derived primitive syncytium across CGB 
genes and LHB locus, total number of tags from RNA-seq data of day 6 of differentiation of 
human ES to syncytiotrophoblast is shown in this plot. 
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Table 4.1. FPKM values of different family of CGB genes 
Gene FPKM(D0) FPKM(D4) FPKM(D6) 
CGB5 0.1 0.8 3050.9 
CGB8 0.2 1.6 1082.3 
CGB 0.6 4.1 1897.4 
CGB1 0.4 3 393.1 
CGB2 0.6 1.1 155.8 
CGB7 0.3 0.9 71 
 
 
While the function of the LGALS family is just beginning to be 
understood, it is known that LGALS13, LGALS14 and LGALS16 are 
expressed on the apical surface of syncytiotrophoblast at the fetal-maternal 
interface (Than et al., 2009). It has been suggested these LGALS family 
members are involved in immune modulation by the suppression of maternal 
NK cells in the decidua (Than et al., 2009). My mRNA-seq data (Table 4.2) 
shows the expression of LGALS, which is absent in human ES cells, is up-
regulated significantly at day 6 of differentiation. 
 
Table 4.2. FPKM value of LGALS family members 
Gene FPKM(D0) FPKM(D4) FPKM(D6) 
LGALS16 0.2 50.9 712.5 
LGALS13 0 2.6 64.6 
  
One of the interesting facts about this cluster of genes is that it is only 
present in primates and not any other species, this emphasizes the fact that 
there are major changes through emergence of new genes in the primate 
placenta which have been involved in the maintenance of primate pregnancy.  
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4.1.2. Positive selection through non-synonymous point mutation 
 
Positive selection on amino acid residues within existing genes can be 
determined by a measure of the non-synonymous to synonymous mutation 
rate, a measure of nucleotide mutations changing amino acid sequence versus 
those within the coding sequence not altering the encoded amino acid. To test 
this hypothesis, the primitive syncytium gene-set was analyzed in this context. 
Using a published data set determining the rate of change in six 
(human/chimp/macaque/dog/mouse/rat) mammalian species (Kosiol et al., 
2008), I found there are several genes that are under positive selection in the 
primate lineage. The very strict shortlist only includes genes that passed one 
test after multiple corrections. This list of primitive syncytium genes under 
positive selection, along with their corresponding expression values from the 
human ES cell to primitive syncytium is presented in Table	  4.	  3.	  	  
 
Table 4. 3 List of genes that are under positive selection in Primitive Syncytium 
Gene D0(FPKM) D4(FPKM) D6(FPKM) allbranches_pvalue 
ADAMTS20 2.3 2 37.6 0.26997 
CCDC59 1.4 19.1 20.6 0.00102 
CD46 0 8.8 89.2 2.84E-05 
CD59 38.1 81.3 379.1 0.00082 
CGA 7 1223.8 37481 1 
CSF2RB 0 0.2 13.5 0.00034 
HSPA1B 15.1 42.8 207.8 0.00012 
HTRA4 0 2.4 63.3 5.6E-06 
MPZL1 25.8 171.3 232.1 0.2118 
SLC30A1 3.5 9.4 34.3 0.00028 
TPRXL 0 0.8 23.5 1.33E-06 
TREM1 0 8.2 161.5 4.84E-07 
 
 
One of the interesting targets in this list is CGA; this gene is required 
for dimerization with CGB genes to make the HCG hormone in the placenta. 
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The expression of this gene is the most abundant gene in terms of FPKM at 
day 4 and 6. CGA is the peptide hormone which essential for dimerization 
with LH and also FSH, the timing of this positive selection is matched with 
duplication of CGB in primate which emphasize the possibility of the 
functional effect of this change and selective pressure in primate lineage for 
this gene, this would be further discussed in the next chapter.  
 
4.2. Novelty through contribution of ERVs/LTRs as exonic coding 
sequences or exonic cis-regulatory elements (TSS, the first exon, and 5´ 
UTR)  
  
4.2.1.ERVs act as coding sequence  
 
To identify the exonic regions that are contributed by ERV/LTRs, first 
the annotated genes from the Ensemble gene set which are known to be the 
result of ERVs and are found in primitive syncytium gene-set were identified 
some of the members are shown in Table 4.4. The functions of these genes 
have been shown to be important in sycytiotrophoblast formation (Mi et al., 
2000) as well as immune suppression in the endometrium in primate and 
human pregnancy (Bouallaga et al., 2007). 
	  
Table 4.4. Expression of annotated ERV family in Ensemble gene list 
Gene FPKM(D0) FPKM(D4) FPKM(D6) 
ERVV-1 0.2 36.9 560.2 
ERVW-1 0.1 20.7 349.3 
ERVFRD-1 0 22.5 196.5 
ERVV-2 0.2 44.9 364 
 
 
Then the question was if there is any new ERV-derived coding 
sequences which have not been identified in the normal RNA-seq pipeline, 
for this reason the RNA-seq data was intersected with repeat masker with the 
focus on identifying ERV-derived CDS which overlapped with the human 
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Ensemble gene set. This was to find the repeats in proximity to the coding 
sequence. The identified loci were manually checked on the UCSC browser 
to see if the level of the raw signal from the locus is sufficient to be 
considered above background. From this annotation, two groups of exons can 
be discovered: first/alternative exons and CDS sequences or novel transcripts 
derived from ERVs. The result from top families based on the highest 
expression of each locus is summarized in Supplementary Table 4.1. 
 
Figure 4.2.	  Expression of GAG transcript (AK127846) adjacent to ERVV1 in human ES-
derived primitive syncytium and villous trophoblast (VT) . (VT track is from GEO accession: 
GSM1127102). Total number of tags is shown in this plot. All the IGV tracks in the thesis is 
generated with IGV (Robinson et al., 2011; Thorvaldsdóttir et al., 2013). 
 
There are a number of novel findings. For instance, PLAC4, which is 
a placenta-specific and primate-specific gene, has not previously been 
reported to be an ERV derived sequence. Another novel transcript is 
AK127846 which is shown in Figure 4.2, is also an interesting finding with 
respect to trophoblast biology as it encodes a GAG protein of ERV origin 
adjacent to ERVV1. AK127846 is simian-specific with mapped ESTs from 
the placenta indicating that it is indeed expressed in this tissue and not just 
my human ES cell-derived culture. The encoded protein is 483 amino acids 
long, and an open reading frame appears conserved over all simians from 
marmosets to man. This finding of GAG expression in syncytiotrophoblast 
cells raises the possibility of the production of ERV particles from these cells, 
as GAG is essential for retroviral packaging. One could speculate that the 
active role of these potential particles could be in the formation of syncytial 
knots; such knots are described in the literature (Fogarty et al., 2013). ERV 
particles may also have a role in the process of syncytialization or the 
attachment of syncytiotrophoblast to endometrium in early implantation 
events.  
Thus, primate-specific coding sequence change has occurred in the 
primate primitive syncytium through gene duplication, positive selection, and 
 75	  
co-option of ERV coding sequence. These changes, implicated in cellular 
fusion, immune suppression, and new hormone evolution (now essential to 
human development) likely contribute to the uniqueness of primate primitive 
syncytium. 
4.2.2. ERVs act as exonic cis-regulatory module (TSS, the first exon, and 
5´ UTR) 
 
LTRs contribute to human trophoblast gene expression; detecting 
transcripts with LTR sequence at the 5´end has identified most of these. For 
example, expression of CYP19A1 in the trophoblast is driven by a 40 million-
year-old LTR inserted 100kb upstream of the translation start site within exon 
2. This LTR contains promoter, transcription start site, 5´ UTR, and a 
splicing donor site. This is spliced into the downstream exon 2 and, in the 
trophoblast isoform of the CYP19A1, results in the 5´ end of the mature 
mRNA containing LTR-derived non-coding sequence. I wanted to identify 
ERV-derived coding sequence within my primitive syncytium gene-set by 
mining the mRNA-seq data.  At the same time, LTRs can act solely as 
enhancers and not contribute directly to the transcriptome. Analyzing my 
ChIP-seq data may reveal such elements.  
In mining the mRNA-seq data, reads mapping to any LTR in the 
genome were first identified and subsequently categorized into their 
respective families, and expression was determined. Differentially expressed 
LTRs between day 6 and day 0 clearly indicate distinct classes are found 
expressed in undifferentiated ES cells and other classes in the primitive 
syncytium as shown in Figure 4.3. The pluripotent-specific HERV-H has 
previously been described and recruits pluripotent-specific transcription 
factors NANOG and OCT4. Presumably, the trophoblast-specific LTR 
families would recruit trophoblast-specific transcription factors. 
To move beyond just a global analysis of LTR classes, and determine 
specific mRNAs in the genome that may be chimeric transcripts with LTRs, 
the LTRs with mapped reads were overlapped with human Ensemble gene 
annotations. From this analysis three groups of exons can be discovered, 1) 
first exons, 2) alternative exons, and 3) entire ERV-derived novel transcripts. 
 76	  
With respect to first/alternative exon, Supplementary Table 4.2 summarizes 
the top findings from these families, and Supplementary Table 4.1, which 
was described earlier, is generated from this analysis. 
 
Figure 4.3. Differentially expressed LTR families in human ES and human ES-derived 
primitive syncytium. Differentially expressed LTRs are ranked based on differential 
expression between day 6 (hES-derived Pr.synT) and day 0  (hES). Test statistic (paired t-test) 
for repeat groups (D0 vs. D6). Repeat groups that show significant differences in expression 
are highlighted in red.   
 
The appropriateness of this approach is confirmed by the identity of 
known chimeric LTR transcripts. For instance, PTN (pleiotrophin) expression 
in the trophoblast is known to be driven by an ape-specific LTR promoter 
inserted into the parental intron 1 of this growth factor. The previously 
mentioned CYP19A1, involve in the E2 biosynthesis pathway, also comes out 
in this analysis. MID1 is another to have a trophoblast-specific LTR acting as 
a new primate-specific first exon. 
A novel finding from this analysis is a LTR-TFPI chimeric transcript, 
this first exon LTR was integrated relatively recently as it is only seen in the 
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human and chimp genomes. As visualized schematically (Figure 4.4.a) and 
also from the IGV tracks (Figure 4.4.b-c) the LTR is inserted into the parental 
gene’s first intron and splices into the downstream exon 2. Exon 2 is the 
location of the translation start site thus there is no alteration in the protein 
coding sequence. 	  	  
	  
Figure 4.4. TFPI chimeric transcript resulted from the integration of primate-specific LTR. 
(a) Schematic visualization of  TFPI-LTR chimeric transcript, blue exon is the LTR-derived 
exon. (b,c) IGV tracks of TFPI locus with low (b) and higher resolution (c), total number of 
tags from RNA-seq data of day 6 of differentiation of human ES to syncytiotrophoblast is 
shown in this plots.  
 
This LTR-TFPI chimeric transcript is supported by ESTs derived from 
the human placenta indicating it is real and not a cell culture artifact. The 
product of this gene, which has been shown to be expressed in the human 
placenta, is a protease inhibitor that plays a role in the inhibition of 
coagulation/blood clotting. Indeed, TFPI has been implicated in preeclampsia. 
As the activation of TFPI on the cell surface has been linked to extracellular 
heparanase (Godoi et al., 2012) it is interesting to note that heparanase activity 
is increased during the in vitro decidualization of human stromal cells 
(Dempsey et al., 2000). As I see abundant expression of TFPI on my primitive 
syncytium, and this hugely up-regulated in transition from day 4 to day 6, it is 
a distinct possibility that TFPI on the primitive syncytium of the implanting 
blastocyst is activated by decidual heparanase.  While perhaps speculative it is 
intriguing to note that early pregnancy loss has been associated with altered 
heparanase activity (D'Souza et al., 2008).  
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4.3. Novelty through emergence of new cis-regulatory elements for 
recruiting transcriptional machinery as promoter and enhancer  
 
There are two major possibilities that a new mode of transcriptional 
regulation can emerge through change in cis-regulatory elements that leads to 
a novel regulation of the old gene in an evolving organ.  	  
(A) A point mutation in DNA can create new transcription factor binding 
sites and thereby recruit new transcriptional machinery. 	  
(B) Integration of a new ERVs/LTRs which can recruit new transcription 
machinery or recruitment of an old transcription machinery to this new unit 
of cis-regulatory element as promoter and enhancer for regulation of a gene 
which can lead to a new function.  
 
Contribution of both these to the emergence of new cis regulatory elements in 
the primitive syncytium is explored in the following sections. 
4.3.1. Point mutation in an old DNA sequence and recruiting new 
transcription machinery 
 
The general mechanism by which a specific regulatory DNA sequence 
undergoes mutation and selection for a new function is a part of Darwinian 
evolution, but the underlying molecular mechanism is not comprehensively 
understood. One consequence of this regulatory evolution is the establishment 
of a species-specific transcriptional regulatory network for each cell type. This 
network works through the co-operation of different tissue-specific 
transcription factors. These sets of transcription factors define the identity of 
each cell type. I was interested to begin to understand the primitive syncytium 
regulatory network and thought to do this by identifying cell-type-specific 
transcription factors and characterizing their in vivo binding sites by ChIP-seq. 
As described in the Introduction base on published data and our results on 
ChIP-qPCR of selected control sites, I hypothesized that two important 
primitive syncytium transcription factors GCM1 and TFAP2A are highly 
likely to regulate primate-specific genes and therefore aid in the identification 
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of primate-specific features of human primitive syncytium. Thus, I decided to 
use chromatin immunoprecipitation (ChIP) to identify all targets of these 
transcription factors in human ES-derived primitive syncytium at day 6 of 
differentiation. 
 
For accurate ChIP-seq data generation, it is essential to have high-
quality antibodies that recognize the epitope of interest in cross-linked 
chromatin. This was not an issue for TFAP2A as ChIP-seq has been 
successfully done with this in other cell types. Prior to my study ChIP-seq has 
not been done for GCM1. Initially, I expended considerable time testing 
various commercially available GCM1 antibodies and even had made a couple 
myself through the use of a custom antibody service. None of these were 
successful in ChIP. Thus, I resorted to using a GCM1-V5 tagged construct 
(Yang et al., 2011) stably transformed into human ES cells where I could use 
the antibody against the V5 tag to perform the ChIP for GCM1. Two stable 
cell lines were established with the use of a lentiviral expression system, one 
H1-V5, in the H1 human ES cell line and the other, HES3-V5 in the HES3 
human ES cell line. 
 To determine if exogenous expression of the GCM1-V5 influenced the 
biology of the cells, I differentiated these into the syncytiotrophoblast using 
my protocol and compared markers of gene expression by TaqMan RT-PCR 
and compared to the wild-type cell lines, shown in Figure 4.5.a. Overall the 
expression of GCM1, TFAP2A and PGF at mRNA levels at day 6 was very 
similar in the V5 stable lines compared with the wild-type cells. To directly 
measure the protein levels of GCM1-V5 and endogenous GCM1, I performed 
western blots using GCM1 and V5 antibodies (Figure 4.5.b). At protein level, 
these stable cells are expressing transcription factors, GCM1, and TFAP2A, 
and the expression level of the GCM1-V5 tagged isoform is expressed at only 
a fraction of the endogenous GCM1. From this analysis, I conclude that the 
GCM1-V5 cell lines faithfully reproduce the biology of the wild-type cells. 
Therefore, I proceeded with ChIP-seq experiments using TFAP2A and V5 
antibodies on chromatin from H1-V5 and HES3-V5 cells differentiated to 
primitive syncytium for six days. ChIP enrichment was tested with qPCR on 
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the control targets (method section); once the targets were confirmed, I 




Figure 4.5.	   Comparing differentiation efficiency of GCM1-V5 stable cell (H1, HES3) lines 
with wild-type human ES cells (H1, HES3). (a) Expression of trophoblast markers (GCM1, 
TFAP2A, and PGF) with RT-qPCR in V5-stable cell line (H1 and HES3) and wild-type cells 
at day 6 of human ES differentiation to primitive syncytium. The values are fold change of 
delta delta CT normalized to GAPDH and control ES cell at day 0. (b) Expression of GCM1 
and GCM1-V5 and TFAP2A are shown at day 6 of human ES differentiation to primitive 
syncytium at protein level by western blot (in the GCM1 panel the thin band around 15 KD 
above the original GCM1 is the V5-GCM1). 
For identification of LTRs which act as promoter and enhancer in 
primitive syncytium, histone modification marks: H3K27ac (promoter and 
enhancer mark) and H3K4me3 (promoter mark) ChIP-seq was performed, 
although the peaks for the histone modification mark is broad but since the 
LTRs are usually 300-1000bp, it gives enough resolution to identify these 
elements in primitive syncytium. In this genome-wide analysis my focus was 
to identify primitive syncytium-specific enhancers. After identification of 
GCM1 and TFAP2A peaks as well as these trophoblast-specific enhancers 
(marked by H3K27ac), the peaks were associated with RNA-seq data from 
H1- and HES3- derived primitive syncytium (day 6 of differentiation). The 
distribution of peaks, which were associated with primitive syncytium gene-
set, was identified for TFAP2A and GCM1 with the use of GREAT. Motif 
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discovery was performed for both transcription factors to show the validity of 
the ChIP-seq peaks. 	  
4.3.1.1. GCM1 regulation of primate-specific genes in the primitive 
syncytium (motif finding, motif validation and distribution of peaks)  	  
Noting that often, key binding sites of a transcription factor are 
represented within the top ChIP-enriched peaks, I manually scanned the top 
GCM1-enriched peaks. Within the top ten GCM1-enriched peaks, four are 
associated with genes (PGF, LMO2, CCNE1, LYN) within my 
syncytiotrophoblast gene set. Two of these sites in proximity to the 
transcription start site of the respective genes located 51 and 507 bases 
upstream of PGF and LMO2, respectively. While LMO2, CCNE1, and LYN 
are not well-known syncytiotrophoblast genes, PGF (placental growth factor) 
is a classic marker of syncytiotrophoblast and has been defined as a target of 
GCM1 (Chang et al., 2008). Such associations of top GCM1 ChIP-seq peaks 
with genes in the human ES-derived syncytium gene set provides confidence 
that my GCM1-V5 strategy is successful at identifying true GCM1 targets. 
 
Figure 4.6.	   GCM1 peak on PGF promoter in human ES-derived primitive syncytium. (a) 
Highlighted region is the GCM1 peak, which is overlapped with H3K27ac and H3K4me3. (b) 
Highlighted regions are the four GCM1 binding sites across different vertebrate form Multiz 
Alignments of 46 Vertebrate track. 
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The highlighted region in Figure 4.6.a-b shows GCM1 peak and 
binding sites on PGF promoter; this has a good correlation with the overlap of 
peaks identified by H3K27ac and H3K4me3, which mark active enhancers 
and promoters.  
 
This PGF binding site, which is the top binding site identified in the 
GCM1 ChIP-seq data set, is found in the proximal promoter of PGF. This 
gene has been previously characterized to be regulated by GCM1 (Chang et 
al., 2008). Interestingly Chang et al. proposed the GCM1 binding site to be 
TGCAGG/CCTGCA at a location 262 bp 5´ to the center of the GCM1 ChIP-
seq peak. Note the Chang et al., motif differs by one base from the core motif, 
CCCGCA, identified by (Akiyama et al., 1996). 
 
Figure 4.7. Luciferase activity of GCM1 binding sites on PGF promoter. (a) Wild-type and 
mutated version of the PGF promoter containing four GCM1 binding sites. (b) Dual luciferase 
activity of wild-type element and mutated element of GCM1 binding sites on PGF promoter 





Strikingly, there are 4 consensus GCM1 motifs (CCCGCA) closely 
localized to the GCM1 ChIP-seq peak in PGF, these binding sites are in the 
proximity of -50 to +50 relative to the center of the GCM1 ChIP-seq peak. 
Besides their proximity to the ChIP-seq peak center, sequence conservation in 
all 4 of these sites appears to be stronger than in the -262 Chang site. This 
suggests these four sites are better candidates for GCM1 binding than that site 
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described by Chang et al. The enhancer activity of this region containing these 
four GCM1 binding sites was tested in luciferase assays (Figure 4.7.a-b). The 
wild-type constructed showed significant activity while the mutant version of 
this (with GCM1 elements deleted) showed low luciferase activity. This 
confirms the binding sites are indeed genuine binding site of GCM1, moreover 
the element identified by Cheng et al (also tested), shows very low activity in 




Figure 4.8. GCM1 works as transcription activator in primitive syncytium. (a) Association of 
GCM1 peaks with up-regulated genes at day 6 of differentiation to primitive syncytium for H1 
and HES3 cells, plot measures the frequency of ChIP-seq binding site density against gene 
expression data. RNA-seq expression data is ranked from most up-regulated to most down-
regulated and then annotated for a binding event within 10 kbp of that gene. The line graph on 
the right of the figure indicates a moving average window and is the ‘density’ of binding of 
GCM1. The further the line moves to the right the more likely those set of genes is bound by 
GCM1 (b) Distribution of GCM1 binding sites in the promoter and enhancer regions of target 
genes in the primitive syncytium gene-set. (c) GCM1 motif found in the GCM1 peaks with 
HOMER. 
 
As shown in Figure 4.8.a, GCM1 peaks are associated with up-
regulated genes from H1 and HES3 differentiated cells at 6 of differentiation, 
these GCM1 binding sites were intersected with the primitive syncytium gene-
set, there are 915 binding sites associated with 487 genes from primitive 
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syncytium gene-set; the result for the top peaks are summarized in the 
Supplementary Table 4.3; the distribution of GCM1 binding sites in primitive 
syncytium are shown in Figure 4.8.b.; a GCM1 motif was identified (Figure 
4.8.c) within the GCM1 ChIP-seq peaks providing support that my chromatin 
IP pulled down specific GCM1 bound regions. 
To validate GCM1 ChIP-seq target genes, knockdown of GCM1 was 
performed on the JEG3 cell line, and the targets were checked by qPCR.  As 
shown in Figure 4.9.a., one of the shRNA clones (clone-1) is more efficient 
in the knockdown; this clone was selected for further validation of targets. In 
this experiment stimulation with cAMP also was performed to observe the 
stimulation of the selected markers compared to control. 
 
	  
Figure 4.9. PGF is a primate-specific Pr.synT marker which is regulated by GCM1.(a) In this 
figure expression of GCM1 and PGF is shown in JEG3 cells and also cAMP-treated cells is 
shown as control. Two replicates of GCM1 shRNA is shown. The values are fold change of 
delta delta CT normalized to GAPDH and control (JEG3) cells. (b) Comparison of GCM1 and 
PFG/Pgf as a target gene in the human and mouse differentiation system. The data in this 
figure are average of FPKM values of GCM1 and PGF from human ES-derived primitive 
syncytium from two cell lines (H1 and HES3) and m.synT (two replicates) 
	  
One of the interesting points about the direct target of GCM1 including 
PGF is that although Gcm1 is expressed in the mouse syncytiotrophoblast 
system, Pgf in not (Figure 4.9.b). This emphasizes the species-specific 
features of these targets with respect to angiogenesis. However, Pgf in the 
mouse is expressed in the spongiotrophoblast, which emphasize this function 
has been acquired by primate primitive syncytium through primate-specific 
GCM1 binding sites in the promoter region of PGF. 
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4.3.1.2. TFAP2A regulation of primate-specific genes in the primitive 
syncytium (motif finding, motif validation and distribution of peaks)  	  
The data in Figure 4.10.a shows TFAP2A peaks were associated with RNA-
seq data from H1 and HES3 differentiated cells at day 4 and 6 of 
differentiation, and the distribution of peaks were calculated. These TFAP2A 
binding sites were intersected with the primitive syncytium gene list, there are 
2292 binding sites associated with 732 genes from primitive syncytium gene-
set; the result for the top peaks are summarized in Supplementary Table 4.4.; 
the distribution of TFAP2A binding sites in primitive syncytium are shown in 
Figure 4.10.b, AP2A motif as shown in Figure 4.10.c, was identified within 
the TFAP2A ChIP-seq peaks which shows the method specifically pulls down 
TFAP2A targets.  
 
Figure 4.10.	  TFAP2A works as transcription activator in primitive syncytium. (a) Association 
of AP2A peaks with up-regulated genes of human ES-derived primitive syncytium, plot 
measures the frequency of ChIP-seq binding site density against gene expression data. RNA-
seq expression data is ranked from most up-regulated to most down-regulated and then 
annotated for a binding event within 10 kbp of that gene. The line graph on the right of the 
figure indicates a moving average window and is the ‘density’ of binding of TFAP2A. The 
further the line moves to the right the more likely those set of genes is bound by TFAP2A. (b) 
Distribution of AP2A binding sites in the promoter and enhancer regions of target genes in the 




I identified ELF3 (-2243) as one of the top peaks within the TFAP2A 
ChIP-seq data (Figure 4.11.a), two elements within this peak fit the TFAP2A 
cis-element consensus (Figure 4.11.b). In addition, this peak has good 
association with the H3K27ac enhancer marks.  
As the bioinformatics motif identification for AP2A binding sites at 
this locus was challenging to correlate, the experimental motif validated by 
SELEX (Mohibullah et al., 1999) was considered for selection of these motifs. 
The activity of this element which contain 2 binding sites of AP2A was tested, 
as shown in figure 4.12.a-b the mutated version of this elements shows much 
lower luciferase activity compared with the wild-type element, this confirms 
the binding sites are indeed real binding sites of TFAP2A. 
There are some other peaks, which are new findings with respect to 
transcriptional regulation of human trophoblast biology such as TNFAIP2 
(12668). This gene has been shown to be involved in immune modulation. 
Another target is TFAP2C, with a binding site 1,359 bases from the 
transcription start site. Like TFAP2A, TFAP2C is also a member of the AP2 




Figure 4.11. TFAP2 peak on ELF3 promoter in human ES-derived primitive syncytium. (a) 
Highlighted region is the AP2A peak, which is overlapped with H3K27ac. (b) Highlighted 
regions are the two TFAP2A binding sites across different vertebrate form Multiz Alignments 
of 46 Vertebrate track. 
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Figure 4.12.	  Luciferase activity of AP2A binding sites on ELF3 promoter. (a) Wild-type and 
mutated version of the ELF3 promoter containing AP2A binding sites. (b) Dual luciferase 
activity of wild-type element and mutated element of AP2A binding sites on ELF3 promoter 
(c) FPKM values of ELF3 in different days of differentiation. 
One of the puzzles for the in vitro human trophoblast differentiation 
system when compared with the mouse trophoblast is the expression of ELF5. 
Elf5 is one of the important transcription factors in mouse trophoblast stem 
cells (Latos and Hemberger, 2013). In the analysis of my human 
differentiation system, ELF5 has very low expression; FPKM of 2.4 at day 4 
and FPKM of 3.4 at day 6 of differentiation (in the RNA-seq analysis in this 
work, FPKM values less than 5 are considered as not expressed gene). This 
lack of expression of ELF5 is consistent with the expression data from human 
trophectoderm isolated from the human embryo (Bai et al., 2011), as shown in 
Figure 4.13. ELF3 is expressed in the mouse system but does not have the 
same expression pattern as Tfap2a, as Tfap2a is not expressed in the mouse 
differentiation system. Elf5 is expressed in mouse trophoblast stem cells but 
does not have a similar expression pattern as I observed in the human 
differentiation system; Elf5 in the mouse is decreasing along with 
differentiation toward syncytiotrophoblast. This suggest that ELF3 could be 
the missing member of the ELF family in the human trophoblast cells and it 
has the same expression pattern as mouse Elf3, although lack of expression of 
Tfap2a in the mouse system suggest that it has different transcriptional 
regulation. On the other hand, this data suggest that Elf5 is functioning in the 
trophoblast stem cell state in the mouse as it goes down along with 
differentiation to syncytiotrophoblast. Moreover, ELF3 is the closest 
parologue of ELF5 thus there is a possibility that ELF3 may compensate for 
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the role of ELF5 in the evolutionary context. This finding from TFAP2A 
ChIP-seq data is addressing one of the important questions in human 
trophoblast biology at the same time it raise the question if ELF5 has any 
function in the human trophoblast biology, as other mouse classical 
trophoblast markers are not expressed in the human system. 
 
 
Figure 4.13.	  Comparison of ELF family in human and mouse differentiation system. The data 
in this figure are average of FPKM values of TFAP2A and ELF family members from human 
ES-derived primitive syncytium (H1, HES3) and mouse TS-derived syncytiotrophoblast (two 
replicates). 
 
The idea of a similarity between human and mouse trophoblast cells 
have been a misleading factor in the field of trophoblast biology. This wrong 
perception makes it difficult to identify any novel and primate-specific 
features of trophoblast and placentation with the use of conventional methods 
and hypothesis-driven projects, which are designed, based on our 
understanding of the mouse system. The main reason for this difference is the 
drastic differences in the gene regulatory networks and transcriptional 
regulation of this cell type in these two species, which leads to the different 
molecular mechanism and eventually different cellular biology. The dataset of 
ChIP-seq of these two TFs on this specific cell lineage of human ES-derived 
primitive syncytium provides new insights in understanding of human 
trophoblast biology by providing in-depth insights into the molecular control 

































4.3.1.3. TFAP2A and GCM1 Co-localization 
 
Transcription factors do not work in isolation but often associate with 
other TFs. I was curious to determine if, on a genome-wide scale, GCM1 and 
TFAP2A co-localized as I noticed co-localization in a number of genes when 
browsing this data on the UCSC Browser. For instance, the human/primate-
specific CGB locus and PGF, both showed GCM1/TFAP2A co-localization. 
This observation was the first suggestion these two TFs may work together as 
a dimer to regulate primate/human-specific genes in the placenta.  
A genome-wide comparison of the two sets (one each from the H1 and 
HES3 lines) of TFAP2A ChIP-seq data and one set (the H1 line) of GCM1 
data clearly showed extensive colocalization (Figure 4.14.b). Cluster 4 from 
this spatial heat map indicates the majority of GCM1 binding locations 
overlaps with TFAP2 sites. There are many more TFAP2A sites identified 
than there were GCM1 sites, so the percentage of TFAP2A sites overlapping 
is lower, but in total there were 10,887 sites of co-localization. These co-
localized peaks correlate with up-regulated genes (Figure 4.14.a.) and 
H3K27ac peaks (Figure 4.15.b.), a marker of active enhancers. Thus, there 
appears to be a comprehensive set of locations where TFAP2A and GCM1 co-
bind and these locations are associated with the active expression of genes. 
 Genes in my primitive syncytium gene-set which are associated with 
AP2A-GCM1 co-localized peaks were identified, and the top genes are listed 
in Supplementary Table 4.5. Distribution of these peaks is shown in Figure 
4.14.c. within this are primate-specific genes like the CGB family and ERV 
family members as well as known trophoblast transcription factors such as 
GATA3 and CEBPA. Co-localization suggested there might be a specific cis-
regulatory element, a co-motif, which may be recruiting both GCM1 and 
TFAP2A to the same genomic locations. By running Fexcom (Hutchins et al., 
2013) we indeed found a co-motif containing recognizable AP2A and GCM1 
cis elements (Figure 4.14.d). In the co-motif, these individual elements 
(AP2A and GCM1 motif) are found separated by -1bp to 8bp. However, in 
the experimental validation of one of this predicted co-motif at -19447 of 
CYP11A1, the element with 0 and +1 possibility of spacing showed no 
luciferase activity at this locus. This discrepancy between bioinformatics 
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prediction and experimental validation needs to be further investigated on 
other predicted sites of this co-motif. 
 
Figure 4.14.	   TFAP2A and GCM1 co-localized peaks, distribution of peaks and association 
with Pr.synT gene-set. (a) AP2A and GCM1 peaks association with up-regulated genes of 
human ES-derived primitive syncytium, plot measures the frequency of ChIP-seq binding site 
density against gene expression data. RNA-seq expression data is ranked from most up-
regulated to most down-regulated and then annotated for a binding event within 10 kbp of that 
gene. The line graph on the right of the figure indicates a moving average window and is the 
‘density’ of binding of the particular TF. The further the line moves to the right the more 
likely those set of genes is bound by the TF. (b) Spatial heatmap of AP2A and GCM1 peaks. 
(c) Distribution of co-localized AP2A and GCM1 peaks, which is associated with primitive 
syncytium gene list. (d) co-motif of AP2A and GCM1, which is identified in this study. 
 
In summary, the ChIP-seq approach I took to identify regulatory 
change in the primitive syncytium was successful at identifying primate-
specific regulatory features. I have uncovered novel primate-specific cis-
regulatory elements bound by GCM1 and TFAP2A in the human primitive 
syncytium. Therefor, the primate-specific regulatory elements may have 
evolved through the accumulation of point mutations (e.g. GCM1 binding of 
PGF). 
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4.3.2. Integration of a new ERVs/LTRs as cis elements  
 
These novel cis-regulatory elements derived from the integration of 
LTRs, which themselves contain enhancer and promoter elements for 
retroviral expression, may be co-opted as promoters and/or enhancers for 
genes in proximity to the insertion site, thus leading these genes to gain a new 
expression domain and a potentially new function.  
To identify all the regulatory regions active in human ES-derived 
primitive syncytium, ChIP was performed for K27ac and K4me3 of histone 3. 
By using this powerful approach, it is possible to identify cell-type specific 
enhancers when such data is compared to similar data sets from other cell 
types. Such an analysis will capture primitive syncytium-specific enhancers 
not identified in the GCM1 and TFAP2A ChIP-seq approach, as there are 
clearly other transcription factors playing a role in this cell type. As an 
example, there were no identifiable GCM1 or TFAP2A binding sites 
associated with GDF15. This is an example of how this histone ChIP-seq data 
provides valuable information to identify other primitive-syncytium specific 
regulatory elements. Identification of such cell-type-specific enhancers will 
also help to identify enhancers that may have been contributed by LTRs, these 
I looked for next.  
Differential peaks from ChIP-seq of H3K27ac on my human ES cell-
derived primitive syncytium (H1 and HES3) cells were compared to similar 
peaks generated by others from various human cell types, specifically from ES 
cells, mesendoderm, mesenchymal stem cells (Xie et al., 2013) and the 
placenta (GEO accession: GSM1102784). As shown in Figure 4.15.a, cluster 1 
and 2 represent peaks that are only present in my primitive syncytium cells 
with some overlap with the syncytiotrophoblast-containing placenta. Other 
cell-type specific clusters are evident in cluster 3 (ES cells), cluster 5 
(mesendodermal cells), and cluster 6 (mesenchymal stem cells). A number of 
these trophoblast-specific clusters would assume to overlap with GCM1 and 
TFAP2A peaks. This has been confirmed with the strong association of these 
peaks with up-regulated genes (Figure 4.15.b). However there are others that 
do not, for instance GDF15, a growth factor highly specific to the placenta and 
dramatically up-regulated in the human ES-derived primitive syncytium (over 
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9-fold from day 4 with an expression of 921 FPKM in day 6), contains two 
enhancers within 15 kb 5´ to its transcription start site.  
	  
Figure 4.15. Identification of trophoblast-specific enhancers. (a) Spatial heat map of 
H3K27ac of human ES-derived primitive syncytium has been clustered with human 
embryonic stem cells at day 0, placenta, mesendoderm and mesenchymal stem cell. In this 
analysis, all the known promoters associated with H3K4me3 enrichment based on RefSeq 
genes has been filtered out. (b) Association of overlap of peaks from HEK27ac/AP2A/GCM1 
with up-regulated genes in human ES-derived primitive syncytium, plot measures the 
frequency of ChIP-seq binding site density against gene expression data. RNA-seq expression 
data is ranked from most up-regulated to most down-regulated and then annotated for a 
binding event within 10 kbp of that gene. The line graph on the right of the figure indicates a 
moving average window and is the ‘density’ of binding of the TFs and H3K27ac. The further 
the line moves to the right the more likely those set of genes is bound by the TF and 
H3K27ac. 
As discussed in the Introduction, there is evidence that ERVs have 
contributed to placenta formation in different species through co-option of 
their coding sequence (e.g. the syncytin genes) but also their LTRs as 
promoters and enhancers (e.g. CYP19A1). The contribution of LTRs to 
regulatory elements is not specific to trophoblast cells as other cell-type 
specific enhancer clusters also have contributions from LTRs, however, LTR 
families seems to have cell-type specific enrichment. There are specific LTR 
families, which are enriched in trophoblast cells; one of the top families is 
MER11A, for instance I identified this LTR acting as an enhancer for the 
corticotropin-releasing hormone (CRH) at two locations at 13kb and 17kb 
from the TSS (Figure 4.16.a). These LTRs are primate-specific (Figure 
4.16.b). Luciferase assays show both of these LTRs have high transcriptional 
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activity in both JEG3 and Bewo cells (Figure 4.16.d). CRH is a hormone, 
which is known to be expressed in the hypothalamus in response to stress. In 
reproductive systems it is known to be expressed in the placenta and has been 
shown to have a role in the immunosuppression and maintenance of pregnancy 
(Makrigiannakis et al., 2001). CRH has also been shown to be involved in the 
E2 biosynthesis pathway in human by signaling to the adrenal cortex and 
leading to the production of DHEAS (Chakravorty et al., 1999). The role of 
this hormone in human embryo implantation is currently not known but it is 
interesting to hypothesize a role in immune modulation and/or hormonal 
regulation considering the importance of both of these events in embryo 
implantation. 
 
Figure 4.16.	  Primate-specific LTRs (MER11A) works as enhancer of CRH. (a) IGV track of 
CRH locus, the LTR-derived enhancers are highlighted. (b) Multiz Alignments of 46 
Vertebrate track, the highlighted regions show the LTRs located at -13kb and -17kb of TSS of 
CRH are primate-specific. (c) Expression of CRH in different day of differentiation day 0, 4, 
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 In this chapter, I will elaborate on some of the primate-specific 
features of the human primitive syncytium with respect to human embryo 
implantation and placental development. There are two major challenges in 
identification of these primate-specific characteristics.  
First, there is a lack of in-depth knowledge in the molecular 
mechanistic and functional data on the events around the window of human 
embryo implantation; therefore it is difficult to have a precise measure of the 
exact criteria we should consider as primate-specific features. Second 
challenge is that, since the placenta is a very diverse organ across species, 
some of the shared features and functions between placentas of different 
species might be through convergent evolution. Such features are difficult to 
track through classical genomic approaches, as the genes related to these 
features may not be true homologues. A great example of this convergent 
evolution is the repeated and independent co-option of ERV envelope protein 
to function as fusogenic and immunosuppressive molecules in the 
syncytiotrophoblast. These have been identified in most of placental mammals 
(Lavialle et al., 2013), each from independent integrations of different families 
of ERVs. Therefore it is necessary to be cautious to name a feature and 
function as a true species-specific feature based on genomic studies unless we 
are fully aware of all biological aspect and making sure that the feature is not 
present in other species through convergent evolution. However, it is correct 
to say that all of these convergently evolved features have species-specific 
molecular regulation. 
 As I am mainly interested in the biological implication of my genomic 
findings with respect to embryo implantation and placentation, in my thesis I 
have tried not to spend too much time on genome-wide numbers.  
The data I have generated in my thesis is, and will be, a useful resource 
for hypothesizing future research in the context of human early embryonic 
development and trophoblast biology, as all the data are novel. 
In this chapter my main aim is to highlight a few examples of how this 
genomic data helped to improve our current understanding of primate-specific 
features of human embryo implantation events. Since the primitive syncytium 
is the main driver in the establishment of primate pregnancy, therefore 
understanding of these primate-specific features will help to understand 
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unique aspects of the biological and physiological features of human embryo 
implantation events and embryonic development. These findings would 
eventually help to identify molecular mechanistic of the primate-specific 
features of embryo implantation and placentation.  
5.1. Primate-specific transcriptional regulatory network of primitive 
syncytium formation 	  
Transcription factors are the main regulators of each cell type and 
define the identity of cells. The formation of primitive syncytium in primates 
at the early stage of embryonic development is a result of installation of a 
primate-specific transcriptional regulatory network, as we do not have this cell 
type in other species at this stage of embryonic development. To begin to 
explore the nodes of this regulatory network I chose to study TFAP2A and 
GCM1 as evidence suggests these were key players. For instance, and as 
described earlier, GCM1 is known to be a master regulator of syncytialization 
and TFAP2A is known to regulate some key hormones in the primitive 
syncytium including the CGBs and HSD17B1. From my ChIP-seq data one 
key connection I found was that TFAP2A is regulating the expression of 
GCM1 in the primitive syncytium. This regulation of GCM1 by TFAP2A at 
this early stage of development seems to be the key to the early initiation of 
syncytialization. This primate-specific transcriptional regulation has been 
acquired in primates through two primate-specific cis-regulatory elements 
upstream of GCM1. There are three TFAP2A binding sites in the vicinity of 4-
8kb from the GCM1 transcription start site. A view of sequence conservation 
of these, indicates that one of these AP2A binding sites is primate-specific 
(Figure 5.1.d, e). Another primate-specific cis-regulatory element I found 
associated with GCM1 expression is an LTR from the MER39 family of 
repeat, this is inserted approximately 53kb from the TSS of GCM1 (Figure 
5.1.d, f). These two primate-specific transcriptional regulatory elements in 
GCM1 are perhaps the key to the earlier expression of GCM1 found in human 
as compared to mouse trophoblast development. This earlier expression of this 
syncytial-driving transcription factor may explain the earlier appearance of 
syncytial cells in the primates. My analysis of the targets of GCM1, a 
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transcription factor also expressed in the later forming syncytiotrophoblast 
with the human placental villi and the mouse syncytiotrophoblast (Figure 
5.1.a, 5.1.b), gives indication of the other members of this primate-specific 
regulatory network active in the formation of the primitive syncytium. There 
are a number of key trophoblast transcription factors represented in the top 
1,000 peaks of GCM1 ChIP-seq peaks, these include CDKN1C, CEBPB, 
DLX3, TEAD3, and VGLL1. This emphasizes that the early formation of the 
primitive syncytium in the primate is the result of this drastic regulatory 
change as compared to mouse in terms of timing of activation (Figure 5.1.c). 
Expression of these transcription factors can regulate hundreds of genes as a 
result of this regulatory change, which subsequently can change the way the 
primate embryo is developing and implanting in the early stage. Further 
investigation on the possibility of cooperation between these TFs would 
provide a better understanding of these early events. 
	  
Figure 5.1.	   Primate-specific transcriptional regulatory network of primitive syncytium 
formation. (a,b) Shared gene between human and mouse syncytiotrophoblast. (c) schematic 
representation of GCM1 target gene in primitive syncytium. (d-e) Two primate-specific cis-
regulatory elements of GCM1 is highlighted (e) Primate-specific AP2A binding site 
highlighted in the Multiz Alignments of 46 Vertebrate track  (f) Primate-specific LTR ( 
MER39B) with AP2A binding site is highlighted in Multiz Alignments of 46 Vertebrate track.   
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5.2. Primate-specific hormonal regulation of the primitive syncytium 	  
One of the unique features of primate embryo implantation is the 
establishment of pregnancy by HCG, this peptide hormone produced by the 
primitive syncytium, signals to the corpus luteum in primate early pregnancy 
to establish and maintain pregnancy through secretion of progesterone. 
Without this hormone, pregnancy will not be established in the simian 
primates. 
Another primate-specific feature of the human embryo related to 
primitive syncytium is the capacity of these cells to convert DHEA-S to active 
estrogen (E2). Based on our analysis of published gene expression data 
(Zhang et al., 2009; Assou et al., 2012) all the enzymes involved in the 
DHEA-S to E2 biosynthesis pathway are expressed in the human blastocyst. 
Expression of these steroid biosynthesis pathway enzymes in the human 
blastocyst suggests an important function of blastocyst-derived E2. Since this 
expression appears to be primate-specific, it implies the presence of a primate-
specific molecular feature that will be explored in this chapter. 
To correlate the molecular mechanisms involved in both the HCG and 
E2 primate-specific hormonal regulation at the early stage of human embryo 
implantation and placental development the following strategies has been 
taken.  
The first step was to identify the active genes in each pathway related 
to the above-mentioned phenotypes and then in the second step correlates 
these differentially expressed genes to two possible molecular mechanisms, 
which can govern this novel phenotype at the transcriptional level. 
1 - If there is any novel primate-specific coding sequence change (from 
gene duplication, positive selection, and ERV), which can be correlated to 
these features. 
2 - Correlation of genes with novel primate-specific cis-regulatory 
elements identified in this work such as ERV/LTRs or single nucleotide 
mutation in TFBS leading to primate-specific cis-regulatory elements. 
Based on this strategy I explored the primate-specific features of the HCG 
formation and the E2 biosynthesis pathway in primitive syncytium. 
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5.2.1. Formation of HCG and transcriptional regulation of CGBs and 
CGA  	  
HCG is a heterodimer protein of CGB genes and CGA produced in the 
placenta of mammals (Figure 5.2.a). This luteotrophic signal first derived from 
the primitive syncytium, signals to the corpus luteum to sustain progesterone 
and prevent menstruation to occur. 
   The beta peptide (CGB) is a simian-specific gene (Maston and 
Ruvolo, 2002), expressed in primitive syncytium, and is derived from a 
duplication of LHB. The exact dating of duplication is not clear but as it has 
been suggested that prosimians (lemurs) and tarsiers do not have a CGB gene 
this duplication likely occurred at the base of simian evolution (Hallast and 
Laan, 2009). Subsequent duplications have led to the six copies of CGB in 
humans (Figure 5.2.b) (Nagirnaja et al., 2010). 
CGA, the alpha peptide of chorionic gonadotropin, is an ancient gene, 
at least 550 million years old, with little evidence for subsequent 
diversification through gene duplication (Uchida et al., 2010). What has 
emerged is a diversity of beta peptides that, when combined with the alpha 
peptide (encoded by CGA) now contributes to four human hormones: CG, 
luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid 
stimulating hormone (TSH). These later three hormones (and their 
corresponding beta peptides) are relatively old themselves as all are found in 
the fishes. Thus the appearance of the ancient CGA in the positive selection 
list suggests adaptive changes may have occurred corresponding to the 
emergence, in the basal simian, of the beta peptide (encoded by CGB) and the 
formation of the new hormone (CG) expressed in the primitive syncytium.  
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Figure 5.2.	   Rapid evolution/positive selection in simian CGA protein. (a) HCG is a 
heterodimer of CGA and CGB. (b) Duplication of CGB genes across primates. (c) Calculation 
of change of non-synonymous mutation to synonymous mutation of CGA (dN/dS ratio, 
omega) across primates. (d,e) alignment of CGA across different vertebrate in Multiz 
Alignments of 46 Vertebrate track. (e) 27 mammalian CGA mature peptides were aligned and 
residues with simian-specific change indicated as red arrow. 
 As the original positive selection on CGA was identified based on an 
analysis of six mammalian genomes (human, chimp, macaque, mouse, rat, 
dog) (Kosiol et al., 2008), I constructed an alignment with many more 
mammalian (and specifically primate) sequences to achieve better resolution 
of amino acid change over evolutionary time. This enabled me to determine 
whether the adaptive change in CGA corresponded to the emergence of CGB. 
Primate-specific conservation can be clearly seen in the coding sequence of 
CGA across primates (Figure 5.2.d,e). To identify the exact timing of positive 
selection and if this positive selection across primates leads to change in 
coding sequence of amino acids, the rate of change of non-synonymous to 
synonymous mutation for coding sequence of CGA was calculated (dN/dS 
ratio, omega)  (Figure 5.2.c). This rate is higher in the simian branch 
suggesting the greatest positive selection in CGA is in simians. A view of 
specific changes in amino acids it is indeed clear there are 12 residues that 
have been positively selected in the simians (Figure 5.2.f). The rate of change 
in the simian CGAs is extreme compared to all other eutherian mammals. Thus 
both the alignment and the calculation of non-synonymous to synonymous 
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mutation is indicative of rapid change (positive selection) in CGA beginning in 
the basal simian approximately 40 million years ago at the same interval when 
CGB first arose from duplication of LHB.  
Another primate- and placenta-specific feature of hCG secretion is the 
expression of CGA and CGB genes in the primate placenta after duplication 
from LHB; LHB is expressed in the pituitary. Different types of regulation for 
placenta-specific expression of CGA has been suggested in the literature to 
explain why CGA is expressed in the primate placenta (Nilson et al., 1991), 
but this has not been comprehensively addressed and has not accounted for the 
very high expression of this gene in the human placenta.  
 With respect to CGB genes, this raises the question what are the 
regulatory changes leading to the emergence of placental expression of the 
CGBs after their duplication from LHB. To check if all the CGB genes have 
the same transcriptional regulation in the primitive syncytium, promoter 
regions of the CGB genes where GCM1 and AP2A bind, based on our ChIP–
seq data is retrieved and aligned with CGB5 promoter; this CGB5 promoter 
was identified in the earlier study (Johnson et al., 1997). The alignment of 
CGB genes was also aligned with human LHB and other primate LHBs. As 
shown in Figure 5.3.a, there are three transcription factor binding sites in this 
region including one AP2A binding site, one AP2A/GCM1 binding site, and 
one SP1 binding site. This alignment shows the SP1 binding site is conserved 
in all CGB genes promoters and not in the LHB of human and other primates. 
The pattern of mutation in LHB promoter with respect to CGB genes is also 
conserved in other primates. This suggests the SP binding site is likely to be a 
key to the expression of CGB and not LHB in the primate placenta. From an 
analysis of the members of SP family, SP6 is expressed at high levels in the 
primitive syncytium (FPKM, 410 and 527 for H1 and HES3-derived primitive 
syncytium), thus providing a good candidate TF for this SP binding site. There 
is also another difference in the level of expression of different members of 
CGB genes in which some are expressed at very high levels (CGB, CGB5 and 
CGB8) and the others (CGB1, CGB2 and CGB7) expressed at much lower 
levels. By checking the AP2A binding site, it appears that those with high 
expression (CGB, CGB5, and CGB8) have an intact AP2A motif while in the 
others with low expression (CGB1, CGB2 and CGB7), this AP2A motif is not 
 102	  
conserved. This suggests that, this AP2A binding site likely plays a role in the 
differing levels of expression of different members of CGB genes after having 
the basal expression of SP binding site.  
This finding provides a new perspective in the formation of HCG and 
transcriptional regulation of CGB genes in the placenta. 
 
Figure 5.3.	   Primate-specific transcriptional regulation of CGB genes in human primitive 
syncytium. (a) AP2A and GCM1 binding site on CGB5 promoter. (b) Highlighted regions are 
binding sites of AP2A, SP1 and AP2A/GCM1 on the promoters of human CGB genes, human 
LHB and other simian LHB. 
5.2.2. Primate-specific features of E2 biosynthesis pathway  	  
The steroid biosynthesis pathway is a multi-step pathway with different 
end products. In the context of the reproductive system, these products include 
estrogen (E2), progesterone (P4) and testosterone (TEST). The ovary in the 
female is the main source of E2 and P4 in the reproductive system. This E2 
and P4 are the main regulators of estrous and menstrual cycle in the placental 
mammals; however the steroid biosynthesis pathway is also active in other 
tissues such as placenta. In the primates, sheep, horse, cat, guinea pig, the 
placenta can substitute the role of the ovary in the maintenance of pregnancy. 
This suggests the capability to produce progesterone. In primates and horse, 
however, the placenta does not express 17α-hydroxylase enzyme (P450c17) 
encoded by CYP17A1 (Iii et al., 1996), which shows different steroid 
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hormonal regulation in these species. The lack of expression of CYP17A1 in 
primates, which is a key primate-specific feature of this pathway, is the main 
reason that estrogen production by way of cholesterol and progesterone is not 
possible. In the primate, the feto-placental unit synthesizes the estrogen from 
substrate (DHEA-S) derived from the fetal adrenal cortex, at least after the 
time (~eight weeks) this structure is developed in the fetus. 
The high systemic levels of DHEA-S is a new evolutionary event in the higher 
primates, emerging approximately 20 mya (Labrie and Labrie, 2013; Labrie, 
2010), and is thought to maintain estrogen levels in peripheral tissues 
especially at the time of menopause in female. However DHEA-S is also the 
most abundant hormone in the blood circulation in non-pregnant, pre-
menopausal women and remains in abundance early in the first trimester, 
falling only later in pregnancy (Milewich et al, 1978) and coincidentally, with 
the development of the fetal adrenal cortex. With respect to early implantation 
events, maternally supplied DHEA-S may indeed provide the substrate for 
estrogen biosynthesis by the primitive syncytium at the site of embryo 
implantation. This argument can be supported by the fact that the human 
blastocyst express all the enzymes involved in E2 biosynthesis pathway 
(Assoue et. Al, 2012)  - encoded by STS (steroid sulfatase (microsomal), 
isozyme S), HSD3B1 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 1), HSD17B1 (hydroxysteroid (17-beta) 
dehydrogenase 1), and CYP19A1 (cytochrome P450, family 19, subfamily A, 
polypeptide 1) (Figure 5.4.a), which are also expressed in the human placenta 
(Diczfalusy, 1964, 2005). Therefore, I was curious to check all components of 
this pathway and also investigate the molecular mechanism of its regulation in 
the human primitive syncytium. 
Expression of STS, HSD3B1, HSD17B1, and CYP19A1, which is 
absent in human ES cells, is abundant in the human ES cell-derived primitive 
syncytium (Figure 5.4.b). While estrogen production by the placenta and 
trophoblast does exist in some other non-primate mammals which implies the 
convergent evolution of this pathway in the mammals (Iii et al., 1996), it is 
clearly absent in the rodent as this might be the basis for diapause.  
Notably, the trophoblast-specific expression of both CYP19A1 and 
HSD17B1 are reported to be driven by primate-specific LTR-based promoters 
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(Cohen et al., 2009) inserted into the human ancestors’ genome ~40 mya. 
Thus, the regulatory evolution of this biochemical pathway in the primate 
trophoblast provides an interesting paradigm to study the molecular 
mechanisms involved in the emergence of a novel pathway in early human 
embryo implantation. It is this, which I sought to explore here.  
5.2.2.1 Functional validation of E2 biosynthesis pathway in human ES-
derived primitive syncytium  
 
I first sought to confirm that indeed the human ES cell-derived 
primitive syncytium, and by extrapolation the implanting human blastocyst, is 
able to produce estrogen from the presumed maternal substrate (i.e. DHEA-S) 
and that STS, HSD3B1, HSD17B1, and CYP19A1 were responsible for this.  
	  
Figure 5.4.	  Expression of different members of E2 biosynthesis pathway in human embryo 
and human ES-derived primitive syncytium. (a) The data from human embryo is from Zhang 
et al, the values are raw signal from microarray. (b) The data from human ES-derived 
primitive syncytium is FPKM values of expression at day 0, 4 and 6 of differentiation. 
To test the functionality of the E2 pathway in the human ES cell-
derived primitive syncytium, I needed to stimulate the pathway with DHEA 
and measure the product of this stimulation. Upon the addition of exogenous 
DHEA (Figure 5.5.a), I observed that E2 and testosterone are being stimulated 
and at the same time progesterone goes down in the system (Figure 5.5.b). 
Thus, clearly, the estrogen pathway is functional in this human ES-derived 
primitive syncytium. Addition of DHEA to the medium will be used as 
background substrate for the next experiment, which is inhibitor assay. One of 
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the observations with respect to the biology of the E2 pathway is that the 
pathway after stimulation with DHEA can work through both directions of 4-
DIONE and TEST. The reason for this argument is that we can see the 
production of both E2 and TEST in the system however the dominant pathway 
in the system is through 4-DIONE and this might be the reason in which 
TEST direction of the pathway was overlooked in the earlier investigation in 
JEG3 cells (Samson et al., 2009). This TEST direction of the pathway might 
have sex-specific features as one of the speculation of the importance of the 
activation of E2 pathway in the placenta has been suggested to be involved in 
the deactivation of androgenic compounds such as DHEA in the maternal 
blood circulation and also DHEA compound from the adrenal cortex to protect 
the mother in the late pregnancy. 
As shown in Figure 5.5.c by addition of DHEA to the human ES cell-
derived primitive syncytium, we can observe the production of E2 and once 
the inhibitors for HSD3B1 (Trilestone), HSD17B1 (Poirier, 2010) (CC-115) 
and CYP19A1 (Letrozole) in the background of DHEA as substrate, we can 
observe inhibition of the E2 production in all combinations where an inhibitor 
for HSD3B1, HSD17B1, and CYP19A1 was used.   
 
Figure 5.5. Functional validation of E2 biosynthesis pathway in the human ES-derived 
primitive syncytium. (a) Schematic representation of steroid biosynthesis pathway. (b) 
Stimulation of E2 biosynthesis pathway by DHEA in the primitive syncytium. (c) Functional 
validation of E2 biosynthesis pathway with inhibitors of the pathway.   
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One interesting observation in the measurement of P4 after substitution 
of DHEA, as can be seen in Figure 5.5.b, once DHEA is added P4 goes down 
drastically. I do not have a clear explanation for this effect, however since this 
key enzyme is shared by both pathways this may be associated to the rate 
limiting effect of HSD3B1 in the cells. This has been shown to be correct 
since once HSD3B1 inhibitor is added; P4 production along with E2 
production is completely down close to zero. From this experiment it can be 
speculated that for the production of both hormones within 
syncytiotrophoblast cells of primate, there is a fine tuning between these two 
pathways, which otherwise they might interfere with the secretion of one 
another especially in late pregnancy in the primate where both E2 and P4 are 
produced at high levels from placenta. 
 From these experiments, it is clear that human ES cell-derived 
primitive syncytium produce estrogen from DHEA-S by the way of STS, 
HSD3B1, HSD17B1, and CYP19A1. In the following part, I will discuss the 
primate-specific transcriptional regulation of all the four genes involved in the 
E2 biosynthesis pathway. 
5.2.2.2. Primate-specific transcriptional regulation of E2 biosynthesis 
pathway  
	  
Figure 5.6.	  Primate-specific LTR-derived first exon of CYP19A1. Highlighted region is a part 
of the LTR (MER21A), which works as TSS, and 5´ regulatory module of CYP19A1 in 
primates placenta.   
 
CYP19A1 expression in the primate trophoblast is indisputably the 
result of an LTR (MER21A) insertion 40 mya that creates a new first exon of 
this gene (Figure 5.6). This LTR acts as a promoter, 5´ UTR, TSS and splicing 
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donor that is splicing into exon 2 located 100 kb downstream but still 5´ to the 
translation initiation site. The protein remains unchanged from that which is 
expressed in other tissues (and other mammals) and driven by other tissue-
specific promoters. In my data, TFAP2A is recruited to the CYP19A1 LTR. 
Earlier work based on in vitro binding assays have suggested binding of 
GCM1 on this location (Yamada et al., 1999) but in my GCM1 ChIP-seq data 
I find no evidence for this.   
While HSD17B1 was previously reported to be similarly driven by an 
LTR (MER21A) acting as a promoter (Cohen et al., 2009) the precision in 
which my data enables, questions this conclusion. In my data as can be seen in 
Figure 5.7.a, this LTR (MER21A) 0.4kb from TSS act as an enhancer by 
definition. There is also a recent segmental duplication 6.6kb upstream of TSS 
creating another (Keller et al., 2006), very similar LTR-based (MER21A) 
enhancer as the first enhancer. For both of these LTRs, we see APA2 and 
GCM1 binding sites in addition to the active enhancer mark (H3K27ac). 
Testing the activity of these elements by luciferase assay shows both of these 
elements have significant activity in JEG3 and Bewo cell lines (Figure 5.7.b).  
 
Figure 5.7. Primate-specific LTR-derived enhancers of HSD17B1. (a) Highlighted regions 
are LTRs located at 0.4 kb and 6.6 kb from TSS which works as HSD17B1 enhancer in the 
primate placenta. (b) Luciferase activity of two LTRs located at 0.4 kb and 6.6 kb of TSS. (c) 
Expression values (FPKM) of HSD17B1 in different days of differentiation. 
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HSD3B1 is another member of the E2 biosynthesis pathway, there is a 
new LTR contributing from LTR19 family of repeat inserted 20kb from TSS 
working as an enhancer (Figure 5.8.a). This enhancer does have H3K27ac 
mark that suggests the functionality of the enhancer in this system however it 
is not bound by either AP2A or GCM1. Immediately adjacent to this LTR-
based enhancer there are peaks for both of these TFs, this raises the possibility 
that the insertion of this repeat opens neighboring chromatin and TF binding 
sites accessible. The LTR insertion is only in higher primates, which 
emphasize the need for higher expression of this enzyme in the higher 
primates, which is important in both E2 and P4 production. Testing of this 





Figure 5.8.	   Primate-specific LTR-derived enhancer of HSD3B1. (a) Highlighted region is 
LTR, which works as HSD3B1 enhancer in the primate. (b) Luciferase activity of LTR at 23 
kb from HSD3B1 TSS. (c) Expression values (FPKM) of HSD3B1 in different days of 
differentiation 	  
I identified two LTRs acting as functional regulatory elements of STS. 
One is derived from the MER31A family and the other from the LTR69 
family. The MER31A element (2.4kb from TSS) act as enhancers and LTR69 
acts as promoter and TSS. The date of insertion for these ERV-derived 
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repeats, based on comparative genomics appears to be primate-specific but 
relatively old as homologous sequence is found in some non-simian primates 
(e.g. tarsier) but lacking in more distal ones (e.g. bushbaby, tree shrew). This 
gene is the bottleneck in the E2 biosynthesis pathway from DHEA-S, This 
might be the reason for having the selection pressure on the regulatory region 
at different sites to guarantee the expression of STS. Both of these ERV-
derived regulatory elements have AP2A and GCM1 binding sites, the 
luciferase assay test showed both of these elements have enhancer activity in 
JEG3 and Bewo cells (Figure 5.9.b).  
 
 
Figure 5.9.	   Primate-specific LTR-derived promoter and enhancers of STS. (a) Highlighted 
regions are LTRs, which works as a promoter (LTR69) and enhancer (MER31A) of STS in 
the primates. (b) Luciferase activity of these LTRs at 0.4 kb and 2.4 kb from TSS. (c) 
Expression values (FPKM) of STS in different days of differentiation. 
 
The emergence of expression of members of E2 biosynthesis pathway 
in the primate lineage appeared to evolve significantly through the insertion of 
LTRs containing trophoblast-specific cis-regulatory elements. The apparent 
conservation of these elements after the time of insertion (~40 million years 
ago) implies the functional importance of this pathway in simians. Production 
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of this E2 at this early stage of embryo development might have a biological 
advantage for primate embryo implantation and development. Experiments in 
the Bonnet monkey have shown that indeed this early rise of E2 is essential 
for primate embryo implantation. If this E2 biosynthesis pathway is blocked 
after implantation and the early events in post-implantation, the decline of E2 
in the monkey’s serum can be directly correlated to low pregnancy outcome in 
the experimental group that received the inhibitor of the biosynthesis pathway 
as compared to control group (Rao et al., 2007). This also has been shown in 
baboon (Albrecht et al., 2000) that E2 is essential for the maintenance of 
primate pregnancy in mid-gestation. This E2 has also been shown to have a 
role in the regulation of angiogenesis and fetal ovary development in primates 
(Albrecht and Pepe, 2010). It is not clear how the E2 biosynthesis pathway is 
involved in human early embryo implantation events, but monkey experiments 
suggest this early production of E2 by the simian primate embryo and later by 
the mature placenta are important for proper placenta formation and 
embryonic development. 
One of the challenges in studying the E2 biosynthesis pathway is that 
since members of this pathway are not expressed in the mouse placenta, nor is 
estrogen made, the knockout mouse of this gene is not informative for 
understanding the function of the gene in the placenta development. However, 
there are some human individuals that have a mutation in CYP19A1 (Jones et 
al., 2007), these individuals can provide useful information on the effect of 
lack of E2 from placenta and early primate implantation. These individuals are 
rare but are viable and in females; there are several signs but the most 
noticeable is hyperandrogenism and virilization with ambiguous genitalia. The 
viability of this individual suggests that the pathway might have some 
alternative root in a way that this individual can use the precursors of E2 for 
survival. This also can be connected to monkey experiments, as some of these 
animals with the blockage of E2 biosynthesis pathway still can survive, 
however there is no information on long-term effects on the proper 
development of these individuals. This opens a new window of possibilities 
especially if this local E2 is required for the successful implantation of the 



































In this work I establish a model, which faithfully represents the human 
primitive syncytium. Based on the transcriptome and transcriptional regulation 
analysis of the cell I was able to generate a lineage of cells which recapitulates 
one of the rare and transient, though essential, cell types in human 
development. This in vivo primitive syncytium is inaccessible because of 
practical and ethical reason related to its developmental timing - at the peri-
implantation to the early post-implantation stage. Thus, the in vitro human ES 
cell-derived system I developed is an extremely valuable model to be used in 
functional studies related to this stage of human development. It is important 
to have such models as the majority of human death (as measured from the 
point of fertilization) occurs at the peri- to the early post-implantation stage. I 
used this model to investigate the molecular evolution of primate-specific 
features of early implantation and placentation. This model is also useful to 
address placental complication and disease. This system is also potentially 
useful to investigate the cause of reproductive predisposed genetically disease 
which does not have a clear etiology at the moment. With the use of this 
system we can make iPS cells from these individuals with reproductive and 
infertility complication and perform this dynamic differentiation and then 
follow up with high-throughput approach to identify the candidate targets in 
the disease group. This system will also provide a platform to perform further 
functional validation of candidate targets from high-throughput methods. 
Syncytiotrophoblast cells form the cellular barrier between the mother and 
fetus and are intimately involved in the transport of nutrients.  As I have 
shown with the E2 biosynthetic pathway, my in vitro system is responsive to 
exogenic stimuli and inhibitors, therefore this cellular model is appropriate for 
functional studies related to this stage of development to test the effect and 
trafficking of drugs and chemicals.  
The mouse trophoblast stem cell differentiation model that I also 
established is very useful for addressing comparative genomic and 
transcriptomic studies. This model appears to represent the mouse labyrinth 
layer faithfully as it expresses both Syn-a and Syn-b. 
My work sheds light on the extent of the differences between human 
and mouse trophoblast biology. While the mouse model system is extremely 
powerful and useful in understanding many aspects of human biology, the 
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divergence between species within the trophoblast and placenta is a notable 
difference. Despite this, many ideas developed in the mouse trophoblast 
system are regularly attempted to apply to the human system, but this can be a 
significant misleading factor in the field of trophoblast biology. If the field 
were to rely on hypothesis-driven projects designed based on our 
understanding of the mouse system there would be little advance in identifying 
novel and primate-specific features of the trophoblast and placentation in 
which, as I have shown here, there are many. The main reason for the 
differences is the drastic differences in the gene regulatory networks and 
transcriptional regulation of this cell type in these two species, these lead to 
the different molecular mechanism and eventually different cellular biology. 
My work on this human ES-derived primitive syncytium provides new 
insights into the understanding of human trophoblast biology by providing in-
depth insights into the molecular control of the human trophoblast lineage. A 
number of the core transcription factors regulating mouse trophoblast biology 
are far from being important in the human system. For example Cdx2, Eomes, 
Esrrb, and Elf5 (Latos and Hemberger, 2013), all essential TFs in mouse 
trophoblast biology are all virtually undetectable in the human embryo and my 
primitive syncytium differentiation system. This emphasizes the need for a 
human system to understand human trophoblast biology. 
In respect to identification of primate-specific features at the 
transcriptome level, the comparison between the human and mouse embryo 
and syncytiotrophoblast gives us a framework for identifying the drastic 
differences between the human and mouse system. In the primate-specific 
primitive syncytium gene list I generated, there are lots of interesting genes 
that appear only in the human system. One class represented is the long 
noncoding RNAs that have been shown to be expressed in the early human 
embryo (Yan et al., 2013). Though out of the scope of my thesis, this area 
would be interesting to follow up on. My cellular system would provide the 
opportunity to explore the possible functions of these molecules, for instance 
by performing functional validation experiments, such as knockdowns of 
relevant lincRNA (Yan et al., 2013) to identify their functions. 
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In identifying new coding genes, while an extensive analysis on all the 
genes found with evidence of positive selection is out of the scope of this 
thesis, one gene in particular caught my attention, CGA. This is the alpha 
peptide of HCG, and the beta peptide is encoded by a gene (CGB) formed 
through a recent gene duplication in the primate lineage.  Thus, chorionic 
gonadotropin (CG) is primate-specific and is essential for maintaining primate 
pregnancy. The timing of positive selection found in CGA entirely matches the 
timing of the CGB from LHB. Presumably the positive selection in CGA is a 
result of the adaptations required to evolve this new hormone, expressed in a 
new domain (i.e. new regulatory features must evolve as well, discussed later).  
An additional interesting aspect of this positive selection in CGA is the 
fact that this very same gene forms the alpha peptide for three additional 
hormones. These hormones are ancient; all present in the fish, and CGA itself 
has been identified in the most distant vertebrate, the hagfish, thus dating this 
gene to at least 550 million years. Presumably through these 100s of millions 
of years of evolution the CGA peptide had optimally evolved in the context of 
the three distinct beta peptides of these three hormones: luteinizing hormone 
(LH), follicle-stimulating hormone (FSH), and thyroid stimulating hormone 
(TSH). An interesting question then emerges, how did these rapid changes in 
CGA (12 of 84 amino acids) effect the behavior of LH, FSH, and TSH? Could 
this actually be the first real example of antagonistic pleiotropy? This is a 
theory proposed by the evolutionary biologist George C. Williams in 1957 but 
has never been proven (Williams G.C., 1957). It states that during the evolution 
of a gene with pleiotropic function at least one trait is beneficial to the 
organism's fitness whereas a second (or third or fourth) is detrimental to the 
organism's fitness. Could changes in CGA, which were beneficial to the 
emergence of HCG in the maintenance of pregnancy, be detrimental to the 
function of any of LH, FSH, or TSH. In this regard, it is interesting to note 
that TSH has been implicated in osteoporosis. This will be a fascinating line of 
investigation to pursue. 
With respect to the emergence of trophoblast-specific regulatory 
elements, there is clear evidence that single nucleotide mutation leading to 
primate-specific expression of genes such as PGF is one of the ways that some 
of the novel functions have been acquired by primitive syncytium which 
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changed the way these cells function in the early implantation events. 
Moreover, another regulatory change created by the insertion of LTRs, which 
work as an enhancer, promoter, the first exon, and TSS of novel genes in the 
primitive syncytium, which also shaped these cells for the novel primate-
specific functions.  
One of the interesting examples around CGBs, primate-specific 
regulatory elements I identified was located in close proximity to the CGBs 
loci. I identified co-binding of AP2A and GCM1 in the promoter regions of all 
six members of the CGB family. Previously, an AP2A binding site was 
identified in the CGB5 promoter (Johnson et al., 1997) but there is no clear 
explanation in respect to transcriptional regulation of the other family 
members of CGBs and LHB. This argues that for this new hormone to emerge 
in the human trophoblast cells three molecular evolutionary events have 
occurred, 1) duplication of LHB to form the CGB cluster, 2) positive selection 
in CGA amino acid sequences to adapt to new protein structure/function 
requirements of the new hormone, and 3) the emergence of regulatory 
elements to drive trophoblast-specific expression of both CGA and CGB.  
The extent of primate-specific hormone production by the primitive 
syncytium is impressive. There are the CGA and CGB genes of human 
chorionic gonadotropin, CYP11A1 the enzyme for the production of 
progesterone, four enzymes leading to the production of estrogen and the 
peptide hormone CRH. Outside of the primates, the ovaries or pituitary 
produce many of these hormones. This emphasizes the fact that the primate 
placenta has emerged into an endocrine organ, one that is only transiently 
functional over a brief period (i.e. nine months) of human development. In this 
context as an endocrine organ, one can understand how maternal nutrition 
and/or stress can have long-term consequences for human health. But it also 
raises the importance of developing primate-specific, perhaps trophoblast cell-
based screening systems, to evaluate the repercussion of environmental toxins 
(often endocrine disruptors) on trophoblast biology, that is, in the field of 
reproductive toxicology. 
 
Although GCM1 and TFAP2A are clearly regulating many important 
genes in the primitive syncytium, they are certainly not the only 
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transcriptional regulators required. My data uncovered ELF3 as a likely 
important transcriptional regulator. I found its proximal regulatory region to 
have the greatest AP2A ChIP-seq peak out of all the thousands of binding sites 
I identified. It is also dramatically up-regulated upon human ES cell-derived 
primitive syncytium formation. A well-known target of ELF3 in other 
epithelial cell systems is TGFBR2. The Elf3 binding site in the proximal 
promoter/5'utr of Tgfbr2 has been thoroughly characterized and is conserved 
throughout eutherians.  TGFBR2 is a gene in my primitive syncytium gene 
set, in addition to the mRNA-seq support, there is also a strong H3K4me3 and 
H3K27ac mark on the promoter region of this gene confirming its activity.  
There was no evidence of any TFAP2A or GCM1 binding sites around 
TGFBR2 in my data sets. This would suggest TGFBR2 expression is not 
regulated by GCM1 or/and TFAP2A but is regulated by ELF3 and thus a 
ChIP-seq of ELF3 would uncover more key links in the syncytiotrophoblast 
regulatory network. Besides TGFBR2, another example of a gene not 
regulated by TFAP2A and/or GCM1 is GDF15. This gene is hugely up in the 
primitive syncytium, is highly specific to the placenta, has been associated 
with preeclampsia but has no obvious GCM1 or TFAP2A sites. My enhancer 
data set (H3K27ac ChIP-seq) clearly indicates two enhancers within 15 kb of 
the GDF15 transcription start site. These enhancers would be ideal to use to 
identify other transcription factors regulating trophoblast-specific gene 
expression by, for instance, an initial ChIP-qPCR strategy. Such transcription 
factors could include ELF3 as well as GATA2; GATA3 and others similarly 
expressed in my primitive syncytium gene set. 
I provided strong evidence that LTRs have strongly influenced the 
regulation of the E2 biosynthesis pathway. These primate-specific events have 
established the possibility of estrogen production via DHEA, through four 
enzymes STS, HSD3B1, HSD17B1, and CYP19A1. The molecular regulation 
of E2 production by using DHEA is a new evolutionary event in the primates. 
Expression of these enzymes in the human blastocyst raises the possibility that 
locally production (i.e. the primitive syncytium) of this hormone plays a role 
in establishing the implantation of the embryo. It has been shown that the 
human embryo in vitro is capable of producing E2 if provided with 
testosterone (Edgar et al., 1993). Perhaps another reason to argue this hormone 
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has an early function is the fact that the expression patterns of its enzymatic 
regulators of this hormone are similar to CGB genes. This suggests they might 
be necessary for the embryo at the implantation sites. It can be speculated that 
this local E2 might work as an immune-suppressive agent since the human 
embryo goes deeply inside the uterus and also the angiogenic effect of this 
local E2 might be also speculated. Certainly the role of this placental E2 has 
been shown to be important in the mature placenta for the growth of the 
placenta unit and also the development of fetal ovaries. 
These new features of expression of ovarian and pituitary hormones 
and enzymes in the primate placenta suggest in the course of evolution it is an 
improvement to the feto-maternal unit to control the outcome of pregnancy. 
This is important especially toward the end of pregnancy and if the fetus is not 
alive the pregnancy will be terminated, this is different in some species like 
cow in which the ovary is controlling the outcome of pregnancy until term by 
providing P4.   
Clearly there are major biological differences between species early in 
the trophoblast lineage. In the primates, we see the emergence of the primitive 
syncytium at the polar end of the implanting blastocyst. This cell type 
mediates attachment to and embedding into the maternal endometrium. On the 
maternal side, the biology is fast evolving too. A radical difference on the 
maternal side that coincides with the emergence of the primitive syncytium 40 
mya is spontaneous decidualization and menstruation; virtually all other 
mammals do not do this. Spontaneous decidualization is a hormone-induced 
(estrogen/progesterone) proliferation of the endometrial stromal cells creating 
an ~3 day "window of implantation" when the endometrium is receptive to 
embryo implantation, the remaining 25 days of the human cycle it is not. At 
~3 days after this "window of implantation" the majority of the endometrium 
is sloughed off (menstruation) if there is no embryo (or the embryo is not good 
enough) before the endometrium is subsequently regenerated. It is different in 
other mammals; decidualization is induced by the presence of an embryo, and 
there is no menstruation. I believe the primitive syncytium co-evolved with 
this spontaneous decidualization/menstruation in primates. The primate-
specific HCG is produced by the primitive syncytium and responsible for 
inhibiting menstruation (that would abort the embryo) by signaling to the 
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corpus luteum. It is unclear why primates evolved the decidualization and 
menstruation processes but one hypothesis is that it provides a system of 
embryo quality control (Lucas et al., 2013), that is, if an embryo is unhealthy 
it would be valuable in evolutionary terms, to reject it early. In this regard, it is 
interesting to note that the human pre-implantation embryo is often 
aneuploidy, thought to be the leading cause of unsuccessful IVF cycles, and 
this aneuploidy is an order of magnitude greater in the human than in the 
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Supplementary Table 2.1. List of primers used for ChIP-qPCR validation   







hActb_Prom2-F CAACACCACACTCTACCTC  
H3K4me3 
hActb_Prom2-R TCAGCTAGCTAAATGTGC  
hActb_Prom1-F AAGCCGGCCTTGCACAT      
H3K4me3 
hActb_Prom1-R GCTATTCTCGCAGCTCACCAT   
nodaL-prom_F  CATCCCCTCTGGCGTACATG 
H3K27me3 
nodal-prom_R TAGGCTGCGGATGATGTCTG 


















CGB5-prm_F  AATGTCCTCTGAGGCTTCGG 
TFAP2A 








Supplementary Table 2.2. List of TaqMan assays used in this study  
Gene Assay ID Species 
ACTB Hs99999903_m1 Human 
CDKN1C Hs00175938_m1 Human 
CGA Hs00174938_m1 Human 
CYP11A1 Hs00167984_m1 Human 
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CYP19A1 Hs00903411_m1 Human 
ERVWE1 Hs00205893_m1 Human 
GAPDH Hs99999905_m1 Human 
GATA3 Hs00231122_m1 Human 
GCM1 Hs00172692_m1 Human 
HOP Hs00261238_m1 Human 
HSD17B1 Hs00166219_g1 Human 
HSD3B1 Hs00426435_m1 Human 
NANOG Hs02387400_g1 Human 
PGF Hs00182176_m1 Human 
POU5F1/OCT4 Hs00742896_s1 Human 
TFAP2A Hs00231461_m1 Human 
TFAP2C Hs00231476_m1 Human 
ACTB Mm00607939_s1 Mouse 
CDX2 Mm00432449_m1 Mouse 
EOMES Mm01351984_m1 Mouse 
ESRRB Mm00442411_m1 Mouse 
GAPDH Mm99999915_g1 Mouse 
GCM1 Mm00492310_m1 Mouse 
Syna Mm02744887_s1 Mouse 
Synb Mm04212067_m1 Mouse 
 
Supplementary Table 2.3. List of primers used for amplification of targets in the luciferase assay  
Gene Dist. TSS Primer Forward Primer Reverse 
CRH 13KB GAACCCACCCCCAGTATTTC 
CCTTGTTGCAGGAAGTC
AGG 
CRH 17KB CAAGAGGTATCAGGGGAACC 
TGCAGTTGAGATAAGGA
CTGAGA 
HSD17B1 6.6KB GTGCCCAACCTCAAAGGATA 
GGGAGGTGGGAGATGA
TTGT 
HSD17B1 0.4KB CCCAGCCTCAAAGCATATTT 
GGGAGGTGGGAGATGA
TTGT 
STS 2.1KB AGCACTTGATAAAGCACAGTAAGG 
CAACCTTCTTCTAGGCC
CATC 
STS 0.06KB ATCAACGATTGCCAAAAAGC 
TTGGGAGTTTCAGGTGA
TCC 









Supplementary Table 3.1. Human trophoblast stem cell markers  
Gene logFC P.value Gene logFC P.value 
NR2F2 7.86 4.56E-19 PHC2 2.22 0.00000301 
WNT6 7.85 3.54E-17 CTSZ 2.21 0.00001 
HAPLN1 6.44 6.21E-17 GALNT11 2.2 0.0000223 
KANK4 6.33 3.21E-11 TBC1D1 2.19 0.00000876 
TACSTD2 6.1 1.79E-11 ARHGAP8 2.17 0.0000131 
FLRT3 5.68 1.37E-12 FST 2.17 0.001156465 
TMPRSS13 5.39 4.08E-09 NQO1 2.13 0.000137975 
MYOF 5.37 1.32E-15 GSTK1 1.88 0.000147434 
AHNAK 5.35 1.83E-13 PRSS8 1.86 0.000114232 
S100A14 5.35 2.75E-14 SLC35D2 1.86 0.000262708 
SMAGP 5.01 2.26E-16 HSD17B11 1.85 0.000239323 
TMEM54 5 1.3E-15 ALAD 1.85 0.000119943 
CCKBR 4.85 1.48E-13 DSC2 1.83 0.000066 
S100A16 4.48 2.49E-13 TMEM106C 1.82 0.000126448 
CLDN4 4.47 1.34E-13 SLC1A3 1.71 0.0000775 
COLEC12 4.37 1.21E-09 ANXA11 1.7 0.000421857 
ANXA3 3.89 8.68E-11 PI4KA 1.67 0.0000865 
KRT19 3.89 5.56E-14 SETD8 1.66 0.000343179 
EFNA1 3.86 9.91E-11 CITED4 1.61 0.003301545 
TPD52L1 3.41 1.16E-10 ATF5 1.59 0.007271397 
LAMB1 3.37 6.97E-10 HEBP2 1.59 0.00101479 
EMP2 3.34 4.98E-08 NIT2 1.58 0.001353879 
CTSL2 3.27 3.14E-08 DHRS7 1.58 0.001337764 
SLC7A7 3.26 4.57E-09 NR1H3 1.57 0.000336063 
CA2 3.22 0.00000055 EFS 1.57 0.000317018 
CAMK2D 3.17 6.99E-10 GSTO1 1.56 0.001013513 
LAMA1 2.99 0.000000317 SEPP1 1.56 0.003696109 
CAPN2 2.93 0.000000214 PTPRF 1.56 0.001145892 
MYO5B 2.82 2.75E-08 ECHDC2 1.54 0.000698608 
PKP2 2.79 0.000000368 TBL1X 1.51 0.000870513 
ATP2B1 2.67 0.00000227 CYFIP1 1.47 0.003386018 
S100A13 2.67 0.00000395 ANP32B 1.44 0.003283526 
ERRFI1 2.61 0.000000376 GAS6 1.42 0.002442543 
PPFIBP2 2.59 0.00000124 BAIAP2L1 1.4 0.001048829 
Library ID Sample # Reads
RMT001 mTS/D0: Undifferentiated mouse TS cells rep.1 43,575,574
RMT002 mTS/F0: Undifferentiated mouse TS cells rep.2 53,025,098
RMT003 mTS/D2A: Mouse TS cells differentiated for 2 days with activin rep.1 47,162,730
RMT004 mTS/F2A: Mouse TS cells differentiated for 2 days with activin rep.2 42,069,054
RMT005 mTS/D2AS: Mouse TS cells differentiated for 2 days with activin + SU5402 rep.1 52,414,022
RMT006 mTS/F2AS: Mouse TS cells differentiated for 2 days with activin + SU5402 rep.2 35,532,146
Mouse TS Cell Differentiation
Library ID Samples # Reads
RHT210 H1/D0:Undifferentiated human ES cells - H1at day 0 66,655,050
RHT211 HES3/D0:Undifferentiated human ES cells - HES3 at day 0 52,059,574
RHT212 H1/D4:Differentiated human ES cells - H1 at day 4 45,308,740
RHT213 HES3/D4:Differentiated human ES cells - HES3 at day 4 50,254,276
RHT214 H1/D6:Differentiated human ES cells - H1 at day 6 71,874,746
RHT215 HES3/D6:Differentiated human ES cells - HES3 at day 6 51,954,642
Human ES Cell Differentiation
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VAMP8 2.55 0.0000003 MANBA 1.37 0.001663535 
RXRA 2.53 0.000000221 SLC44A2 1.34 0.005876337 
EMILIN2 2.4 0.000000981 C4orf48 1.31 0.003284077 
ELOVL1 2.39 0.00000101 SHISA5 1.3 0.004982514 
JDP2 2.39 0.000000172 PXN 1.28 0.007199892 
KHDRBS3 2.35 0.000000919 PALLD 1.22 0.004265196 







Supplementary Table 3.2.Human primitive syncytium gene-set (Pr.synT) 
Gene  H1-D0 HES3-D0 H1-D4 HES3-D4 H1-D6 HES3-D6 
7SK 0.0 0.0 1.5 6.1 160.3 48.2 
AADAT 3.6 5.1 22.6 8.6 56.6 19.2 
AAK1 1.4 1.6 3.7 3.0 19.2 22.5 
ABCB8 6.0 5.6 7.7 10.3 23.8 16.8 
ABHD4 12.0 12.8 14.8 20.0 38.8 43.9 
ABHD5 5.8 8.7 20.5 18.3 93.9 96.3 
ABTB2 2.6 2.1 9.2 9.2 233.3 208.2 
AC002117.1 6.3 4.6 28.6 36.8 142.9 173.0 
AC005176.2 0.0 0.0 7.1 5.6 45.8 58.4 
AC005786.7 4.0 3.4 3.8 4.4 64.8 15.5 
AC008738.1 0.1 0.1 28.2 32.3 92.0 108.5 
AC010145.3 0.0 0.0 0.8 1.5 13.1 12.2 
AC025262.1 0.0 7.1 15.6 0.0 114.9 20.9 
AC068491.1 2.8 1.9 13.5 21.2 35.6 35.5 
AC091736.10 0.0 0.0 1.6 1.8 20.3 16.1 
AC092597.3 0.1 0.1 3.2 2.8 27.0 18.3 
AC107016.1 6.3 5.1 22.6 84.9 311.6 190.6 
AC114772.1 1.6 1.3 7.1 6.9 28.2 23.5 
AC132217.4 0.8 0.0 79.3 26.2 304.4 128.0 
ACE2 0.1 0.1 2.1 6.8 18.6 49.4 
ACER2 2.2 1.9 3.4 3.8 18.6 16.5 
ACER3 4.6 6.3 12.2 7.3 18.0 22.3 
ACOT2 7.3 9.4 11.5 10.5 32.2 20.4 
ACOX3 1.9 2.3 9.4 14.7 34.4 28.0 
ACSL1 2.6 1.9 5.5 3.0 22.4 12.1 
ACVR1 4.8 3.9 8.6 13.5 18.4 52.0 
ADA 7.4 6.7 39.5 32.9 180.6 52.0 
ADAM19 3.4 1.3 5.1 3.3 77.2 31.0 
ADAMTS1 2.7 2.4 37.9 22.5 184.4 99.0 
ADAMTS20 2.8 1.8 3.1 0.9 54.3 20.9 
ADAMTS3 1.1 1.0 2.4 1.0 19.3 10.8 
ADAT3 2.7 3.6 4.4 4.7 12.5 11.0 
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ADCK2 2.2 3.4 8.5 11.5 53.6 29.0 
ADM 16.3 36.5 26.0 32.8 187.5 107.0 
ADRM1 81.6 71.9 70.2 94.7 280.0 239.4 
AEBP2 16.7 16.3 20.2 10.7 44.6 28.6 
AES 77.4 59.4 101.1 99.2 350.7 178.2 
AF011889.5 0.3 0.5 0.6 0.4 15.7 10.5 
AFF1 9.3 10.9 9.4 13.7 93.4 101.3 
AFTPH 5.6 5.7 7.3 5.4 15.9 15.2 
AGFG1 28.2 30.8 50.6 54.8 154.6 119.3 
AHR 1.2 1.5 2.1 1.2 16.8 11.5 
AIM1 2.2 2.6 2.8 2.5 22.4 19.0 
AK3 12.0 20.6 25.7 19.4 85.8 56.7 
AKAP13 5.9 4.7 6.7 7.2 16.1 13.3 
AKAP17A 7.2 6.7 9.5 11.2 37.3 32.4 
AKAP17A 7.2 6.7 9.5 11.2 37.3 32.4 
AKAP8 10.1 9.1 10.5 13.3 43.7 32.7 
AKT1S1 23.6 18.4 30.8 37.3 148.2 95.6 
AL049836.1 0.2 0.0 4.3 13.4 106.8 100.4 
AL512428.1 464.4 0.0 609.5 362.8 7,671.5 9,430.0 
AL773572.7 0.0 0.0 0.9 0.6 98.1 96.3 
ALAS1 17.0 15.9 100.0 126.9 275.7 239.1 
ALG12 9.9 7.9 11.2 13.8 34.7 19.4 
ALG2 13.0 12.8 20.6 23.7 57.3 49.5 
ALG5 12.8 9.9 18.5 14.3 56.9 28.1 
AMD1 67.4 66.1 41.8 29.7 181.2 124.4 
AMMECR1 9.4 22.4 7.3 10.6 35.7 50.8 
ANGPT4 0.0 0.1 6.2 5.5 31.4 28.9 
ANGPTL4 0.7 1.3 9.5 7.7 48.9 16.7 
ANKRD37 2.0 4.3 0.7 2.1 19.3 17.5 
ANO1 1.0 2.0 4.3 2.6 20.4 18.4 
ANXA1 4.3 1.5 254.0 356.7 1,854.6 3,219.1 
ANXA5 100.9 117.8 148.9 185.9 505.3 345.2 
ANXA6 28.0 21.7 29.1 21.3 147.2 45.1 
AP000758.1 0.0 0.0 0.0 3.3 17.2 15.4 
APOA2 2.7 0.0 76.2 59.7 216.3 197.9 
APOBEC2 0.1 0.0 1.5 2.0 18.8 21.9 
APPBP2 3.4 4.7 9.6 6.7 51.4 55.8 
AQP3 1.2 0.7 7.4 15.9 64.2 32.8 
ARF1 111.0 112.9 175.0 203.0 475.4 395.5 
ARF4 110.9 111.7 150.9 136.5 381.5 306.4 
ARF6 23.0 26.2 65.3 74.0 169.9 144.4 
ARFGAP3 7.4 8.9 12.8 12.2 32.3 24.3 
ARHGAP17 17.8 13.8 18.5 26.2 104.8 30.3 
ARHGAP18 1.3 1.2 13.2 8.0 51.3 53.0 
ARHGAP27 3.3 2.9 6.0 7.9 18.6 10.6 
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ARHGAP42 7.1 10.0 8.2 6.8 49.2 30.2 
ARHGEF12 4.1 5.2 7.6 6.4 18.4 16.9 
ARID3A 14.4 13.1 96.7 119.3 503.7 431.0 
ARID5B 0.1 0.0 2.2 1.5 14.9 15.7 
ARIH1 15.5 15.9 27.2 23.8 76.4 76.7 
ARL5A 17.5 17.1 53.4 51.1 202.5 214.9 
ARL6IP5 15.8 15.0 29.2 24.4 114.8 46.7 
ARL8B 13.9 19.3 33.2 29.5 109.9 103.2 
ASAP1 5.5 5.6 23.8 19.1 67.1 59.0 
ASB6 4.5 4.1 5.6 8.1 19.0 14.8 
ATAD1 16.5 26.0 23.6 19.0 165.7 87.5 
ATF3 5.5 7.8 25.2 25.8 265.3 138.9 
ATF6 2.3 3.4 9.3 8.7 41.6 30.8 
ATG13 16.4 15.8 21.2 29.4 72.1 54.8 
ATG2A 3.4 2.8 7.4 9.0 21.9 20.3 
ATG9B 2.0 1.5 7.7 9.7 39.1 29.7 
ATP10D 0.7 1.1 29.0 18.8 210.9 152.1 
ATP13A3 26.3 33.0 52.5 30.8 68.7 124.4 
ATP1A4 0.1 0.1 14.7 16.3 34.7 36.6 
ATP1B1 15.7 11.9 19.7 18.1 152.7 182.0 
ATP2A3 4.2 4.6 0.4 1.0 16.6 24.6 
ATP2B4 7.1 5.7 85.9 70.0 324.3 210.0 
ATP6V0A1 12.4 13.0 27.0 31.7 93.9 63.9 
ATP6V0C 87.4 98.6 153.3 197.2 477.4 357.5 
ATP6V1C1 20.7 23.2 18.5 13.8 67.5 43.0 
ATXN2 16.2 18.1 23.3 21.3 118.0 68.6 
ATXN2L 40.4 53.7 50.7 76.0 177.4 154.6 
ATXN7 2.7 3.4 6.9 6.5 16.9 16.7 
AVPI1 3.8 3.5 13.8 15.6 81.9 132.0 
AXIN2 8.9 7.6 8.8 6.4 51.4 20.8 
AZIN1 76.6 99.1 87.3 88.6 362.4 273.3 
B3GALNT2 5.4 8.1 6.2 5.1 26.1 12.5 
BACE2 2.6 2.3 1.9 3.5 34.0 18.2 
BACE2-IT1 0.0 0.0 0.2 0.2 69.3 40.9 
BAG3 3.8 4.6 29.5 37.8 79.6 77.9 
BAIAP2 4.8 3.1 19.7 24.6 91.5 50.0 
BASP1 62.8 62.8 132.3 186.2 618.7 355.6 
BCAR4 0.0 0.2 19.9 27.1 174.4 196.7 
BCAS3 4.6 7.1 3.7 7.0 17.0 12.0 
BCL2 0.6 0.6 4.2 2.0 37.1 16.2 
BCL2L1 43.2 40.0 78.2 103.4 211.0 205.3 
BCL2L11 5.0 6.2 7.4 9.7 18.9 53.6 
BCORL1 1.3 1.8 7.2 19.0 39.4 80.0 
BCR 24.0 15.8 28.2 31.4 94.7 57.7 
BGN 1.0 1.2 19.2 37.7 220.5 172.9 
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BHLHA15 0.6 0.8 2.0 2.5 13.9 30.4 
BHLHE40 1.4 10.7 19.1 24.0 75.0 87.1 
BLNK 0.1 0.0 2.2 5.8 16.2 37.1 
BLOC1S3 2.4 2.0 5.9 10.6 17.1 18.3 
BMP1 2.3 2.2 4.5 6.4 32.3 15.8 
BNIP2 22.4 23.0 35.7 23.4 174.0 116.5 
BNIP3L 29.3 32.5 17.1 14.9 91.8 79.0 
BOLA2 7.5 7.0 6.9 8.0 25.6 10.4 
BPGM 11.2 10.4 12.6 11.1 65.9 51.7 
BRAF 5.8 7.6 8.3 8.9 48.5 20.9 
BRD2 63.0 61.9 69.8 106.0 247.5 302.9 
BRD4 13.9 15.4 26.6 33.2 78.8 79.8 
BTBD9 0.5 0.8 1.4 1.5 14.4 10.9 
BTG1 15.3 14.4 68.1 63.6 636.2 520.2 
BTG2 2.4 2.1 19.2 29.0 119.9 159.4 
BTG3 9.5 12.8 55.4 43.9 119.5 131.6 
BZW2 36.8 34.6 173.5 164.0 456.5 457.9 
C10orf10 1.8 1.5 34.9 56.7 501.2 527.1 
C10orf32 2.7 2.5 5.3 4.7 16.1 10.7 
C10orf54 0.0 0.1 5.7 5.9 271.7 107.6 
C10orf95 1.3 1.4 13.4 23.5 47.5 59.1 
C12orf44 21.5 16.3 18.6 22.9 72.3 43.4 
C16orf72 9.4 8.1 11.8 14.2 52.8 123.0 
C16orf74 1.5 2.1 5.3 6.6 35.6 19.0 
C19orf10 27.0 28.2 52.8 67.9 210.2 119.3 
C19ORF24 10.4 13.3 15.6 17.5 47.5 25.7 
C19orf24 12.8 10.6 13.3 24.2 42.0 35.7 
C1GALT1 29.6 50.5 59.9 49.5 199.1 129.8 
C1orf115 2.2 1.9 25.2 34.4 86.8 63.3 
C1orf21 34.6 36.3 31.7 28.5 157.6 100.1 
C1orf27 4.9 6.6 11.0 6.1 24.6 24.8 
C1QTNF1 0.3 0.3 0.8 2.6 25.4 32.8 
C20orf111 15.7 16.5 20.7 25.0 95.5 91.8 
C20orf24 49.6 47.4 62.5 80.8 209.3 151.3 
C21orf91 7.3 8.3 10.7 8.5 39.9 31.9 
C2orf49 7.3 7.1 12.0 11.0 35.9 23.5 
C2orf72 0.9 0.9 33.2 30.7 98.6 109.0 
C3orf38 10.3 8.2 10.0 8.2 21.8 21.0 
C4orf19 0.2 0.1 10.9 12.0 60.0 56.9 
C4orf36 1.5 2.3 1.6 2.2 11.7 12.1 
C5orf45 15.3 17.6 54.1 98.2 193.3 228.9 
C7orf60 2.1 3.2 4.7 3.4 13.2 17.3 
C8orf42 29.5 26.2 87.5 76.1 187.7 239.3 
C8orf58 6.7 7.2 6.6 7.3 18.5 13.5 
C9orf3 1.8 2.1 4.3 2.7 38.7 13.9 
 138	  
CA5BP1 8.2 9.4 10.7 11.6 37.3 20.5 
CACUL1 7.8 7.5 9.2 7.7 17.6 19.5 
CALB2 1.4 2.0 6.1 4.3 127.6 47.3 
CALR 252.6 220.6 380.2 428.3 2,447.0 1,261.8 
CALU 69.0 79.0 92.4 77.3 252.6 157.1 
CAMSAP2 4.9 5.9 12.0 5.8 37.6 39.9 
CANT1 8.3 7.4 18.4 27.8 80.3 63.4 
CAP2 5.3 4.2 7.7 4.3 19.7 12.0 
CAPN6 3.0 5.3 44.2 83.1 125.4 195.1 
CARS 20.3 34.9 23.2 34.2 89.9 65.1 
CASP4 0.0 0.1 2.1 1.5 16.8 11.5 
CAV1 3.9 2.3 6.0 3.0 12.1 14.9 
CBLB 6.2 6.3 47.0 38.1 197.1 190.3 
CCBP2 0.1 0.0 6.5 6.3 45.7 37.4 
CCDC6 21.7 20.5 28.4 18.7 56.7 50.1 
CCDC86 19.8 17.0 10.8 15.3 77.6 17.2 
CCDC9 8.4 7.4 15.6 21.7 65.1 71.1 
CCNDBP1 11.6 12.2 37.4 39.3 87.5 78.4 
CCNE1 14.0 13.1 93.1 70.6 553.7 257.3 
CCNT2 12.8 14.9 20.3 11.7 32.5 48.0 
CCR7 0.2 0.1 93.8 63.5 359.3 138.3 
CCSAP 4.6 3.4 7.9 4.7 56.6 25.3 
CCSER2 3.8 4.6 11.7 8.2 38.7 43.7 
CD164 47.8 51.2 122.4 84.6 227.0 230.6 
CD274 0.1 0.0 12.0 5.6 109.3 69.2 
CD55 7.9 11.8 47.0 62.0 175.4 228.6 
CD59 29.0 47.2 78.4 84.3 411.4 346.7 
CD63 325.0 275.8 570.7 605.9 1,956.4 947.2 
CDH5 0.1 0.0 8.0 9.9 167.1 86.6 
CDK19 4.9 3.7 6.1 4.3 37.7 46.3 
CDKN1A 7.7 7.1 55.1 81.0 186.4 166.8 
CDKN1C 12.0 5.4 524.0 521.7 1,532.9 1,259.0 
CDYL 51.6 56.3 34.9 43.2 238.9 161.0 
CEBPA 0.6 0.5 66.5 69.2 219.5 234.4 
CEBPB 5.2 7.8 66.6 75.6 465.6 287.4 
CEP68 5.7 4.7 6.7 10.5 34.3 36.7 
CEP85 12.0 12.5 41.6 78.2 219.7 367.1 
CGA 8.3 5.6 1,160.1 1,287.5 
47,941.
8 27,020.2 
CGB 0.5 0.7 5.8 2.3 2,620.1 1,174.6 
CGB1 0.5 0.3 4.7 1.3 558.0 228.3 
CGB2 0.6 0.5 1.7 0.5 210.5 101.2 
CGB5 0.1 0.0 1.4 0.2 4,681.6 1,420.1 
CGB7 0.2 0.3 0.9 1.0 110.6 31.4 
CGB8 0.2 0.1 2.6 0.6 1,539.5 625.0 
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CGREF1 1.8 2.0 0.3 0.8 23.3 11.1 
CHMP4B 31.2 37.3 63.7 94.8 188.5 153.8 
CHPF 18.9 17.8 31.8 36.6 163.9 89.9 
CHST2 4.6 4.1 4.1 24.2 29.4 44.6 
CHSY1 11.2 10.0 9.9 12.8 57.3 51.7 
CKMT1A 13.0 5.2 6.8 10.1 130.9 70.8 
CKMT1B 14.6 26.9 8.3 9.1 164.6 60.4 
CKS2 308.8 263.8 203.2 309.2 753.4 1,508.0 
CLEC11A 2.7 2.7 10.1 10.9 40.5 18.7 
CLEC1A 0.1 0.1 7.5 2.4 50.4 23.0 
CLIC3 0.0 0.0 10.1 7.9 112.4 34.0 
CLN3 11.9 10.6 33.8 63.9 150.7 99.1 
CLN8 6.0 6.3 7.2 14.3 61.1 43.7 
CLP1 14.3 11.4 11.4 14.0 38.4 32.9 
CLPB 3.0 3.4 9.9 9.0 35.8 28.8 
CLPX 16.5 18.9 20.9 15.0 39.8 45.5 
CNNM2 4.3 4.8 3.3 5.6 36.4 29.9 
CNOT3 27.4 23.7 24.5 28.1 62.8 49.5 
COBLL1 1.0 1.5 19.4 11.7 122.0 186.9 
COG3 4.7 4.5 10.2 7.8 32.5 38.2 
COL12A1 0.4 0.3 7.3 3.5 19.1 11.2 
COL5A1 2.4 1.9 8.6 5.4 21.0 17.5 
COMMD8 8.5 7.0 28.6 11.2 85.1 39.2 
COMT 13.9 3.9 21.4 7.1 107.5 18.8 
COQ10B 7.5 6.7 10.6 9.0 43.4 37.4 
CPEB4 2.6 4.1 11.0 7.8 88.4 76.3 
CPM 0.5 0.6 13.0 16.3 104.8 110.1 
CRB3 8.7 9.6 13.7 17.6 42.1 31.9 
CREB3L1 2.9 3.2 12.3 17.6 20.8 44.3 
CREB3L2 5.8 5.5 22.1 24.7 95.2 75.9 
CRELD2 11.2 7.1 15.6 17.0 67.3 25.9 
CREM 13.4 14.9 16.5 17.7 57.9 59.5 
CRH 0.1 0.2 58.8 26.6 349.5 70.5 
CRIP2 2.3 0.6 4.0 1.0 467.0 65.4 
CRIPT 6.5 6.8 10.2 7.2 40.2 21.7 
CRISPLD1 10.9 8.0 10.9 7.7 44.8 21.6 
CRISPLD2 1.4 0.4 2.1 3.7 24.7 10.3 
CRLF3 8.3 8.0 7.6 7.0 28.8 24.2 
CRTC2 11.6 10.3 13.2 15.7 37.2 25.5 
CRYAB 0.9 0.5 7.9 7.4 75.4 26.4 
CSF2RB 0.0 0.0 0.2 0.2 17.0 10.1 
CSF3R 0.1 0.1 57.0 43.5 138.6 112.8 
CSGALNACT
1 0.1 0.1 5.6 4.3 37.2 25.6 
CSNK1A1 53.1 70.4 81.8 79.7 291.8 264.9 
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CSNK1E 82.0 82.7 72.0 93.5 285.9 137.8 
CSNK2A2 24.3 17.5 28.6 33.4 115.9 52.1 
CSRNP1 2.5 1.9 5.6 6.1 19.3 14.5 
CSRP1 4.4 3.0 30.2 25.8 107.9 52.2 
CTB-60B18.12 0.1 0.1 0.3 0.5 10.7 15.9 
CTD-
2540B15.7 1.2 0.6 102.4 114.2 377.2 445.0 
CTD-
2620I22.3 0.0 0.0 16.0 17.1 147.0 227.9 
CTD-
3193O13.13 11.1 7.3 7.4 11.8 23.0 17.4 
CTD-
3222D19.11 2.7 4.0 7.8 12.0 28.2 22.9 
CTDP1 10.4 7.9 8.0 11.0 22.1 18.1 
CTSA 17.7 16.0 31.3 42.1 129.2 81.3 
CTSB 10.9 13.5 113.7 133.1 473.2 493.0 
CTSH 11.9 9.5 24.6 34.9 100.8 39.3 
CTSL1 17.7 22.5 325.8 375.1 1,052.6 1,066.4 
CUL2 13.2 16.5 16.1 11.9 32.7 46.7 
CYB561D2 6.9 6.3 9.6 11.8 29.7 19.6 
CYP11A1 1.6 1.6 56.6 89.1 958.3 669.1 
CYP19A1 0.2 0.2 84.8 65.7 608.4 609.5 
CYP1A1 0.1 0.1 12.7 17.6 46.0 49.0 
CYP2C18 0.1 0.0 3.5 4.6 87.6 88.8 
CYTH3 3.7 4.1 5.7 7.6 29.9 28.7 
CYYR1 13.0 10.5 11.3 9.6 62.1 26.9 
DAB2 1.4 1.1 51.8 48.9 541.9 557.3 
DACT2 1.1 1.4 1.4 3.0 120.9 66.4 
DAP 13.3 16.3 31.5 40.0 132.8 80.1 
DAPK3 22.3 19.0 45.6 52.8 188.0 110.6 
DAXX 26.0 25.1 18.2 27.3 120.6 43.8 
DAZAP2 27.4 20.4 38.0 35.3 177.2 159.3 
DCAF12 8.7 10.5 27.9 29.5 170.9 157.7 
DDA1 27.5 21.9 42.0 44.8 143.7 78.6 
DDB1 80.1 77.3 143.0 165.4 397.4 322.5 
DDX3X 75.9 91.2 72.1 58.8 174.4 213.3 
DDX59 9.5 8.4 9.9 9.0 23.4 16.3 
DDX6 22.7 29.7 24.9 21.6 72.6 73.3 
DEDD2 16.7 18.3 24.8 33.0 94.1 84.3 
DEPDC1B 29.0 26.1 16.8 13.8 77.7 87.9 
DHRS2 0.7 1.5 0.5 0.9 25.2 27.2 
DHRS9 0.0 0.0 0.1 0.0 17.8 10.0 
DHX32 7.5 9.4 16.5 20.6 55.6 49.5 
DIAPH1 18.2 16.6 20.8 29.2 67.7 45.8 
DIO3 0.7 0.1 73.0 140.3 1,650.1 728.7 
DIO3OS 0.1 0.0 7.8 7.9 72.3 41.4 
DIRC2 4.4 4.3 25.4 44.0 195.6 168.6 
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DLX3 0.2 0.2 63.3 98.7 203.6 187.3 
DLX4 0.3 0.3 7.6 12.0 43.7 18.9 
DNAJA1 79.5 68.0 91.3 73.0 334.8 266.7 
DNAJA2 30.0 30.8 42.4 40.0 120.9 129.9 
DNAJB9 4.4 5.0 21.2 13.0 118.7 129.0 
DNAJC3 3.2 3.5 9.0 5.9 45.6 40.1 
DPH1 7.4 6.8 9.6 14.1 34.0 17.4 
DUSP1 1.9 2.7 2.3 3.8 21.1 33.8 
DUSP5 6.5 5.9 46.3 59.1 266.1 186.4 
DUSP8 1.2 1.2 1.9 2.6 20.8 12.5 
DUSP9 0.4 0.4 7.1 11.7 148.4 72.4 
DVL3 13.9 13.8 46.7 43.0 187.8 154.3 
DYM 16.6 20.4 19.5 23.9 55.0 35.0 
DYRK2 6.7 6.7 5.2 4.5 51.0 26.8 
DYSF 1.8 2.0 14.5 21.7 105.8 63.3 
E2F8 2.5 2.4 5.7 3.1 27.9 10.9 
EAF1 4.5 4.7 6.7 8.8 62.7 38.4 
EAF1-AS1 8.0 12.0 13.5 17.6 136.4 85.7 
ECM1 0.5 0.3 0.9 1.1 42.9 18.5 
EDARADD 1.5 1.6 3.3 5.3 11.2 16.6 
EDEM1 2.8 4.0 11.1 11.0 55.8 47.1 
EEPD1 1.8 2.3 4.5 4.3 55.2 29.5 
EFHD1 1.9 1.4 7.0 15.9 71.1 41.4 
EGFR 0.5 0.5 5.2 4.5 23.9 23.6 
EHD1 12.4 9.8 29.3 44.6 326.0 341.0 
EHD3 3.3 3.0 3.0 2.5 44.1 11.7 
EIF1 208.5 239.5 397.6 506.3 1,050.7 1,116.9 
EIF1AD 10.1 8.7 8.3 13.9 32.4 17.6 
EIF2AK3 4.8 6.1 6.3 6.3 19.7 22.4 
EIF2B2 14.0 14.6 44.3 38.9 333.2 208.1 
EIF3B 81.0 88.1 66.5 92.5 245.3 164.1 
EIF3J 31.7 30.8 41.4 33.8 93.0 76.7 
EIF4G1 84.3 75.6 120.4 154.3 388.1 291.1 
EIF4G2 307.8 291.9 421.1 357.1 1,209.6 1,364.7 
ELF3 6.0 4.5 43.2 76.9 207.9 201.5 
ELL 2.8 2.7 5.1 8.7 58.7 52.2 
ELMO1 3.8 3.7 23.0 25.4 79.9 59.7 
EMC3 15.4 12.7 24.3 29.0 70.3 44.6 
ENDOU 0.0 0.1 5.3 3.5 67.8 52.7 
ENG 0.9 1.2 7.1 8.2 65.4 55.2 
ENGASE 6.3 6.2 6.4 8.9 46.0 19.2 
EPAS1 0.5 0.6 218.3 158.0 600.4 380.9 
EPB41L3 5.5 5.5 91.8 47.3 221.0 226.1 
EPHB4 35.5 29.2 42.9 53.3 255.4 194.4 
EPS8L1 13.0 12.2 41.7 26.4 225.6 157.3 
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EPS8L2 15.4 16.7 33.8 34.1 109.0 81.6 
ERC1 3.6 5.1 6.5 6.2 14.8 12.4 
ERN1 0.2 0.4 2.4 2.2 12.3 14.4 
ERVFRD-1 0.0 0.0 19.1 25.9 161.0 232.0 
ERVH48-1 12.6 1.2 15.7 5.1 40.6 30.9 
ERVV-1 0.1 0.2 39.1 34.7 525.2 595.1 
ERVV-2 0.3 0.1 44.1 45.8 344.8 383.3 
ERVW-1 0.1 0.1 22.4 19.1 427.1 271.6 
ESRRA 10.1 9.7 18.8 19.1 51.6 35.8 
ESRRG 0.5 0.4 12.4 5.4 63.7 74.2 
ETF1 47.6 45.3 52.6 48.3 145.3 161.1 
ETV4 33.7 31.9 3.7 1.6 177.2 51.5 
EXO1 9.4 11.4 4.8 6.3 32.0 16.1 
EXOC6B 8.2 9.0 8.1 6.8 16.6 23.5 
EXT1 7.4 7.3 5.2 13.1 31.9 12.5 
EZR 77.4 72.5 222.1 388.1 921.3 539.3 
FADS3 17.1 15.8 22.0 20.7 148.6 64.6 
FAM102A 7.8 7.1 17.5 20.6 74.4 68.1 
FAM104A 12.8 12.3 18.3 21.8 70.7 41.9 
FAM107B 8.6 9.6 27.3 24.4 101.8 58.0 
FAM120A 11.9 12.9 19.2 20.3 59.0 35.9 
FAM129B 14.1 10.9 38.6 45.2 173.3 137.0 
FAM131A 5.4 6.3 8.6 12.1 38.2 36.1 
FAM135A 11.3 12.2 13.5 7.9 23.4 31.2 
FAM13A 4.9 6.5 6.2 3.9 20.9 16.4 
FAM214A 3.2 3.2 26.1 13.7 69.8 98.7 
FAM25C 0.0 0.0 0.7 0.4 12.8 17.4 
FAM43A 1.2 1.2 5.4 8.9 93.9 62.6 
FAM46A 0.8 0.9 23.5 16.2 239.1 166.5 
FAM49A 1.1 0.9 30.9 25.1 177.6 222.5 
FAM58A 8.0 7.4 11.2 11.5 42.4 20.6 
FAM65B 4.5 1.6 8.6 7.0 150.4 130.0 
FAM83D 22.9 24.0 10.5 19.9 84.2 50.1 
FAM83F 3.5 3.8 8.2 11.4 155.4 136.1 
FAM83G 5.5 5.0 9.8 11.8 57.0 35.1 
FANCA 18.6 13.8 14.1 17.9 83.6 30.9 
FANCE 4.6 5.1 7.0 9.6 40.8 21.8 
FAR2 14.4 13.3 10.0 4.5 174.1 121.4 
FBRS 3.4 3.0 25.7 29.4 163.6 130.5 
FBXL3 6.9 6.2 14.4 7.9 24.8 21.9 
FBXO11 14.5 13.2 36.1 29.9 74.9 109.1 
FBXO32 0.2 0.2 2.6 2.1 36.0 28.6 
FBXO33 4.1 4.8 5.8 5.1 11.3 12.5 
FCHO2 3.1 2.2 9.6 4.6 27.1 20.1 
FDX1 6.0 6.4 23.4 28.5 328.5 209.5 
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FEZ2 9.3 11.2 48.7 59.5 96.3 146.1 
FGD6 4.6 7.2 10.3 6.5 41.3 52.6 
FGF18 0.3 0.1 3.9 4.7 42.8 23.9 
FHDC1 4.2 3.7 27.2 32.7 226.3 203.8 
FIBCD1 1.6 2.0 1.8 1.7 110.3 33.4 
FIP1L1 22.8 19.3 61.4 43.1 184.6 150.6 
FKBP2 30.8 27.6 48.3 53.0 152.2 90.4 
FKSG52 3.6 3.3 6.3 4.8 14.5 18.8 
FLCN 6.6 7.6 8.4 14.8 21.1 34.3 
FLVCR2 2.5 3.9 8.7 11.9 72.7 73.5 
FMNL2 13.0 10.8 29.3 14.7 49.6 54.9 
FNBP1 6.1 7.0 7.8 12.0 39.2 17.6 
FNDC3A 7.6 8.3 14.5 6.4 66.8 21.5 
FOS 2.3 2.5 2.2 2.4 18.2 10.7 
FOSB 0.1 0.2 5.1 3.6 65.0 33.0 
FOXI3 3.9 4.4 13.0 14.5 56.0 47.2 
FOXO6 1.3 1.3 35.9 36.3 155.5 187.1 
FRMD4A 6.4 4.8 26.5 23.8 119.8 55.8 
FRRS1 1.0 0.8 9.8 3.5 29.8 11.4 
FURIN 7.0 7.0 87.3 109.7 545.2 451.2 
FXYD3 0.2 0.1 10.1 16.0 33.8 37.4 
FYN 24.6 29.9 36.5 36.6 125.5 92.5 
GABPB1 16.7 15.6 18.1 19.0 44.0 35.0 
GADD45B 2.1 2.2 6.3 9.6 37.6 38.0 
GADD45G 8.3 6.1 58.5 75.9 502.3 411.0 
GALNT2 15.4 16.7 18.1 17.2 242.4 93.6 
GAPVD1 5.1 7.5 8.0 8.2 20.2 20.2 
GAS2L3 3.7 4.7 7.7 7.6 11.0 29.8 
GAST 0.0 0.0 16.3 28.2 109.5 110.9 
GATA2 0.3 0.1 126.4 148.1 667.1 476.9 
GATA3-AS1 0.0 0.0 11.1 10.7 30.0 23.9 
GCLM 2.6 4.5 3.7 4.3 10.4 11.9 
GCM1 0.0 0.0 28.9 22.4 98.5 71.5 
GCNT1 7.3 9.2 6.8 4.9 129.9 29.0 
GDAP2 3.9 4.7 5.7 4.7 18.0 15.5 
GDE1 21.9 25.5 43.1 57.5 128.1 97.5 
GDF15 1.5 1.6 162.7 219.7 996.1 851.3 
GDPD5 1.4 1.4 6.1 6.9 75.9 38.6 
GET4 22.8 24.1 50.4 50.7 358.0 224.7 
GFPT1 18.8 21.5 26.4 23.1 78.4 58.9 
GLA 16.4 21.9 46.9 76.4 109.2 183.6 
GLCCI1 7.3 10.2 10.1 8.9 27.8 15.6 
GLDN 0.2 0.2 9.8 4.2 29.9 28.8 
GLTP 6.1 5.0 10.9 13.1 59.0 32.2 
GLTPD1 3.7 3.5 6.9 8.8 19.8 13.6 
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GM2A 9.5 10.6 34.2 29.6 155.7 49.2 
GMEB1 5.1 5.2 7.6 9.7 28.4 31.1 
GMEB2 4.7 3.5 4.5 5.1 12.2 13.1 
GMPPB 6.8 5.6 12.4 15.5 51.0 44.8 
GNA11 4.5 4.6 8.6 11.9 27.1 17.4 
GNAI1 8.4 9.3 15.9 12.3 43.5 44.1 
GNB1L 4.9 7.1 5.4 7.7 20.0 16.8 
GNE 2.4 2.3 5.3 4.3 40.1 15.2 
GNG12 9.8 11.7 29.7 13.5 113.0 68.4 
GNS 8.5 8.2 19.2 19.2 51.8 31.1 
GOLGA2 9.7 7.9 19.4 22.6 52.8 43.6 
GOLGA3 3.2 2.1 6.8 6.8 20.0 11.3 
GOLT1B 22.9 23.4 20.9 14.1 71.5 41.7 
GOPC 7.6 8.8 15.9 10.2 30.7 31.0 
GORASP2 34.0 39.3 40.6 53.7 105.7 97.3 
GPC1 10.8 7.8 36.4 34.9 151.0 86.1 
GPR126 0.7 0.8 10.4 3.3 42.6 22.9 
GPR157 1.0 0.5 18.0 24.8 60.6 61.4 
GPR32 0.0 0.0 1.6 2.4 15.6 13.8 
GPR37 3.3 1.4 7.1 6.6 20.5 11.5 
GPRC5C 9.1 9.5 6.0 11.3 91.6 27.9 
GPX3 15.9 17.3 10.1 13.9 69.3 38.0 
GRAMD1B 2.5 2.1 4.4 4.7 17.6 10.2 
GRAMD3 4.4 3.2 25.9 21.7 177.9 167.6 
GRB7 10.4 12.1 13.3 19.0 41.7 33.7 
GRHL3 0.7 0.8 8.2 16.6 22.2 42.1 
GSE1 13.9 17.2 43.5 49.6 146.9 130.7 
GSK3B 11.4 11.0 36.8 36.7 131.8 120.6 
GSTA3 0.1 0.0 0.1 0.1 17.4 21.3 
GTPBP4 29.0 27.2 22.0 19.6 79.1 50.5 
GYS1 10.4 13.1 20.0 24.6 71.3 38.5 
H2AFX 58.8 54.9 49.6 89.4 154.1 153.3 
HAP1 0.6 0.5 9.5 8.1 28.3 23.7 
HBEGF 1.0 0.9 0.6 0.3 16.7 13.3 
HBP1 11.5 14.9 15.4 15.8 49.5 84.1 
HDAC5 15.8 11.9 41.6 50.6 270.7 197.7 
HEATR5A 6.1 7.7 10.1 9.0 50.0 17.8 
HERPUD1 4.3 9.0 90.1 138.6 373.3 414.5 
HES1 9.8 10.0 8.1 10.2 70.6 86.1 
HES2 0.2 0.2 1.6 2.2 66.8 20.2 
HEXIM1 6.8 5.5 32.8 36.5 186.3 244.6 
HEY1 0.8 0.6 16.2 12.4 211.2 116.9 
HID1 4.2 4.0 15.7 13.5 46.9 22.0 
HIST1H1C 6.0 3.6 5.4 5.1 27.4 18.7 
HIST1H2AC 3.5 2.2 12.2 7.8 19.5 22.7 
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HIST1H2BK 10.1 8.3 23.5 17.9 93.8 85.8 
HIST1H2BO 0.4 0.5 1.7 1.2 11.8 10.5 
HIST2H2AA3 1.0 0.5 1.7 2.9 54.6 54.0 
HIST2H2AA4 1.9 1.0 6.5 8.6 210.5 216.7 
HIST3H2A 7.1 3.2 30.0 39.4 171.2 225.9 
HLA-DRB1 2.6 4.3 3.4 15.9 14.7 72.2 
HMG20B 29.4 27.7 33.7 49.0 232.3 66.6 
HMGCS2 0.0 0.0 2.9 2.4 113.6 110.2 
HMOX1 6.8 6.2 158.7 231.0 615.1 644.9 
HOOK3 3.5 3.9 10.4 7.3 16.7 26.7 
HOPX 0.2 0.2 178.8 168.2 1,516.6 1,088.1 
HPCAL1 1.8 1.9 10.1 17.3 117.5 94.5 
HSD11B2 10.3 9.1 20.4 50.5 116.3 144.5 
HSD17B1 0.2 0.5 21.0 19.4 142.1 111.3 
HSD3B1 0.2 0.6 44.1 60.6 627.5 646.5 
HSPA13 11.6 16.1 13.0 9.2 40.2 38.1 
HSPA1A 12.3 13.8 16.2 31.4 134.9 86.8 
HSPA1B 13.8 16.4 26.9 58.6 234.6 181.0 
HSPA5 116.7 98.1 145.5 158.7 723.3 632.7 
HSPA8 860.6 747.6 828.0 899.0 2,189.1 1,591.5 
HSPB1 102.4 91.5 522.5 918.9 4,019.9 2,901.7 
HSPB1P1 1.6 1.9 4.1 8.5 38.8 23.0 
HSPB8 5.5 9.4 160.1 192.9 1,284.7 1,099.8 
HSPH1 37.0 35.0 36.3 29.0 82.0 83.7 
HTRA4 0.0 0.0 3.0 1.9 105.1 21.5 
HYOU1 54.7 54.4 47.4 63.5 195.5 119.5 
ICK 1.8 2.7 8.6 6.4 24.0 22.3 
ID4 6.5 4.1 19.2 28.6 101.1 135.5 
IDH3A 9.0 14.0 12.7 12.3 54.7 36.6 
IDS 7.7 9.7 7.3 11.0 66.5 37.9 
IER2 20.2 20.6 28.1 38.0 158.9 100.0 
IER3 12.3 7.7 36.9 42.9 183.1 54.6 
IER5L 0.3 0.2 12.6 17.1 59.0 29.4 
IFI6 5.8 8.8 160.8 121.7 669.0 334.1 
IFNGR1 13.1 13.3 16.7 11.2 39.6 34.0 
IFRD1 17.4 25.3 93.3 84.8 312.6 353.5 
IFT20 14.5 12.0 25.7 22.0 62.8 52.2 
IGF2 0.6 0.3 178.8 111.8 459.7 312.1 
IGSF5 1.4 1.3 0.4 2.1 21.0 22.2 
IL10RB 1.2 0.8 4.3 5.8 12.0 11.4 
IL20RB 0.9 0.9 1.0 1.0 18.0 14.9 
ILVBL 16.7 17.7 19.1 22.8 51.9 36.0 
ING2 10.2 9.1 10.3 10.4 26.9 19.3 
INHA 0.5 0.3 0.7 0.9 173.6 63.3 
INSIG1 25.9 24.7 15.5 23.2 111.0 86.9 
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INSL4 0.0 0.0 0.9 0.4 48.9 28.3 
IRF2BP2 8.0 5.6 16.3 19.1 48.6 38.9 
IRF7 3.6 3.1 7.9 9.2 23.7 16.6 
IRX4 0.4 0.3 8.3 5.1 23.2 13.8 
ISG15 11.1 11.0 25.5 20.9 61.9 60.2 
ITCH 6.7 9.9 15.4 16.4 88.2 83.9 
ITGA1 1.0 1.1 7.7 3.3 13.6 16.0 
ITGB1BP1 15.0 16.6 31.8 26.4 99.4 57.3 
ITSN1 23.7 23.1 30.4 30.1 69.0 81.7 
JUNB 2.0 2.5 9.0 15.2 76.9 66.0 
JUND 31.3 24.0 118.6 161.6 532.5 529.1 
KALRN 1.6 1.1 17.4 14.9 58.1 64.2 
KAT2B 0.4 0.5 9.3 5.8 19.4 15.7 
KATNBL1 18.3 23.7 86.2 75.2 231.4 448.0 
KAZN 3.0 3.1 8.0 7.3 40.7 16.4 
KCNK1 8.5 8.9 12.5 13.7 31.1 23.3 
KCNN4 0.5 0.2 7.9 5.2 144.6 58.3 
KCTD5 10.6 9.8 14.0 19.1 35.7 34.0 
KDELR2 29.7 27.3 61.8 67.3 210.1 147.6 
KDSR 9.5 15.8 25.1 26.1 92.5 53.8 
KHK 3.4 4.2 2.0 2.1 165.0 56.3 
KIAA0040 1.2 3.9 10.9 5.6 134.5 86.7 
KIAA0100 16.2 16.9 17.7 22.6 62.1 39.1 
KIAA1671 3.3 3.2 6.2 9.2 35.0 35.7 
KIF13A 10.3 12.5 8.8 8.6 42.8 32.7 
KIF21A 8.7 10.0 18.1 8.3 29.6 36.1 
KIF2A 18.0 21.6 17.5 12.3 70.9 65.3 
KLF10 5.2 7.5 11.5 19.4 52.5 53.3 
KLF16 9.3 7.8 6.7 10.7 24.6 16.0 
KLF4 0.9 0.8 21.6 36.6 56.1 79.6 
KLHL21 4.1 4.5 6.8 9.9 17.5 17.5 
KLHL8 1.4 1.9 2.2 1.3 22.1 15.7 
KMO 0.0 0.0 1.8 0.7 24.9 22.8 
KPNA6 12.5 10.7 11.4 17.6 34.5 25.3 
KRT17 0.2 0.1 6.1 3.6 17.5 15.9 
KRT18 116.0 82.0 636.7 887.5 4,567.6 3,275.6 
KRT23 0.1 0.1 73.2 85.9 237.4 393.3 
KRT8 163.6 87.7 1,281.8 1,522.1 5,343.8 3,433.9 
KRT80 0.0 0.0 25.5 12.4 73.1 67.5 
KYNU 0.1 0.1 11.6 5.5 106.3 76.1 
LARP4B 12.2 12.8 20.8 24.8 75.1 61.0 
LATS2 4.2 4.2 12.6 12.2 48.0 38.8 
LGALS13 0.0 0.0 3.2 2.0 81.3 47.8 
LGALS16 0.1 0.3 42.2 59.7 610.9 814.1 
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LGALS8 5.6 9.0 14.0 11.1 22.6 32.8 
LGALSL 7.9 11.2 29.8 23.3 88.8 50.8 
LGR4 25.0 27.3 44.5 29.7 108.2 107.5 
LIN37 3.6 3.2 18.6 23.3 72.5 63.6 
LINC00085 2.9 2.0 4.6 2.3 19.2 11.5 
LIPG 3.6 3.8 4.1 8.5 12.7 16.1 
LMNA 11.2 11.2 75.1 97.6 201.1 175.1 
LMO2 0.7 0.4 18.5 15.9 99.7 73.7 
LPHN3 3.6 4.2 13.8 7.3 33.7 28.4 
LPIN2 3.2 4.2 9.4 13.4 31.1 19.4 
LRRC59 32.9 28.6 36.4 41.9 115.6 68.4 
LURAP1L 0.1 0.4 4.0 2.5 29.4 25.8 
LYN 15.9 15.1 105.9 109.1 392.1 402.4 
LYPD3 1.9 2.2 23.2 43.0 130.3 103.7 
LYPD5 0.5 0.2 17.9 12.3 93.4 32.5 
MAFF 1.1 1.5 15.4 16.9 128.0 75.4 
MAFG 9.0 11.9 13.8 21.3 36.2 35.9 
MAFK 4.3 4.0 14.0 13.4 142.2 53.6 
MAGI1 13.7 15.2 11.4 11.1 75.7 47.5 
MAGT1 13.0 12.7 15.5 12.3 33.7 26.9 
MAML3 1.5 0.9 6.0 5.2 17.3 14.5 
MAN1A2 3.5 4.1 22.4 15.6 219.0 232.7 
MANF 46.3 32.6 67.9 65.3 263.3 174.0 
MAOA 1.9 1.1 22.1 22.3 146.5 40.6 
MAP1LC3A 2.9 3.7 4.8 11.2 21.1 12.4 
MAP1LC3B 19.0 16.4 27.7 42.0 68.1 110.8 
MAP1LC3B2 2.8 2.2 4.0 6.3 15.1 22.7 
MAP3K13 4.1 4.7 6.8 6.7 16.8 14.2 
MAP3K4 8.7 7.7 11.9 9.1 28.8 17.1 
MAP3K8 2.2 4.7 11.8 12.7 52.5 43.8 
MAP7 20.5 24.4 16.6 18.8 77.6 86.8 
MAPK4 1.4 1.4 4.1 5.8 17.7 12.4 
MARCH6 22.1 26.9 31.8 34.6 78.3 61.6 
MARK2 10.1 9.9 23.1 33.3 62.2 67.8 
MAST4 0.4 0.5 1.4 2.8 23.7 26.7 
MATN2 2.4 3.7 7.2 6.1 18.9 11.7 
MBD3 25.3 18.9 32.6 33.3 105.0 56.2 
MBNL2 0.7 0.6 27.8 9.7 75.9 62.8 
MBNL3 1.6 2.3 59.1 69.6 112.4 317.7 
MCFD2 23.0 24.9 33.8 29.0 132.8 75.1 
MED10 13.2 13.2 34.5 32.2 74.3 74.2 
MED12L 1.0 1.5 14.6 13.1 29.0 34.3 
MED13 6.0 6.3 20.0 15.8 50.3 74.7 
MED26 3.0 2.4 3.8 6.2 11.6 13.5 
MED27 18.1 19.6 18.0 21.4 45.5 38.2 
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MED31 6.9 5.8 9.1 8.9 19.9 17.7 
Metazoa_SRP 7.9 4.4 15.0 6.7 45.4 27.6 
METRNL 5.3 6.0 63.2 62.7 171.8 166.9 
MEX3D 19.2 13.8 31.4 35.2 124.5 50.4 
MFAP5 0.2 0.4 37.2 12.8 219.6 85.6 
MFI2 0.7 0.7 2.1 2.3 13.3 10.0 
MFSD12 16.4 15.3 17.4 20.3 289.7 81.8 
MGAT1 30.2 27.9 46.0 53.3 256.2 113.8 
MGAT4A 1.0 1.7 19.5 9.4 106.6 72.4 
MICALL2 1.4 1.4 3.4 4.5 73.1 18.8 
MIDN 37.8 34.3 59.4 85.5 265.6 371.0 
MIER3 8.4 9.1 21.6 14.6 27.3 55.7 
MIR22HG 1.5 1.3 14.3 10.8 35.0 43.3 
MKNK2 37.1 32.7 64.1 67.4 380.8 205.0 
MLL3 4.2 3.6 10.4 7.1 26.3 27.6 
MLLT1 7.2 6.4 33.2 33.1 264.0 197.0 
MLPH 4.7 5.0 5.4 4.4 15.2 11.9 
MME 6.4 5.5 19.7 4.1 37.6 41.9 
MMP15 16.2 11.3 22.3 27.3 91.1 51.1 
MMP19 1.7 2.5 7.5 8.7 18.7 16.1 
MMP2 14.7 6.9 21.4 28.4 272.5 150.8 
MOB3B 6.1 9.3 13.4 14.5 33.3 32.5 
MON1B 7.7 9.0 12.1 19.1 48.1 46.5 
MORC4 0.6 1.7 6.6 12.1 19.5 36.7 
MOSPD1 8.6 16.4 24.0 32.1 117.3 174.3 
MPP1 5.0 6.4 53.5 46.5 135.6 117.9 
MREG 7.8 7.4 8.3 12.2 43.8 35.8 
MRGPRX1 0.1 0.1 94.5 79.7 399.4 612.0 
MRGPRX3 0.1 0.0 4.9 4.3 20.2 31.2 
MT1E 22.0 34.9 9.1 7.1 133.4 41.7 
MT2A 21.1 42.7 8.4 11.3 129.0 49.3 
MTAP 15.7 19.8 18.2 17.5 77.5 42.8 
MTHFD1L 31.9 41.4 31.6 46.9 196.0 74.8 
MTM1 3.5 5.3 3.2 3.1 15.2 28.3 
MTMR4 6.2 6.5 12.2 11.5 92.8 29.4 
MTSS1 2.4 2.0 0.8 0.5 90.3 39.8 
MTUS1 1.4 1.4 23.8 15.5 71.1 80.4 
MUC15 0.1 0.1 70.8 52.2 254.0 430.7 
MUCL1 0.0 0.0 0.3 1.1 30.7 56.0 
MVP 1.1 1.4 4.8 4.1 56.7 35.3 
MX1 1.3 1.7 6.5 5.7 29.6 21.6 
MYC 13.9 14.4 6.0 5.0 53.9 15.3 
MYO10 23.3 25.7 16.5 18.5 49.0 71.4 
N4BP1 8.7 9.8 6.4 7.4 36.5 27.8 
NABP1 0.8 0.6 37.4 22.7 74.4 102.0 
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NACC2 3.1 2.7 2.3 3.3 26.3 11.7 
NBPF10 4.7 2.9 8.6 6.8 37.6 30.7 
NBPF14 5.5 7.2 4.4 8.9 14.2 40.3 
NCOA3 4.2 4.8 24.5 23.5 72.0 106.5 
NCOA4 29.9 31.9 74.8 75.8 183.4 245.7 
NEDD4L 19.4 21.9 18.6 25.6 53.6 72.3 
NEDD9 1.6 1.3 10.6 11.2 22.5 27.6 
NEK7 3.7 3.4 16.4 9.2 40.0 47.5 
NEURL 0.3 0.2 58.4 75.1 553.4 351.2 
NFATC3 5.6 7.1 4.3 6.2 21.4 14.8 
NFE2L3 26.7 36.1 60.2 33.8 156.5 145.2 
NFKB2 10.6 11.5 11.8 22.6 52.5 48.4 
NFKBIA 13.0 11.6 28.5 38.6 180.1 150.2 
NFYA 10.3 10.7 17.7 14.5 66.4 37.2 
NHSL1 3.0 2.9 7.1 8.2 29.1 26.6 
NIPAL3 2.1 2.7 5.5 6.9 19.0 10.7 
NKIRAS1 2.9 2.8 4.0 4.7 20.4 13.1 
NLRP7 1.1 1.1 6.4 4.3 18.8 17.8 
NMNAT2 3.3 4.8 9.8 10.1 28.9 18.5 
NMT1 26.6 23.9 25.1 29.0 82.4 50.5 
NOL12 9.0 6.6 6.6 8.7 19.5 15.1 
NOS2 0.4 0.1 17.9 6.9 76.2 36.2 
NOS3 1.7 1.4 3.6 4.8 11.8 12.7 
NR1H2 15.7 14.0 13.9 19.2 37.2 31.6 
NR2F6 40.4 33.8 111.4 116.6 422.1 252.3 
NR4A1 6.3 7.0 3.0 3.2 106.1 62.6 
NRBF2 12.0 10.9 15.7 16.6 73.7 107.3 
NSF 6.3 7.0 10.6 12.2 45.0 50.5 
NSFP1 2.0 3.8 2.6 3.8 18.1 22.7 
NSMAF 7.5 9.0 12.1 14.0 17.9 39.0 
NUCB2 11.2 9.3 67.4 31.5 275.4 190.2 
NUFIP2 18.9 27.2 35.2 28.3 132.9 230.0 
NUP50 25.5 29.1 40.3 33.8 90.6 78.9 
NUPL1 12.9 14.1 21.4 13.3 61.4 72.5 
NUPR1 0.3 0.5 13.0 16.7 72.4 46.6 
NUS1 29.5 27.5 46.3 43.5 176.1 197.5 
NUS1P1 1.7 2.4 3.2 3.4 27.5 33.2 
ODC1 33.8 22.2 68.5 44.1 239.6 125.6 
OFD1 9.0 8.5 14.2 7.5 23.2 22.6 
OPHN1 1.5 1.5 3.8 4.9 23.1 110.3 
OPN3 9.5 8.4 66.6 58.8 363.9 262.8 
OSBPL2 6.4 5.6 11.2 13.1 34.8 21.2 
OSTF1 6.7 6.5 19.0 17.0 82.6 46.0 
OTUB2 1.5 1.2 2.9 2.1 116.3 64.9 
OVOL1 0.6 1.2 43.1 58.1 81.3 152.4 
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P2RY6 0.1 0.0 17.3 8.2 35.0 19.8 
P4HB 174.6 157.7 305.2 354.7 1,177.6 833.3 
PABPC1 940.3 1,103.6 1,698.7 1,674.6 4,624.8 3,363.4 
PACSIN2 17.7 18.8 30.3 36.0 107.6 82.6 
PAFAH1B1 27.9 29.0 33.8 35.9 76.2 71.8 
PAGE4 0.5 0.3 10.9 6.7 35.9 54.0 
PAIP1 44.9 46.8 107.5 88.3 230.8 216.6 
PAK3 0.8 2.2 2.3 3.6 17.3 41.1 
PAK4 23.3 21.0 35.5 41.6 84.8 81.1 
PCTP 6.8 6.8 17.8 20.5 41.1 41.6 
PCYT1A 6.1 9.8 11.9 14.8 32.7 33.2 
PDE4DIP 12.1 12.3 23.0 37.9 266.2 279.8 
PDIA3 218.4 241.7 256.3 292.3 1,866.3 1,143.4 
PDIA3P 6.8 6.7 7.4 7.8 41.3 31.1 
PDIA5 11.4 11.0 13.9 17.3 50.1 25.4 
PDLIM2 16.6 14.1 45.2 38.7 464.0 202.7 
PDLIM3 3.8 1.5 1.3 1.3 11.5 15.4 
PDLIM5 9.0 14.5 7.0 10.4 53.8 55.7 
PELO 6.6 7.7 14.2 15.7 61.5 55.4 
PGC 0.1 0.1 1.9 2.2 14.9 11.5 
PGF 1.4 1.1 227.8 258.4 1,896.4 1,375.3 
PGM2 12.2 10.9 28.9 25.5 99.1 156.1 
PGPEP1 3.8 3.4 6.6 9.2 37.9 33.3 
PGRMC2 31.8 35.2 42.4 44.2 164.4 79.4 
PHF23 24.8 20.3 24.3 36.1 62.4 71.4 
PHKG2 17.2 15.6 49.3 45.1 137.6 75.1 
PHLDA2 2.9 3.3 117.5 116.8 753.9 508.2 
PHLDB3 2.6 2.4 39.5 50.3 99.8 119.9 
PHLPP1 9.5 9.8 8.1 9.5 39.9 31.6 
PHOSPHO1 0.2 0.1 3.3 7.0 271.5 299.2 
PHTF2 5.9 7.9 12.4 7.6 39.4 51.8 
PHYHIPL 0.5 0.6 3.5 4.2 89.8 104.5 
PID1 0.6 2.0 18.0 17.5 58.5 26.6 
PIGA 3.2 4.6 4.8 3.9 13.4 12.1 
PIK3C2A 11.7 13.6 24.7 10.4 37.6 91.6 
PIK3C2B 3.0 2.6 2.7 6.4 26.7 35.7 
PIK3R1 2.7 1.8 5.9 2.4 11.0 10.1 
PIM3 11.5 15.1 41.9 43.7 217.6 134.6 
PITPNA 15.2 19.4 28.5 38.0 136.2 90.2 
PITPNB 22.9 26.2 41.8 27.0 94.2 61.5 
PLA2G15 2.5 3.3 6.3 11.1 21.9 20.8 
PLCD3 7.2 7.4 16.7 17.8 130.2 92.3 
PLCL2 6.0 5.8 13.4 9.7 44.6 51.1 
PLCXD1 13.8 14.6 12.4 17.4 28.5 55.4 
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PLCXD1 13.8 14.5 12.4 17.4 28.5 55.3 
PLCXD2 0.7 0.4 0.3 0.3 13.6 10.8 
PLEC 7.4 5.5 11.0 14.9 63.7 39.8 
PLEKHA6 1.7 1.4 9.5 14.1 58.0 41.9 
PLEKHA8 6.0 8.3 5.6 4.8 23.6 16.2 
PLEKHB2 21.5 21.0 37.3 48.2 144.2 103.4 
PLEKHF1 4.0 3.1 14.7 21.6 37.1 48.2 
PLIN2 14.5 18.9 144.0 267.2 637.3 1,396.6 
PLK3 2.2 2.1 3.4 2.6 18.2 11.9 
PLXND1 7.4 5.2 20.7 16.6 50.0 30.6 
PNPLA2 13.2 10.5 19.8 26.9 68.8 39.2 
PNPLA8 6.4 6.5 10.4 6.2 17.9 23.3 
POLR2J4 12.0 7.1 10.7 15.2 15.1 66.1 
POLR3H 8.5 10.4 10.4 11.7 45.6 21.1 
POU2F3 0.7 1.7 2.6 2.6 19.2 11.8 
PPAP2B 14.2 15.7 42.8 42.5 200.1 235.1 
PPARD 4.7 5.3 24.8 27.6 147.1 103.8 
PPFIBP1 5.5 5.3 13.8 7.5 94.4 35.5 
PPIB 277.6 247.0 419.8 387.3 1,204.1 673.6 
PPM1B 50.7 63.6 91.5 76.5 351.8 391.4 
PPM1D 4.8 4.6 12.0 9.3 63.4 59.1 
PPM1N 4.6 5.0 6.2 7.3 35.3 17.3 
PPP1CB 43.7 39.6 153.3 87.4 309.4 327.9 
PPP1R15B 11.4 11.7 18.1 22.5 62.6 59.6 
PPTC7 5.2 5.1 5.9 3.8 22.6 13.3 
PPY 0.1 0.0 1.2 4.5 10.9 12.5 
PRKAG2 6.3 6.5 11.6 9.8 88.2 31.6 
PRKCH 2.1 4.0 67.1 55.3 140.9 140.6 
PRKCZ 10.5 11.7 37.5 38.1 363.3 236.2 
PRLR 0.5 0.7 3.6 1.8 38.4 23.3 
PRR5 7.1 5.1 42.1 44.5 127.8 68.6 
PRR9 0.2 0.1 63.3 45.6 1,324.0 607.6 
PRRG1 4.2 7.1 8.4 6.7 16.6 15.0 
PRSS23 2.9 2.8 14.2 11.1 41.7 33.1 
PSMA6 140.6 142.9 169.9 182.8 494.6 358.6 
PSMC1 53.9 59.2 67.5 77.5 176.4 165.5 
PSMC1P1 3.9 3.9 5.5 5.3 13.2 12.2 
PSMC2 54.4 51.3 62.9 55.5 132.9 150.4 
PSMC4 46.5 47.2 56.9 73.8 206.4 156.6 
PSMD11 48.6 56.8 64.4 77.6 232.8 204.4 
PSMD12 26.7 32.6 26.3 21.7 59.9 73.6 
PSMD2 117.1 140.4 147.6 191.0 460.5 378.8 
PTDSS1 41.6 50.5 43.7 64.2 180.8 160.0 
PTEN 12.3 14.0 28.8 22.5 232.9 129.8 
PTGES 1.0 0.8 8.5 21.0 80.4 72.0 
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PTP4A1 30.4 26.0 87.5 90.4 188.5 195.9 
PTP4A2 68.0 69.6 81.1 103.0 494.1 435.0 
PTPN14 2.9 3.7 3.8 6.0 21.1 14.0 
PTPN21 3.9 3.1 24.8 35.1 382.8 627.6 
PTPRE 0.2 0.2 8.4 5.6 23.3 26.1 
PTRH2 20.6 16.0 18.4 16.1 77.7 35.7 
PVRL3 12.7 12.7 40.0 22.7 285.2 322.7 
PVRL4 0.1 0.3 26.6 25.9 80.5 61.7 
PWWP2B 3.3 3.2 18.9 21.9 134.3 94.8 
PXDC1 0.9 1.1 34.7 24.5 163.1 128.2 
QKI 46.9 62.4 40.5 33.5 184.1 137.3 
QSOX1 33.1 32.7 51.0 64.2 267.6 161.5 
RAB11A 122.0 152.2 293.7 294.7 772.2 718.4 
RAB11FIP5 4.4 5.7 18.1 29.9 58.7 61.2 
RAB18 22.1 26.9 43.5 27.6 81.8 79.4 
RAB21 7.0 8.4 11.8 13.5 28.6 31.3 
RAB2A 33.9 39.5 59.0 56.5 148.1 135.9 
RAB31 8.4 8.2 45.0 25.8 207.9 151.2 
RAB32 1.8 2.7 5.8 8.0 15.1 14.1 
RAB3IL1 1.5 2.0 7.5 7.6 34.9 21.3 
RAB8B 14.3 16.4 9.6 7.7 36.9 39.3 
RAB9A 14.5 14.9 22.6 20.9 77.1 78.5 
RABGEF1 4.1 4.0 4.6 4.6 23.9 21.1 
RAI14 49.9 64.8 61.0 38.1 230.5 300.0 
RALB 8.7 10.0 24.7 27.0 73.1 67.9 
RALGAPB 8.0 9.6 8.0 7.3 22.8 16.3 
RANGRF 26.3 23.1 21.3 27.2 81.5 48.7 
RAP1B 49.1 47.4 107.1 68.5 602.8 621.9 
RAPGEF2 13.9 14.2 21.8 20.4 29.2 69.4 
RARRES1 0.0 0.3 5.3 6.9 18.0 10.5 
RASA1 11.0 12.1 37.0 17.9 223.5 170.8 
RASAL2 4.9 6.6 14.5 9.1 45.9 55.0 
RASSF3 15.8 14.2 12.0 11.9 52.0 21.1 
RBBP6 18.9 18.1 34.7 32.2 202.9 260.1 
RBBP7 59.5 121.4 89.1 162.7 244.1 316.8 
RBM24 1.0 0.6 0.7 0.3 85.9 53.9 
RBM38 19.7 19.6 21.4 24.7 73.0 68.1 
RBM47 17.6 21.2 74.7 79.5 141.9 190.4 
RBMS1 27.0 20.4 45.8 29.7 152.0 111.3 
RCL1 8.5 7.3 8.3 11.0 59.9 22.2 
RDH10 1.6 2.5 7.1 6.6 47.9 32.2 
RDH13 7.5 6.2 19.9 13.8 74.1 47.2 
RDX 28.3 32.9 63.9 40.5 235.7 223.1 
RELL1 0.6 0.7 9.6 13.3 87.3 88.0 
RELT 1.0 1.2 2.9 3.3 25.8 16.6 
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RER1 35.5 33.9 70.9 86.0 264.5 141.7 
REXO1 13.8 8.3 12.9 13.9 30.9 25.0 
RFK 4.9 5.0 9.5 5.7 47.9 18.1 
RGS16 3.6 2.5 22.6 17.0 82.3 52.9 
RGS3 5.7 4.4 6.4 10.1 31.2 31.4 
RHEB 79.0 72.4 85.0 109.7 250.8 215.7 
RHOB 5.5 10.0 36.2 47.2 85.0 97.9 
RHOBTB1 3.3 2.5 34.5 24.4 379.3 187.0 
RHOG 12.5 12.4 17.4 24.7 53.0 48.5 
RHOV 1.0 1.4 7.3 9.6 66.8 46.4 
RICTOR 3.0 3.1 5.3 3.5 19.7 27.3 
RIN3 0.3 0.4 11.0 16.1 41.6 69.2 
RIPK2 9.8 11.8 17.9 15.0 60.9 50.2 
RIT1 10.1 9.3 21.5 16.6 63.4 64.8 
RLBP1 0.0 0.0 0.1 0.3 23.6 15.0 
RMND1 7.2 9.0 8.2 7.7 22.5 16.2 
RN7SL2 342.2 330.7 1,279.8 649.5 2,115.8 3,282.6 
RNF103 2.3 2.7 10.8 11.3 26.9 30.8 
RNF11 22.5 23.8 47.7 39.7 176.7 145.0 
RNF111 10.0 10.0 25.9 19.2 49.9 67.9 
RNF139 10.5 10.3 13.5 15.2 42.8 28.9 
RNF14 5.2 7.6 12.4 13.9 51.6 36.1 
RNF149 9.4 11.5 38.0 43.8 101.0 116.7 
RNF6 4.0 4.4 12.2 6.9 31.7 31.8 
RNPEPL1 2.8 2.8 12.7 14.9 42.7 24.9 
RNU6-11 199.6 324.4 304.7 307.7 1,061.0 1,478.6 
RNU6-25 194.9 499.9 379.1 344.2 976.3 1,313.8 
RNU6-26 194.9 499.9 379.1 344.2 976.3 1,313.8 
RNU6-31 241.7 354.5 298.2 274.2 647.8 1,469.2 
RP1-117B12.4 8.4 9.9 10.2 15.0 47.0 27.7 
RP11-
1100L3.7 20.5 14.2 17.3 19.0 65.5 40.5 
RP11-
1100L3.8 5.1 4.5 2.3 3.1 98.4 49.7 
RP11-
148K1.12 3.3 2.7 7.4 7.7 24.3 15.5 
RP11-
181G12.2 1.3 1.6 4.1 4.3 13.6 13.3 
RP11-18I14.7 2.4 3.1 9.2 5.6 44.7 18.3 
RP11-
192H23.7 6.3 9.0 6.1 8.5 20.3 13.8 
RP11-214C8.5 0.9 0.6 5.7 5.6 21.1 19.4 
RP11-
228B15.4 0.4 0.3 1.6 2.2 18.6 15.7 
RP11-24N18.1 42.9 47.7 66.1 98.5 224.5 171.1 
RP11-266L9.2 0.1 0.2 49.1 39.2 275.8 251.4 
RP11-
295G20.2 3.5 5.2 3.5 4.3 32.5 17.0 
RP11-297K8.2 2.1 2.7 10.4 10.1 30.1 27.0 
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RP11-
323N12.5 9.0 8.8 14.8 17.3 48.7 29.0 
RP11-353N4.1 0.2 0.2 1.5 6.4 37.0 65.2 
RP11-356I2.2 0.0 0.0 3.6 0.9 18.0 12.8 
RP11-
361D15.2 1.9 1.9 3.7 2.4 35.5 21.0 
RP11-363E7.4 3.4 1.9 6.8 6.6 21.5 16.7 
RP11-
366K18.3 0.0 0.0 0.9 1.1 11.1 10.3 
RP11-379F12.3 0.0 0.0 2.4 1.5 17.6 11.5 
RP11-
395P17.11 5.0 2.9 7.0 5.8 27.2 20.4 
RP11-400F19.6 4.8 4.7 18.5 20.8 53.8 48.3 
RP11-466P24.2 6.6 5.7 15.2 8.2 57.1 56.0 
RP11-473I1.9 3.7 3.8 6.4 9.5 13.9 22.9 
RP11-498C9.2 73.7 63.5 145.4 158.7 582.1 360.9 
RP11-530C5.1 11.3 12.1 10.9 10.4 46.2 18.7 
RP11-583F24.8 0.0 0.0 3.6 3.4 12.1 19.0 
RP11-676F20.1 0.0 0.0 1.0 0.5 11.6 20.0 
RP11-
707G14.1 9.4 14.6 12.4 13.1 29.8 33.6 
RP11-734I18.1 0.6 0.4 2.6 7.5 50.5 89.5 
RP11-796E2.4 1.3 1.3 4.7 4.8 46.6 38.2 
RP11-809N8.2 1.1 0.6 3.3 3.1 25.5 16.6 
RP11-
950C14.3 1.4 1.6 3.3 2.3 31.4 19.4 
RP11-973D8.4 6.7 5.6 36.3 36.8 85.4 73.8 
RP3-527G5.1 0.0 0.0 6.6 9.8 22.1 31.0 
RP4-781K5.2 19.2 12.4 40.8 46.6 207.4 181.6 
RP5-1129J21.3 0.6 1.6 3.6 6.5 10.6 12.8 
RP5-899B16.1 0.0 0.0 4.6 3.6 16.8 12.6 
RPN1 66.6 66.4 93.9 114.7 289.4 167.2 
RPS6KA5 1.0 0.6 6.0 3.3 31.9 26.5 
RPS6KB1 5.6 7.6 8.7 5.6 20.2 16.9 
RPUSD1 13.2 13.1 15.2 19.9 52.8 26.1 
RRBP1 22.5 18.5 28.0 30.0 201.7 123.9 
RREB1 2.4 2.5 10.1 12.2 35.7 26.6 
RTN2 5.7 4.5 13.0 14.6 44.7 17.0 
RUNX1 0.1 0.0 5.3 3.6 20.2 14.6 
RYBP 14.9 16.1 34.8 30.2 168.5 182.8 
S100A4 19.9 16.0 8.1 8.2 80.8 32.8 
S100A9 0.0 0.0 2.1 1.1 49.0 13.4 
S100P 0.0 0.2 105.6 160.7 909.1 793.9 
SAMD8 3.6 3.5 11.6 16.5 26.4 51.6 
SAR1B 10.7 8.9 28.7 20.1 53.9 56.3 
SAT1 33.4 32.0 79.6 155.1 423.5 260.2 
SBSN 0.1 0.1 2.3 1.3 55.4 22.8 
SCIN 0.1 0.6 3.7 5.9 24.0 18.4 
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SDC1 13.0 8.8 83.5 110.4 1,075.9 737.1 
SDCBP 56.6 56.4 91.3 46.3 475.1 413.9 
SDE2 6.8 7.1 6.9 7.2 18.4 18.5 
SDF2L1 19.0 13.7 41.1 41.9 146.3 76.8 
SEC11C 46.8 37.2 24.9 32.3 171.4 75.8 
SEC22B 13.9 14.5 29.0 27.2 62.4 62.7 
SEC24A 8.3 12.1 12.7 9.1 31.2 33.0 
SEC24D 18.2 17.7 18.8 12.1 52.9 53.0 
SEC31A 38.2 35.9 67.7 49.0 163.4 137.4 
SEC61A1 45.5 39.4 92.2 100.4 246.7 204.6 
SEC61B 138.4 128.4 171.9 170.1 438.7 347.0 
SECISBP2L 4.3 6.4 15.5 6.7 53.8 48.6 
SELT 40.9 42.7 113.6 114.2 654.3 543.6 
SEMA7A 4.1 4.5 56.3 55.6 256.0 219.6 
SENP5 3.9 3.1 5.9 6.5 13.0 14.7 
SERINC1 15.7 14.2 33.1 18.1 52.3 62.9 
SERP1 52.2 59.0 94.7 78.9 399.0 308.2 
SERPINB2 0.0 0.0 3.4 1.8 57.8 33.6 
SERPINB9 26.9 29.3 93.3 86.8 236.2 193.1 
SERPINE1 0.5 0.4 13.7 34.7 275.3 417.2 
SESTD1 6.2 6.8 8.3 12.9 188.2 194.7 
SETD1B 2.4 1.9 4.6 6.1 16.1 10.1 
SFXN1 17.7 19.9 20.7 21.8 70.4 55.2 
SGK1 5.8 5.9 109.2 106.8 959.3 825.9 
SGTA 31.2 25.4 34.3 40.2 100.1 65.6 
SH2B2 6.0 6.0 36.7 39.0 157.1 98.0 
SH3BP4 13.3 10.5 18.4 27.1 45.0 51.2 
SH3BP5 6.2 6.4 60.1 48.6 165.8 139.4 
SH3GLB1 10.1 11.2 29.4 24.9 68.1 63.3 
SH3TC2 0.1 0.1 0.4 0.7 14.4 12.0 
SHANK2 6.0 5.7 8.9 5.8 56.8 37.3 
SIAH1 19.8 17.6 61.5 43.1 505.6 330.9 
SIAH2 6.4 10.3 52.1 33.4 193.7 123.1 
SIK1 1.4 1.7 7.9 12.0 37.1 28.9 
SIK3 5.6 5.4 6.7 8.9 20.7 15.0 
SIN3B 15.0 21.6 41.3 60.4 139.6 118.8 
SIRT7 5.8 5.1 14.2 18.8 63.3 37.1 
SKI 13.7 11.7 10.2 17.5 48.2 35.7 
SLAIN2 8.9 7.2 9.6 7.3 35.5 25.1 
SLC13A4 3.2 2.6 98.5 64.9 543.0 337.6 
SLC16A3 23.9 19.1 32.4 34.8 121.9 57.9 
SLC19A1 43.9 33.8 48.9 64.3 378.1 315.7 
SLC1A2 0.1 0.1 0.3 0.3 20.3 15.0 
SLC22A11 0.0 0.0 4.2 2.5 63.2 24.1 
SLC25A25 4.1 3.3 4.8 6.6 28.0 30.1 
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SLC27A2 2.4 4.1 12.5 5.1 148.3 55.9 
SLC2A1 95.9 175.9 199.7 214.8 1,805.5 1,433.7 
SLC2A11 4.0 4.7 9.9 9.8 28.4 18.5 
SLC2A12 2.6 2.8 4.8 4.9 75.2 38.6 
SLC30A1 2.3 4.8 11.2 7.6 38.8 29.9 
SLC30A2 0.0 0.1 4.7 4.4 36.1 22.2 
SLC30A7 3.4 3.8 6.8 5.9 29.3 20.5 
SLC31A1 9.8 16.2 12.4 16.8 71.7 47.3 
SLC35E1 5.4 6.2 12.2 13.5 45.0 38.2 
SLC38A2 141.5 124.9 97.6 48.6 381.8 204.6 
SLC38A3 0.5 0.6 4.6 1.3 168.7 62.9 
SLC38A6 4.7 5.0 8.5 7.9 29.7 28.0 
SLC38A9 18.9 20.9 41.5 27.2 200.5 128.0 
SLC3A2 116.9 139.5 299.6 406.7 1,127.8 1,067.0 
SLC40A1 0.7 0.2 102.8 78.2 714.0 564.3 
SLC43A2 3.5 2.7 43.0 47.8 367.0 295.4 
SLC44A1 18.1 18.5 10.3 14.1 54.5 34.9 
SLC4A2 20.4 16.0 38.6 47.6 146.7 97.5 
SLC52A3 1.2 1.5 3.8 7.6 28.1 38.2 
SLC6A8 41.1 22.9 14.9 19.0 141.6 58.2 
SLC7A5 42.1 54.4 63.1 94.8 281.6 103.9 
SLC7A6 8.7 8.9 41.1 47.2 154.6 164.4 
SLC7A8 42.2 41.6 145.7 198.8 545.1 605.9 
SLC9A1 7.1 5.8 44.6 56.8 240.8 213.8 
SLN 0.0 0.1 16.3 4.8 83.0 20.8 
SMAD7 3.1 2.4 21.8 22.0 320.6 284.4 
SMCHD1 6.9 8.6 12.7 7.0 23.9 22.3 
SMG7 16.3 16.6 19.1 22.1 51.7 46.3 
SMG8 6.1 7.5 8.0 10.4 50.1 31.3 
SMIM13 2.7 2.8 5.4 4.7 33.8 19.0 
SMIM4 20.9 31.9 18.6 23.9 87.9 36.6 
SMOC1 0.9 0.3 7.1 6.6 24.9 43.9 
SMOX 2.5 3.6 8.9 11.0 75.7 32.9 
SMPD2 4.3 4.2 6.0 8.0 21.0 12.8 
SNHG9 7.7 10.6 9.1 9.5 86.6 32.1 
SNORA31 7.1 0.0 0.0 0.0 42.6 12.7 
SNORA70F 0.0 0.0 0.0 0.0 13.4 16.0 
SNORA77 0.0 0.0 0.0 0.0 189.5 33.6 
SNORA79 0.0 0.0 0.0 0.0 10.5 12.5 
SNORD89 0.0 0.0 46.1 0.0 51.3 328.2 
SNX13 5.4 7.8 12.9 8.6 28.9 37.0 
SNX27 6.5 5.0 12.5 12.2 105.3 98.4 
SNX5 85.6 82.7 151.3 138.3 436.9 493.9 
SNX8 13.6 14.4 21.8 31.7 72.7 65.0 
SOCS1 12.4 10.2 19.9 25.0 73.7 88.1 
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SOCS3 5.8 4.2 29.9 40.0 43.3 147.1 
SOCS6 4.9 6.1 18.5 18.3 32.7 64.1 
SORBS1 5.9 8.9 0.7 0.9 45.5 38.9 
SOX13 30.4 28.5 42.6 57.4 126.5 112.4 
SP110 1.4 1.1 3.5 2.8 16.9 10.9 
SP2 5.3 4.3 4.9 7.1 13.6 17.4 
SP6 0.9 0.4 133.7 167.0 410.1 527.0 
SPAG9 12.1 15.7 21.7 15.4 54.2 50.5 
SPATA13 3.0 2.7 2.6 2.0 13.8 11.1 
SPCS3 26.5 26.4 44.3 42.6 487.0 241.5 
SPHK1 0.9 0.7 12.9 6.2 46.6 21.9 
SPIRE2 3.3 3.5 12.4 14.2 90.5 48.3 
SPRTN 3.2 3.2 4.9 3.7 11.4 12.9 
SPSB1 1.8 1.4 15.0 20.6 29.0 48.1 
SPTY2D1 3.4 3.6 6.4 5.0 19.2 25.3 
SQLE 58.5 52.2 35.4 42.6 381.0 235.3 
SQSTM1 25.9 39.7 95.7 189.7 390.0 469.0 
SRCAP 7.7 7.5 10.4 14.8 28.5 24.7 
SRPK1 25.3 29.9 35.2 30.6 85.4 66.2 
SRPR 19.1 18.2 31.3 39.9 147.5 97.0 
SRXN1 4.0 6.6 6.3 19.3 24.9 34.4 
SSR1 32.6 35.0 46.6 32.8 182.1 105.8 
SSR3 60.3 62.9 76.8 73.2 393.9 204.7 
ST3GAL1 1.0 0.8 8.7 9.3 130.3 59.0 
ST3GAL4 5.3 5.2 20.5 30.7 167.4 103.9 
STAM2 2.9 2.2 5.3 4.0 11.8 12.3 
STARD10 14.0 11.7 122.6 115.2 319.1 219.1 
STK10 4.7 3.2 9.9 11.7 54.6 24.7 
STK11IP 7.5 6.9 5.8 7.6 21.3 13.3 
STK40 5.8 5.3 23.4 27.8 97.5 99.3 
STRA6 5.3 3.1 23.5 16.6 56.6 38.2 
STRIP2 2.2 2.5 2.9 2.5 11.7 14.0 
STT3B 41.2 37.3 73.2 53.6 154.3 122.2 
STX5 9.8 10.2 30.8 33.7 83.7 85.9 
SUPT6H 15.0 15.0 16.6 22.3 41.9 38.3 
SUPV3L1 18.1 17.1 15.0 18.8 47.7 43.9 
SURF4 55.0 49.6 95.6 109.0 334.7 210.6 
SUSD2 1.1 0.6 7.4 8.8 104.9 16.3 
SWAP70 10.5 12.0 11.3 6.1 64.0 36.2 
SYAP1 7.2 14.0 9.1 15.2 17.7 32.6 
SYDE1 3.6 3.9 1.3 1.2 72.7 25.8 
SYNJ1 1.1 1.6 4.3 2.9 19.3 15.9 
SYNJ2 1.4 2.3 6.2 8.1 19.8 21.0 
SYVN1 7.4 9.5 14.8 18.7 73.3 37.8 
TAB3 3.9 4.7 9.2 6.1 18.4 16.9 
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TACC2 9.7 9.8 8.2 8.6 26.0 25.2 
TAF13 15.4 15.2 34.6 28.2 116.6 114.4 
TAF4 6.6 6.4 6.7 8.9 29.4 16.2 
TANK 7.1 10.1 17.2 11.1 43.0 51.1 
TAOK3 1.9 2.4 4.0 3.9 11.0 11.0 
TAPBP 5.8 7.8 8.3 9.6 44.1 19.3 
TBC1D10A 2.7 2.4 15.1 14.0 78.5 49.7 
TBC1D20 3.8 4.3 11.9 13.7 40.2 26.7 
TBC1D2B 3.9 4.0 8.8 11.5 19.9 26.9 
TBK1 8.7 9.0 14.1 8.8 27.4 32.3 
TBPL1 29.9 26.1 26.5 24.6 244.2 117.0 
TBX20 0.0 0.0 0.4 0.2 17.0 19.6 
TBX3 1.0 0.2 61.8 55.8 416.8 301.3 
TCL1B 3.9 3.7 5.0 18.9 177.2 275.0 
TCL6 0.5 0.5 3.8 4.7 104.7 119.6 
TCP11L2 1.2 0.9 2.1 1.4 31.9 11.1 
TEAD3 11.7 9.4 74.3 96.6 271.4 235.5 
TEX30 5.2 5.5 15.2 11.9 98.3 70.6 
TFAP2A 0.3 0.3 110.9 176.2 301.9 330.5 
TFAP2C 3.3 3.0 97.2 115.1 365.9 336.8 
TFB2M 11.5 11.0 8.9 8.0 30.3 20.9 
TFPI 3.3 4.0 26.3 25.5 661.8 399.6 
TFRC 25.6 28.3 36.2 36.9 257.5 142.5 
TGFB1 2.6 2.7 2.4 3.6 19.3 17.1 
TGFBI 2.7 2.7 18.4 7.4 99.7 44.9 
TGFBR2 1.8 1.8 14.9 12.0 123.7 172.0 
TGFBR3 0.8 0.6 3.8 3.7 32.8 30.2 
TGM2 0.4 0.2 1.9 0.9 54.8 12.8 
TIGD2 1.6 2.2 4.5 4.2 10.1 12.8 
TIMM8A 11.0 9.8 8.5 9.6 37.6 22.1 
TIMP3 0.7 0.3 18.1 25.8 300.9 239.1 
TIPARP 1.5 2.4 4.3 3.7 46.4 48.7 
TLE2 2.0 1.7 3.3 8.8 14.6 17.9 
TLK1 14.5 15.8 10.3 7.2 36.4 34.8 
TM9SF3 41.8 47.1 52.7 43.5 140.5 128.9 
TMBIM1 14.2 16.0 48.3 52.8 185.4 99.5 
TMEM180 3.2 3.6 11.9 18.5 48.9 46.6 
TMEM184B 16.6 16.3 21.7 23.1 138.6 50.6 
TMEM208 29.8 26.5 35.1 40.3 97.1 63.9 
TMEM33 24.3 23.7 28.2 25.9 117.8 93.9 
TMEM37 3.8 3.0 12.9 15.8 53.9 20.3 
TMEM39A 15.0 18.9 22.2 21.9 62.7 55.3 
TMEM40 0.0 0.0 11.6 12.2 88.8 59.0 
TMEM41B 14.4 13.6 20.7 14.1 44.9 34.2 
TMEM5 4.8 3.5 10.4 7.4 121.4 29.9 
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TMEM80 7.9 6.7 9.3 8.9 20.1 17.6 
TMEM8A 33.7 29.5 24.2 25.2 122.6 56.0 
TMF1 2.7 3.0 7.9 3.5 23.6 19.7 
TMPRSS2 4.2 5.6 8.9 22.6 48.3 74.9 
TNFAIP2 4.3 2.6 29.2 19.1 227.9 55.5 
TNFAIP3 0.6 1.0 36.7 30.2 78.1 82.1 
TNFAIP8 9.0 14.1 15.0 10.9 62.3 43.0 
TNFRSF1B 0.5 0.5 39.3 48.2 703.3 351.6 
TNFRSF21 12.0 12.2 37.5 45.9 174.8 127.3 
TNIP1 13.0 11.4 14.4 19.8 66.0 34.6 
TNIP2 11.5 12.0 24.8 28.6 67.8 57.8 
TNPO1 54.2 64.6 85.1 37.3 210.6 195.1 
TNS3 4.1 3.2 14.1 14.8 77.8 55.8 
TOM1 7.5 5.4 21.8 24.8 64.6 49.4 
TOM1L2 0.7 1.2 13.8 12.6 41.0 34.9 
TOP1 27.7 31.4 38.7 34.7 237.0 157.0 
TOR1AIP2 3.9 3.8 11.7 11.0 37.8 32.5 
TOR1B 5.4 5.8 8.3 9.1 29.4 12.2 
TOX4 17.7 18.9 26.8 36.0 64.0 70.5 
TPPP3 0.8 0.0 19.2 27.6 90.6 81.8 
TPRG1L 7.6 5.4 12.5 20.4 40.9 45.4 
TPRN 5.4 5.4 5.5 7.4 21.2 13.1 
TPRXL 0.0 0.0 0.7 0.9 24.2 22.8 
TREM1 0.0 0.0 6.1 10.2 186.5 136.4 
TREML2 0.0 0.0 7.8 21.7 90.5 148.4 
TRIB1 14.9 13.7 9.6 10.0 41.8 28.2 
TRIB3 1.8 2.9 6.4 13.5 14.4 40.0 
TRIM17 0.6 0.1 14.6 18.0 51.8 48.9 
TRIM33 10.9 13.4 24.3 13.3 70.8 95.5 
TRIM55 0.0 0.0 17.8 4.9 43.8 20.4 
TRMT44 3.9 3.3 13.9 12.3 34.8 20.8 
TRPV2 0.4 0.6 21.6 20.8 210.6 191.5 
TSC22D2 8.2 6.9 41.8 40.1 110.2 104.0 
TSPAN12 7.8 6.6 21.4 9.3 79.2 57.3 
TSPAN14 14.9 12.7 26.1 26.4 95.0 45.9 
TSPAN9 7.2 5.1 8.0 6.4 49.1 43.6 
TSSC4 14.1 10.4 15.9 20.3 50.8 35.7 
TTC7A 3.9 3.2 5.9 7.7 32.0 11.1 
TTC7B 3.4 3.4 26.8 33.4 120.6 64.9 
TUBB3 76.3 53.0 24.1 30.5 257.8 122.0 
TUBB4B 112.6 83.3 123.3 174.1 433.1 359.2 
TUFT1 2.9 3.1 31.6 49.1 101.4 142.6 
TUSC3 47.8 51.0 151.4 154.6 628.0 393.4 
TWIST2 0.4 0.3 1.1 1.3 41.8 24.5 
TYRO3 16.7 15.5 82.1 122.1 286.5 252.2 
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UAP1 11.6 10.5 15.1 9.4 64.8 52.8 
UBALD1 17.7 19.7 25.5 30.5 145.9 68.9 
UBALD2 10.1 11.6 95.4 109.3 586.5 502.7 
UBAP1 14.2 13.0 22.1 27.1 100.6 85.7 
UBE2A 26.8 32.4 29.4 36.4 83.6 57.8 
UBE2B 28.5 30.2 77.7 77.4 301.7 347.9 
UBE2D3 203.6 221.3 256.6 216.2 509.3 527.7 
UBE2G1 56.6 66.3 48.7 49.3 170.3 183.8 
UBE2H 20.4 24.1 44.6 54.5 104.0 128.6 
UBE2J1 7.3 9.1 27.1 27.2 61.2 56.1 
UBE2K 51.8 56.8 49.0 50.5 159.8 121.1 
UBE2M 36.2 29.3 45.2 55.6 130.2 92.9 
UBE2QL1 0.1 0.3 2.5 2.8 12.4 13.7 
UBIAD1 6.6 6.3 5.4 8.0 26.0 21.3 
UBQLN1 36.2 41.0 37.9 42.3 90.7 103.2 
UGGT1 7.3 8.8 8.7 7.9 20.6 19.1 
ULK4 1.5 3.8 2.7 4.7 13.5 10.0 
UQCR11 2.4 5.7 4.9 6.4 15.0 18.8 
USP15 10.9 9.6 17.9 9.4 34.7 32.2 
USP16 7.5 7.8 8.9 5.1 15.6 19.2 
USP3 5.5 6.9 9.4 9.9 26.9 16.7 
USP43 1.7 1.8 3.2 5.7 35.4 30.9 
USP53 4.0 4.0 10.6 7.8 16.1 25.0 
VASP 39.3 33.4 52.3 58.7 151.4 107.4 
VAV3 2.7 4.7 12.2 7.2 50.0 35.1 
VCP 137.1 100.5 202.3 219.0 550.8 525.8 
VEZT 19.5 23.8 29.1 12.8 55.0 56.0 
VGF 2.1 3.4 5.4 6.1 27.0 12.3 
VGLL1 0.1 0.2 112.2 161.3 285.8 357.9 
VIMP 24.3 21.7 43.9 53.9 155.2 117.2 
VPS37A 11.0 15.6 22.5 20.5 46.8 54.9 
VPS4B 9.8 9.0 15.4 9.2 39.3 49.0 
VTI1A 5.2 5.5 8.5 9.7 19.0 20.1 
WAPAL 17.5 15.9 18.6 14.8 34.1 38.0 
WDR26 18.2 18.1 29.8 30.0 99.1 100.7 
WFS1 8.5 8.1 8.2 13.0 25.6 19.2 
WI2-
1896O14.1 0.5 0.6 5.6 12.6 82.9 92.6 
WIPF2 6.1 8.2 7.0 10.5 19.0 18.2 
WIPI1 6.4 7.5 40.9 35.9 147.6 122.4 
WNK2 11.0 15.0 7.4 4.8 58.0 26.6 
WNT11 0.1 0.0 6.5 6.3 32.9 20.1 
WRAP73 10.8 8.4 10.7 11.8 36.0 40.2 
WWC1 10.4 8.1 22.9 28.7 120.5 85.6 
WWTR1 2.7 3.6 17.3 11.5 64.3 34.4 
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WWTR1-AS1 1.2 1.5 4.4 3.0 17.3 10.3 
XAGE2 0.1 0.1 24.8 33.7 216.0 174.7 
XAGE2B 0.1 0.1 25.1 33.3 203.0 165.4 
XBP1 35.8 39.9 112.0 128.1 396.8 467.3 
XIAP 4.7 9.0 7.7 5.3 15.9 27.3 
XXbac-
BPG181M17.6 9.0 12.1 7.9 15.2 35.6 49.0 
YIPF2 22.6 23.6 51.4 54.5 142.6 90.0 
YIPF4 9.7 10.4 18.8 16.1 38.3 33.9 
YIPF6 10.2 14.0 17.4 17.9 63.4 50.8 
YOD1 6.0 5.2 7.2 4.4 11.8 13.9 
YRDC 9.5 7.5 11.6 14.6 40.5 30.4 
YTHDF2 53.5 41.0 72.5 80.9 191.5 221.0 
YWHAZ 250.6 286.8 460.8 446.0 992.5 1,176.4 
YY1AP1 17.0 17.0 48.5 62.4 145.1 189.6 
Z98256.1 0.9 0.2 19.0 29.4 453.0 368.0 
ZBTB10 2.3 3.3 18.1 11.7 31.5 30.8 
ZBTB38 2.2 1.9 5.0 3.9 14.0 11.2 
ZBTB7A 2.9 3.3 7.0 8.6 32.4 26.8 
ZBTB7B 7.3 7.7 19.4 30.9 55.0 52.6 
ZBTB7C 0.0 0.1 5.2 9.4 16.0 15.0 
ZC3H11A 34.7 34.4 53.4 36.6 109.1 119.4 
ZCCHC6 3.8 3.9 10.5 6.5 23.5 28.4 
ZCCHC8 11.0 12.6 33.5 24.0 55.3 69.5 
ZDHHC1 1.6 2.1 4.8 7.0 16.3 16.2 
ZDHHC20 17.2 22.1 25.8 20.1 50.7 91.7 
ZDHHC3 18.7 20.1 21.8 31.7 78.3 55.3 
ZDHHC5 12.4 14.9 25.1 29.5 75.0 61.5 
ZFAND2A 10.9 10.2 20.4 25.6 64.4 67.6 
ZFHX3 0.3 0.1 6.2 4.8 36.0 34.4 
ZFP36L1 47.1 49.5 83.3 87.1 226.4 177.3 
ZFP36L2 28.5 24.1 22.3 53.1 96.3 80.7 
ZFPL1 7.0 7.9 17.7 18.5 44.7 33.0 
ZNF114 3.3 4.3 14.8 21.7 21.0 64.6 
ZNF217 15.9 20.9 23.6 19.4 40.6 48.9 
ZNF292 5.9 5.7 7.7 5.8 27.9 43.9 
ZNF354B 2.5 3.9 6.6 5.2 19.2 16.4 
ZNF385A 6.0 5.6 23.6 25.0 69.0 45.3 
ZNF394 4.2 3.3 7.2 7.4 20.0 16.8 
ZNF440 1.3 1.0 5.9 3.1 10.2 11.5 
ZNF488 2.6 2.7 17.4 23.3 99.4 80.5 
ZNF592 4.9 4.6 4.1 4.9 19.5 11.8 
ZNF611 1.4 1.5 5.2 3.7 11.6 11.0 
ZNF668 3.4 2.8 3.0 4.1 14.3 13.0 
ZNF668 4.5 3.9 3.7 5.7 13.8 11.5 
 162	  
ZNF701 2.2 2.1 3.4 3.0 10.8 10.1 
ZNF702P 1.8 0.8 8.7 3.9 36.0 40.5 
ZNF703 0.6 0.5 18.6 19.6 232.2 135.0 
ZNF836 4.9 5.2 11.2 14.0 42.1 18.2 
ZNF845 3.7 2.8 6.8 3.4 14.9 16.0 
ZNF888 11.9 18.0 19.0 53.5 310.8 203.5 
ZRANB1 6.8 7.4 8.3 8.3 41.6 25.1 
ZZEF1 2.9 3.3 6.4 7.0 15.5 15.3 
 
 
Supplementary Table 3.3. Mouse syncytiotrophoblast markers (m.SynT) 
Gene  logFC P.value Gene  logFC P.value 
Cmklr1 7.5 5.2425E-27 Cxcr4 4.3 0.000494009 
Slc13a4 7.1 3.08688E-15 Adh1 4.2 0.007851277 
Gm15887 6.6 2.10778E-24 Serpinb6c 4.2 0.007851277 
Gjb2 6.2 9.73855E-22 Gab2 4.2 8.44904E-07 
Ldoc1 6 1.49985E-14 1700086L19Rik 4.1 0.003451779 
Gm10664 5.8 2.38369E-14 AW822252 4.1 0.000148082 
Lonrf3 5.7 1.65927E-08 Rsad2 4.1 0.000279836 
Dio3 5.7 9.89669E-07 Tmprss4 4.1 0.006399116 
Gabrp 5.4 0.000494009 C1ql2 4.1 0.00099024 
Slc22a3 5.4 4.44695E-09 Mx2 4.1 0.000527274 
Sgk2 5.2 1.65927E-08 Cebpa 4.1 3.33223E-13 
Syna 5 5.57339E-08 Pparg 4.1 8.46507E-19 
Ascl2 5 5.23534E-20 Tmprss2 4 1.25092E-11 
A730090H04Rik 5 3.10459E-06 Batf3 4 4.43638E-19 
Gcm1 4.9 4.11563E-05 Dmkn 4 8.18427E-11 
Dlx3 4.9 6.90126E-25 Klk6 4 0.007851277 
Gm9112 4.9 1.07012E-13 Kcnt1 4 0.006399116 
Vav3 4.9 3.07697E-16 Smarca2 4 3.39811E-09 
Olr1 4.9 1.56296E-05 Vnn1 3.9 7.26894E-12 
Nacad 4.8 4.39952E-07 Elf3 3.9 1.2258E-14 
Hsd11b2 4.8 1.62065E-06 Aldh3b2 3.9 1.34242E-11 
Lpl 4.8 0.000124048 Hcn2 3.9 9.86301E-10 
Itm2a 4.7 2.92358E-14 Vgll1 3.9 1.7129E-06 
Plac1 4.7 7.4813E-17 Nxf7 3.8 3.01218E-13 
Dmrtc1b 4.7 3.11711E-05 Arhgef6 3.8 7.7188E-20 
Phlda2 4.7 5.67765E-18 Zfp36l3 3.8 4.59209E-20 
Slc22a18 4.7 1.03359E-20 Gata2 3.7 1.01382E-13 
4932442L08Rik 4.7 3.20162E-08 Kitl 3.7 3.71153E-05 
Synb 4.7 2.16266E-05 Irx4 3.7 6.29403E-09 
Gm4234 4.6 0.003931191 Gm17099 3.7 0.003451779 
Myl4 4.6 7.01907E-23 Tceanc 3.7 1.54343E-10 
Caskin1 4.5 4.65309E-10 Dnase1l3 3.7 6.80835E-05 
Fam101a 4.4 1.12453E-08 Tubb4a 3.6 2.01699E-05 
Vtcn1 4.3 0.000527274 D830030K20Rik 3.6 0.001852767 
Cxcr4 4.3 0.000494009 Zxda 3.6 0.000148082 






Supplementary Table 3.4. Down-regulated genes in mTS upon differentiation to m.SynT   
Gene  logFC P.value Gene  logFC P.value 
Sox3 8.4 2.36359E-28 Cdx2 5.2 7.78373E-26 
Nr0b1 8.4 9.261E-23 Il5ra 5.2 0.001968723 
Sox2 8.0 1.93421E-27 O3far1 5.1 0.000247528 
Dusp6 7.8 8.39146E-32 Eomes 5.1 7.57855E-19 
Cyp26a1 7.7 2.97554E-27 Ntf3 5.1 0.000986101 
Esrrb 7.1 1.53816E-25 Gm9847 5.0 1.56296E-05 
Zic2 7.0 4.36739E-15 Ppp2r2c 5.0 4.6235E-26 
T 7.0 2.95754E-08 Gm14414 5.0 4.81855E-11 
Cldn26 7.0 8.598E-23 Gm11635 5.0 0.007851277 
Etv4 6.9 5.02973E-31 Inpp1 5.0 9.17322E-26 
Calca 6.9 3.40881E-14 Nptxr 5.0 3.72586E-17 
Spry4 6.8 5.01321E-14 Bves 4.9 7.83825E-06 
Prss46 6.7 4.00151E-09 Mapk12 4.8 7.77103E-11 
Nat8l 6.5 1.44343E-29 Tmem181c-ps 4.8 2.74216E-24 
Duox2 6.5 5.08159E-10 Ccdc3 4.8 6.1727E-08 
Zic5 6.4 7.96373E-09 Etv5 4.8 7.15578E-16 
Bmp4 6.4 1.24165E-28 Mmp9 4.8 2.79963E-17 
Duoxa2 6.3 1.30809E-21 Tm6sf1 4.8 0.000247528 
mmu-mir-1194 6.2 7.55352E-05 Rbp4 4.7 1.56296E-05 
Spry2 6.2 2.36549E-18 Gm14323 4.7 1.26661E-09 
Trim9 6.2 4.96668E-07 Dok2 4.7 1.28718E-20 
Insm1 6.1 1.25154E-07 Tbx18 4.6 0.007851277 
Sox21 6.0 7.80231E-20 Pth1r 4.6 2.89276E-23 
Gm4675 6.0 1.5852E-08 Fgfr4 4.5 2.24311E-11 
2210019I11Rik 6.0 4.5768E-11 Hs3st3b1 4.5 3.51672E-20 
Ddah1 6.0 3.96164E-31 Crabp1 4.5 0.000494009 
Gdf6 5.9 1.05053E-12 Mageb16-ps2 4.5 0.000124048 
Duoxa1 5.9 7.83825E-06 C77370 4.5 1.56296E-05 
Ly6a 5.9 1.05053E-12 Kdr 4.4 4.11563E-05 
Dusp4 5.7 1.93664E-13 Nrp2 4.4 2.29989E-09 
Socs2 5.6 1.29317E-27 Prss50 4.4 1.52711E-14 
Ak1 5.6 8.341E-29 Egr1 4.3 1.65927E-08 
Spred1 5.3 6.46333E-11 Gm12139 4.3 5.80238E-21 
Gm1673 5.3 2.92055E-20 Stard8 4.3 1.88073E-11 
 
 
Supplementary Table 3.5. Primate-specific primitive syncytium gene list (Ps.Pr.synT)  
(FPKM values of different days of differentiation is presented for H1 and HES3 cells)  
Gene H1-D0 HES3-D0 H1-D4 HES3-D4 H1-D6 HES3-D6 
ACER3 4.6 6.3 12.2 7.3 18.0 22.3 
ADAMTS1 2.7 2.4 37.9 22.5 184.4 99.0 
ADAMTS20 2.8 1.8 3.1 0.9 54.3 20.9 
AMMECR1 9.4 22.4 7.3 10.6 35.7 50.8 
ANO1 1.0 2.0 4.3 2.6 20.4 18.4 
APOA2 2.7 0.0 76.2 59.7 216.3 197.9 
C10orf10 1.8 1.5 34.9 56.7 501.2 527.1 
C10orf32 2.7 2.5 5.3 4.7 16.1 10.7 
C1orf21 34.6 36.3 31.7 28.5 157.6 100.1 
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C1orf27 4.9 6.6 11.0 6.1 24.6 24.8 
C4orf19 0.2 0.1 10.9 12.0 60.0 56.9 
C8orf42 29.5 26.2 87.5 76.1 187.7 239.3 
CAPN6 3.0 5.3 44.2 83.1 125.4 195.1 
CAV1 3.9 2.3 6.0 3.0 12.1 14.9 
CCR7 0.2 0.1 93.8 63.5 359.3 138.3 
CD274 0.1 0.0 12.0 5.6 109.3 69.2 
CDKN1C 12.0 5.4 524.0 521.7 1532.9 1259.0 
CDYL 51.6 56.3 34.9 43.2 238.9 161.0 
CEBPB 5.2 7.8 66.6 75.6 465.6 287.4 
CGA 8.3 5.6 1160.1 1287.5 47941.8 27020.2 
CGB 0.5 0.7 5.8 2.3 2620.1 1174.6 
CGB5 0.1 0.0 1.4 0.2 4681.6 1420.1 
CGB7 0.2 0.3 0.9 1.0 110.6 31.4 
CHST2 4.6 4.1 4.1 24.2 29.4 44.6 
CLEC1A 0.1 0.1 7.5 2.4 50.4 23.0 
CLIC3 0.0 0.0 10.1 7.9 112.4 34.0 
CLN3 11.9 10.6 33.8 63.9 150.7 99.1 
COMT 13.9 3.9 21.4 7.1 107.5 18.8 
CYP19A1 0.2 0.2 84.8 65.7 608.4 609.5 
CYP1A1 0.1 0.1 12.7 17.6 46.0 49.0 
DACT2 1.1 1.4 1.4 3.0 120.9 66.4 
DLX3 0.2 0.2 63.3 98.7 203.6 187.3 
DLX4 0.3 0.3 7.6 12.0 43.7 18.9 
EPB41L3 5.5 5.5 91.8 47.3 221.0 226.1 
ERVFRD-1 0.0 0.0 19.1 25.9 161.0 232.0 
ERVW-1 0.1 0.1 22.4 19.1 427.1 271.6 
ESRRG 0.5 0.4 12.4 5.4 63.7 74.2 
FAM131A 5.4 6.3 8.6 12.1 38.2 36.1 
FAM49A 1.1 0.9 30.9 25.1 177.6 222.5 
FAM83F 3.5 3.8 8.2 11.4 155.4 136.1 
FGF18 0.3 0.1 3.9 4.7 42.8 23.9 
FHDC1 4.2 3.7 27.2 32.7 226.3 203.8 
FOXO6 1.3 1.3 35.9 36.3 155.5 187.1 
FRMD4A 6.4 4.8 26.5 23.8 119.8 55.8 
GADD45G 8.3 6.1 58.5 75.9 502.3 411.0 
GAST 0.0 0.0 16.3 28.2 109.5 110.9 
GCM1 0.0 0.0 28.9 22.4 98.5 71.5 
GLDN 0.2 0.2 9.8 4.2 29.9 28.8 
GNE 2.4 2.3 5.3 4.3 40.1 15.2 
GPC1 10.8 7.8 36.4 34.9 151.0 86.1 
GPR126 0.7 0.8 10.4 3.3 42.6 22.9 
GRAMD3 4.4 3.2 25.9 21.7 177.9 167.6 
GRHL3 0.7 0.8 8.2 16.6 22.2 42.1 
HDAC5 15.8 11.9 41.6 50.6 270.7 197.7 
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HOOK3 3.5 3.9 10.4 7.3 16.7 26.7 
HOPX 0.2 0.2 178.8 168.2 1516.6 1088.1 
HSD17B1 0.2 0.5 21.0 19.4 142.1 111.3 
HSD3B1 0.2 0.6 44.1 60.6 627.5 646.5 
HTRA4 0.0 0.0 3.0 1.9 105.1 21.5 
IFI6 5.8 8.8 160.8 121.7 669.0 334.1 
IRX4 0.4 0.3 8.3 5.1 23.2 13.8 
KCNK1 8.5 8.9 12.5 13.7 31.1 23.3 
KCNN4 0.5 0.2 7.9 5.2 144.6 58.3 
KRT23 0.1 0.1 73.2 85.9 237.4 393.3 
KYNU 0.1 0.1 11.6 5.5 106.3 76.1 
LGALS13 0.0 0.0 3.2 2.0 81.3 47.8 
LYN 15.9 15.1 105.9 109.1 392.1 402.4 
LYPD3 1.9 2.2 23.2 43.0 130.3 103.7 
MAGI1 13.7 15.2 11.4 11.1 75.7 47.5 
MAML3 1.5 0.9 6.0 5.2 17.3 14.5 
METRNL 5.3 6.0 63.2 62.7 171.8 166.9 
MORC4 0.6 1.7 6.6 12.1 19.5 36.7 
MRGPRX1 0.1 0.1 94.5 79.7 399.4 612.0 
MUC15 0.1 0.1 70.8 52.2 254.0 430.7 
MX1 1.3 1.7 6.5 5.7 29.6 21.6 
NFE2L3 26.7 36.1 60.2 33.8 156.5 145.2 
NR2F6 40.4 33.8 111.4 116.6 422.1 252.3 
NUCB2 11.2 9.3 67.4 31.5 275.4 190.2 
OPN3 9.5 8.4 66.6 58.8 363.9 262.8 
OVOL1 0.6 1.2 43.1 58.1 81.3 152.4 
PAK3 0.8 2.2 2.3 3.6 17.3 41.1 
PDLIM2 16.6 14.1 45.2 38.7 464.0 202.7 
PGC 0.1 0.1 1.9 2.2 14.9 11.5 
PGF 1.4 1.1 227.8 258.4 1896.4 1375.3 
PHKG2 17.2 15.6 49.3 45.1 137.6 75.1 
PHLDB3 2.6 2.4 39.5 50.3 99.8 119.9 
PID1 0.6 2.0 18.0 17.5 58.5 26.6 
PLEKHA8 6.0 8.3 5.6 4.8 23.6 16.2 
PLXND1 7.4 5.2 20.7 16.6 50.0 30.6 
PRKCH 2.1 4.0 67.1 55.3 140.9 140.6 
PRR9 0.2 0.1 63.3 45.6 1324.0 607.6 
PTPRE 0.2 0.2 8.4 5.6 23.3 26.1 
PWWP2B 3.3 3.2 18.9 21.9 134.3 94.8 
QKI 46.9 62.4 40.5 33.5 184.1 137.3 
RANGRF 26.3 23.1 21.3 27.2 81.5 48.7 
RGS16 3.6 2.5 22.6 17.0 82.3 52.9 
RGS3 5.7 4.4 6.4 10.1 31.2 31.4 
RHOBTB1 3.3 2.5 34.5 24.4 379.3 187.0 
RIN3 0.3 0.4 11.0 16.1 41.6 69.2 
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S100P 0.0 0.2 105.6 160.7 909.1 793.9 
SDC1 13.0 8.8 83.5 110.4 1075.9 737.1 
SEC24D 18.2 17.7 18.8 12.1 52.9 53.0 
SELT 40.9 42.7 113.6 114.2 654.3 543.6 
SERPINB9 26.9 29.3 93.3 86.8 236.2 193.1 
SERPINE1 0.5 0.4 13.7 34.7 275.3 417.2 
SH2B2 6.0 6.0 36.7 39.0 157.1 98.0 
SH3BP4 13.3 10.5 18.4 27.1 45.0 51.2 
SLC13A4 3.2 2.6 98.5 64.9 543.0 337.6 
SLC16A3 23.9 19.1 32.4 34.8 121.9 57.9 
SLC19A1 43.9 33.8 48.9 64.3 378.1 315.7 
SLC22A11 0.0 0.0 4.2 2.5 63.2 24.1 
SLC27A2 2.4 4.1 12.5 5.1 148.3 55.9 
SLC30A2 0.0 0.1 4.7 4.4 36.1 22.2 
SLC38A6 4.7 5.0 8.5 7.9 29.7 28.0 
SLC38A9 18.9 20.9 41.5 27.2 200.5 128.0 
SOCS1 12.4 10.2 19.9 25.0 73.7 88.1 
SOCS3 5.8 4.2 29.9 40.0 43.3 147.1 
SP6 0.9 0.4 133.7 167.0 410.1 527.0 
SPATA13 3.0 2.7 2.6 2.0 13.8 11.1 
ST3GAL1 1.0 0.8 8.7 9.3 130.3 59.0 
STRA6 5.3 3.1 23.5 16.6 56.6 38.2 
TANK 7.1 10.1 17.2 11.1 43.0 51.1 
TEAD3 11.7 9.4 74.3 96.6 271.4 235.5 
TFAP2A 0.3 0.3 110.9 176.2 301.9 330.5 
TGFBR2 1.8 1.8 14.9 12.0 123.7 172.0 
TGFBR3 0.8 0.6 3.8 3.7 32.8 30.2 
TNFAIP3 0.6 1.0 36.7 30.2 78.1 82.1 
TNFAIP8 9.0 14.1 15.0 10.9 62.3 43.0 
TNFRSF21 12.0 12.2 37.5 45.9 174.8 127.3 
TREM1 0.0 0.0 6.1 10.2 186.5 136.4 
TREML2 0.0 0.0 7.8 21.7 90.5 148.4 
TRPV2 0.4 0.6 21.6 20.8 210.6 191.5 
VGLL1 0.1 0.2 112.2 161.3 285.8 357.9 
ZNF292 5.9 5.7 7.7 5.8 27.9 43.9 
ZNF703 0.6 0.5 18.6 19.6 232.2 135.0 





Supplementary Table 4.1. Expression of novel/non-annotated ERV-derived CDS in Pr.synT 
Gene/Transcript Repeat Name Repeat Family Locus (called) 
TCL6d1/5 UTR LTR12C ERV1 chr14:96116743-96117225 
7SK.201/new 
transcript./AK125932 MER21A ERVL 
chr17:34220747-
34221697 
AK056728 PRIMA41-int ERV1 chr16:25154230-25158597 





new transcript HERVIP10F-int ERV1 
chr14:101786032-
101789814 
new transcript HERVK3-int ERVK chr5:70869081-70873745 
new transcript HERVK3-int ERVK chr14:70278178-70282315 
new transcript/5UTR/ first 
exon HERV17-int ERV1 
chr8:125912788-
125916298 
new transcript/in the intron 
of BTBD9 HERV9-int ERV1 
chr6:38,581,336-
38,595,054 
new transcript LTR17 ERV1 chr8:125918705-125920244 
ERVPB1 MER4E1 + MER51-int ERV1 
chr14:93087647-
93088785 








LINC00379 MLT1D ERVL-MaLR chr13:91783346-91783542 
new transcript  LTR12F ERV1 chr6:38591810-38592262 
new transcript/ 3UTR of 
ANGPT4  MLT1K ERVL-MaLR chr20:850431-850795 
new transcript MLT1D ERVL-MaLR chr10:96750915-96751106 
new transcript  LTR3A ERVK chr14:70282317-70282740 
new transcript  MLT1F2 ERVL-MaLR chr2:113821917-113822201 
 
 
Supplementary Table 4.2. Top Differentially expressed LTR in Pr.synT 
Gene/Transcript  Repeat Name Repeat Family Locus (called) 
PTN  LTR2B+ Harlequin ERV1 
chr7:136947257-
136953593 
TFPI/first exon Harlequin-int ERV1 chr2:188375215-188381339 
MID1/first exon HERVE_a-int ERV1 chrX:10557348-10558380 
ANKS1A/new exon  HERVE_a-int ERV1 chr6:34966136-34972084 
C4orf19/new exon  HERVE_a-int ERV1 chr4:37547809-37554088 
CYP19A1/TFBS/first exon MER21A ERVL chr15:51630468-51631187 
CLCN3/new exon MER21A ERVL chr4:170546991-170547846 
OGDH/new exon MER21A ERVL chr7:44658236-
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44659080 
AZIN1/TFBS/first exon MER21A ERVL chr8:103884154-103884944 
CEP85/CCDC21/first exon LTR10A ERV1 chr1:26595321-26595896 
CSF2RB/new exon in the 
intron MLT1J ERVL-MaLR 
chr22:37314734-
37315220 
GPR32/extended exon MLT1J ERVL-MaLR chr19:51275750-51276043 
 	  
Supplementary Table 4.3. GCM1 top peaks intersection with Pr.synT gene-set  
Gene Peak Locus Dist_to_TSS Rank 
PGF chr14:75422118-75422918 -51 3 
LMO2 chr11:33891641-33892391 -645 10 
TBC1D10A chr22:30703979-30704679 18626 18 
CSRNP1 chr3:39188478-39189178 6274 23 
CCNE1 chr19:30332082-30332782 29532 26 
ZBTB38 chr3:141121178-141121878 78474 47 
CHST2 chr3:142839428-142840128 1161 57 
SLC7A6 chr16:68298822-68299472 729 65 
CRISPLD2 chr16:84859672-84860472 6486 111 
DDB1 chr11:61100541-61101091 -132 130 
VASP chr19:46024432-46025232 14145 146 
MED12L chr3:150794328-150794928 -10047 173 
CCNE1 chr19:30310832-30311332 8182 185 
GRHL3 chr1:24648063-24648713 -1141 198 
SPIRE2 chr16:89894072-89894822 -459 251 
PPTC7 chr12:111008134-111008734 12630 266 
REXO1 chr19:1836632-1837432 11420 309 
MFAP5 chr12:8813634-8814084 1574 314 
FAM25C chr10:49195554-49196654 11721 342 
PDLIM2 chr8:22436143-22437193 415 344 
PDLIM2 chr8:22436143-22437193 -1318 346 
MICALL2 chr7:1509754-1510354 -10945 401 
GET4 chr7:921954-922504 6039 405 
LYN chr8:56791543-56791993 -617 427 
DACT2 chr6:168719882-168720832 45 439 
DAP chr5:10734349-10734799 26813 441 
PHKG2 chr16:30760072-30760722 778 465 
PRKAG2 chr7:151380904-151381754 -51985 467 
LARP4B chr10:976554-977054 841 473 
RBM38 chr20:55966090-55967190 187 516 
PWWP2B chr10:134209454-134210254 -847 527 
SYDE1 chr19:15217832-15218282 -156 536 
SLC38A3 chr3:50243078-50243678 687 542 
DDB1 chr11:61099741-61100141 743 548 
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SLC19A1 chr21:46948243-46948743 6049 554 
GSTA3 chr6:52787782-52788282 -13536 598 
SERPINB9 chr6:2908832-2909932 -5836 620 
NFKB2 chr10:104151404-104152004 -2162 624 
SUSD2 chr22:24576829-24577479 -289 650 
FHDC1 chr4:153909874-153910424 46015 667 
APOBEC2 chr6:41025732-41026882 5368 671 
SESTD1 chr2:180142137-180142587 -13012 699 
CRIP2 chr14:105940118-105940768 1169 706 
TWIST2 chr2:239757787-239758287 1365 709 
ADCK2 chr7:140340804-140341304 -31898 718 
DDA1 chr19:17422382-17423232 2471 720 
CRISPLD2 chr16:84852522-84852972 -839 748 
SLC19A1 chr21:46953793-46954193 549 752 
CAV1 chr7:116165654-116166504 -332 759 
CAV1 chr7:116165654-116166504 1241 761 
HERPUD1 chr16:56945822-56946322 -19929 767 
SYNJ2 chr6:158402532-158402982 -130 783 
SOCS3 chr17:76337819-76338719 17891 788 
TGFBR3 chr1:92351063-92351663 473 794 
MED10 chr5:6396899-6397499 -18560 819 
PDLIM2 chr8:22445193-22445843 7532 830 
UBALD2 chr17:74258819-74259369 -2191 876 
GMEB2 chr20:62257440-62258190 566 881 
MLLT1 chr19:6220932-6221382 58802 886 
PTGES chr9:132513984-132514534 1085 889 
HBP1 chr7:106849054-106849454 39795 890 
CDKN1C chr11:2910741-2911241 -3996 905 
DLX4 chr17:48050619-48051119 740 920 
TSPAN9 chr12:3180434-3180834 -5886 952 
SLC43A2 chr17:1508369-1508869 -291 1003 
PLEC chr8:145048543-145048943 -1046 1007 
BPGM chr7:134395354-134395954 64124 1008 
DACT2 chr6:168757282-168759682 -38080 1012 
ING2 chr4:184425124-184425574 -870 1017 
TSPAN9 chr12:3306734-3308084 120889 1053 
WWC1 chr5:167743249-167743699 24410 1079 
NMNAT2 chr1:183261363-183261713 12471 1094 
C2orf72 chr2:231901987-231902437 -68 1168 
UBALD1 chr16:4662972-4663372 1755 1182 
ELMO1 chr7:37486054-37486504 2276 1184 
MYC chr8:128680943-128681493 -67096 1193 
PACSIN2 chr22:43374479-43374879 -18792 1230 
SLC4A2 chr7:150760004-150760754 746 1238 
SERPINE1 chr7:100761604-100762104 -8515 1242 
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SLC19A1 chr21:46935593-46936093 18699 1248 
WWTR1 chr3:149374628-149375028 984 1263 
WWTR1 chr3:149374628-149375028 1060 1264 
WWTR1-AS1 chr3:149374628-149375028 -1168 1265 
VAV3 chr1:108588713-108589113 -81368 1289 
MICALL2 chr7:1508304-1508854 -9470 1301 
RREB1 chr6:7141082-7141532 33222 1304 
DLX4 chr17:48049069-48049719 -735 1320 
MIDN chr19:1248182-1248882 -19 1324 
PLXND1 chr3:129306478-129307028 18829 1379 
IER2 chr19:13262382-13262932 1376 1404 
GALNT2 chr1:230193413-230194013 -9242 1415 
CPM chr12:69326934-69327284 -130 1418 
COBLL1 chr2:165697787-165698437 -184 1420 
COBLL1 chr2:165697787-165698437 566 1422 
FAM131A chr3:184051028-184051428 -2488 1431 
N4BP1 chr16:48558372-48558822 85523 1452 
TNS3 chr7:47615754-47616554 5588 1467 
WIPI1 chr17:66442819-66443219 10634 1488 
CGB8 chr19:49552482-49552782 -264 1494 
CGA chr6:87832232-87832582 -27542 1511 
CGB5 chr19:49546732-49547082 -194 1540 
MBD3 chr19:1582282-1582832 10203 1581 
GSK3B chr3:119876578-119876978 -63514 1621 
FAM13A chr4:89890474-89891124 87547 1667 
CRELD2 chr22:50331279-50331729 19227 1675 
EHD1 chr11:64644341-64644691 1724 1696 
SUSD2 chr22:24607129-24607479 29861 1715 
TSPAN9 chr12:3186084-3186434 -261 1718 
VGF chr7:100807504-100807904 1148 1733 
PRKAG2 chr7:151328754-151329804 65 1741 
NOS2 chr17:26130269-26130669 -2914 1744 
RAB11FIP5 chr2:73340137-73340737 -291 1751 
ARHGAP17 chr16:24946722-24947022 79803 1774 
SLC3A2 chr11:62626091-62626541 2833 1792 
PLXND1 chr3:129316828-129317228 8554 1793 
ATXN7 chr3:63860528-63860828 10446 1795 
STT3B chr3:31529928-31530328 -44362 1802 
BAG3 chr10:121419454-121419804 8748 1815 
FIBCD1 chr9:133814334-133814784 -320 1855 
NFKBIA chr14:35821268-35821568 52542 1857 
CUL2 chr10:35266654-35267354 96254 1860 
NACC2 chr9:138982984-138983284 3997 1883 
TGM2 chr20:36788690-36789090 4810 1885 
MCFD2 chr2:47263187-47263587 -94393 1926 
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KIAA1671 chr22:25445279-25446329 21864 1939 
MAP3K4 chr6:161377482-161378132 -35014 1945 
CRISPLD2 chr16:84839922-84840572 -13339 1948 
OSBPL2 chr20:60836390-60836740 23025 1949 
NSMAF chr8:59601643-59601993 -29414 1953 
USP43 chr17:9548719-9549019 16 1955 
PGC chr6:41725932-41726232 -10943 1998 
NACC2 chr9:138987584-138987934 -628 2050 
RAB11A chr15:66234811-66235111 73165 2070 
PLEC chr8:145040443-145040893 7029 2085 
SLC19A1 chr21:47060593-47061193 -98508 2095 
ID4 chr6:19838432-19838732 982 2113 
LATS2 chr13:21635399-21635999 23 2123 
SPSB1 chr1:9366063-9366413 13298 2126 
MMP15 chr16:58047172-58047472 -11959 2182 
PITPNB chr22:28288179-28288479 26873 2183 
CLPB chr11:72122941-72123191 22658 2188 
ANXA1 chr9:75702434-75702884 -64121 2192 
WWTR1 chr3:149404678-149405128 16157 2215 
PTPRE chr10:129863254-129863704 17667 2221 
SOX13 chr1:204063613-204063913 21518 2244 
MTUS1 chr8:17658443-17659143 -367 2254 
GCLM chr1:94374413-94375263 174 2264 
RASSF3 chr12:64936684-64937084 -67408 2271 
HES1 chr3:193850778-193851178 -2952 2307 
 
 
Supplementary Table 4. 4. TFAP2A top peaks intersect with Pr.synT gene-set 
Gene Peak Locus Dist_to_TSS Rank 
ELF3 chr1:201976921-201977971 -2243 35 
HES1 chr3:193858319-193860519 5489 38 
ZBTB7B chr1:154972221-154975421 -1284 57 
ZFP36L1 chr14:69261981-69264331 -196 67 
MTUS1 chr8:17658221-17659521 -445 77 
ABCB8 chr7:150723007-150725557 -1226 83 
TFAP2C chr20:55204891-55206541 1359 85 
SEC22B chr1:145092271-145093021 -3760 142 
GRHL3 chr1:24647821-24649171 -1033 221 
SGK1 chr6:134495843-134496893 -334 231 
SGK1 chr6:134495843-134496893 702 232 
ST3GAL4 chr11:126252133-126253783 -20352 235 
DLX4 chr17:48052619-48054169 3265 295 
BMP1 chr8:22027071-22028321 5044 320 
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MAGI1 chr3:66024569-66025919 -735 355 
TNFAIP2 chr14:103604881-103605781 12668 427 
PDLIM2 chr8:22436121-22437321 468 439 
PDLIM2 chr8:22436121-22437321 -1265 441 
MAML3 chr4:141071900-141073350 2608 474 
PDE4DIP chr1:144931921-144932871 -31 490 
TEAD3 chr6:35459143-35460143 5218 499 
CKMT1B chr15:43885723-43887073 1147 532 
SP2 chr17:45961319-45962219 -11746 541 
COMT chr22:19946800-19947700 -2819 548 
FURIN chr15:91412323-91413423 989 551 
FIBCD1 chr9:133814222-133815022 -383 569 
FAM25C chr10:49195624-49196724 11651 591 
ULK4 chr3:42054569-42055969 -51609 605 
PLK3 chr1:45265171-45266221 -339 607 
GSE1 chr16:85644204-85646004 -1737 664 
CKMT1A chr15:43985573-43986873 1140 669 
GLDN chr15:51632773-51634123 -264 688 
TWIST2 chr2:239757601-239758501 1379 701 
GSTA3 chr6:52786993-52788343 -13172 702 
ST3GAL4 chr11:126234933-126236033 9695 720 
CD63 chr12:56121718-56123268 964 733 
CD63 chr12:56121718-56123268 -921 737 
TEAD3 chr6:35453943-35454743 10518 742 
TRIB1 chr8:126441671-126442721 -366 770 
DNAJA2 chr16:47006504-47007954 396 776 
HID1 chr17:72964319-72965169 4156 780 
MIDN chr19:1248076-1249826 400 795 
CEBPA chr19:33784626-33785426 8404 810 
PWWP2B chr10:134209224-134210424 -877 813 
LATS2 chr13:21634500-21636150 397 876 
SLC19A1 chr21:46935402-46936252 18715 879 
TNFAIP3 chr6:138187143-138188543 -481 890 
YTHDF2 chr1:29062671-29063571 -14 965 
DDA1 chr19:17422376-17424026 2865 992 
TNFAIP8 chr5:118690553-118691353 -642 1002 
MMP15 chr16:58058304-58059904 -177 1013 
IFT20 chr17:26662419-26663469 -429 1035 
SPIRE2 chr16:89893804-89895154 -427 1046 
CRB3 chr19:6472576-6473426 8742 1078 
TGM2 chr20:36797241-36798091 -3966 1091 
SLC38A3 chr3:50242669-50243719 503 1097 
RREB1 chr6:7140993-7141943 33383 1108 
TMEM37 chr2:120188851-120189701 -169 1135 
KCNN4 chr19:44288626-44289826 -3817 1160 
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DVL3 chr3:183874369-183875369 1586 1162 
SUSD2 chr22:24576400-24577550 -468 1180 
BHLHE40 chr3:5019269-5020919 -1002 1183 
SP6 chr17:45928469-45929219 -328 1207 
STRA6 chr15:74492773-74493923 1872 1232 
GADD45G chr9:92207922-92209272 -11329 1236 
DYSF chr2:71679651-71681051 -401 1257 
CEBPA chr19:33792976-33794226 -171 1262 
P2RY6 chr11:72982083-72983383 -453 1267 
P2RY6 chr11:72982083-72983383 1795 1268 
BAG3 chr10:121410324-121411174 -132 1269 
KAT2B chr3:20081419-20083369 871 1289 
FBXO32 chr8:124553321-124554471 -403 1301 
RFK chr9:79009072-79010222 -203 1307 
GMEB2 chr20:62257391-62258341 515 1395 
NUCB2 chr11:17297433-17298433 -352 1419 
DDB1 chr11:61099783-61101133 226 1455 
BCL2L1 chr20:30311041-30311791 -760 1475 
INHA chr2:220436101-220437301 -252 1504 
SMPD2 chr6:109744993-109745943 -16462 1544 
TMEM40 chr3:12800719-12801869 -486 1568 
GATA3-AS1 chr10:8092324-8094224 2173 1582 
ING2 chr4:184424900-184425850 -844 1594 
NR2F6 chr19:17358626-17359676 -3000 1603 
VASP chr19:46009726-46010976 -336 1611 
SMAD7 chr18:46478208-46479558 -1802 1631 
TMPRSS2 chr21:42908102-42908902 -28417 1653 
SWAP70 chr11:9685583-9686583 456 1705 
ZNF488 chr10:48354474-48355274 -214 1709 
AADAT chr4:171010950-171011700 47 1719 
AADAT chr4:171010950-171011700 -142 1720 
PDE4DIP chr1:144992571-144993121 2187 1728 
RHOBTB1 chr10:62755924-62756624 4462 1735 
VASP chr19:46024126-46025176 13964 1754 
UBE2H chr7:129598407-129599107 -5957 1756 
HMOX1 chr22:35775050-35775900 -1584 1764 
AVPI1 chr10:99446874-99447674 -259 1789 
MKNK2 chr19:2059376-2060176 -8533 1793 
SDC1 chr2:20431351-20432951 -6957 1797 
FANCE chr6:35370093-35370743 -49719 1812 
PIM3 chr22:50353500-50354800 8 1857 
EPS8L2 chr11:707033-708633 1714 1894 
PIM3 chr22:50344850-50346300 -8567 1904 
ANGPT4 chr20:893891-894641 2694 1938 
HSD17B1 chr17:40703969-40704819 411 1947 
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RALB chr2:121009801-121010951 -37 1975 
GCLM chr1:94374171-94375421 216 1979 
RALB chr2:121002251-121003451 -7562 1984 
S100A9 chr1:153336321-153337171 6417 2004 
RAB31 chr18:9707858-9709108 256 2006 
AZIN1 chr8:103884421-103885171 -8399 2012 
KIF21A chr12:39836418-39837618 174 2027 
WWTR1 chr3:149404369-149405269 16241 2036 
DAB2 chr5:39424553-39425403 357 2061 
SLC7A6 chr16:68298754-68299554 736 2067 
SLC19A1 chr21:46972702-46973452 -10692 2119 
FANCE chr6:35419893-35420793 206 2167 
ERC1 chr12:1099768-1100968 -35 2195 
FRMD4A chr10:14338124-14338724 34442 2197 
ZNF703 chr8:37551821-37553421 -679 2209 
MICALL2 chr7:1509707-1510507 -10998 2244 
AKT1S1 chr19:50380426-50381526 637 2256 
AKT1S1 chr19:50380426-50381526 -1470 2257 
AKT1S1 chr19:50380426-50381526 -332 2260 
EZR chr6:159239243-159240793 438 2276 
EZR chr6:159239243-159240793 -678 2277 
SOCS3 chr17:76337719-76338669 17966 2280 
HSPB8 chr12:119615718-119616868 -301 2317 
TSPAN14 chr10:82201474-82202124 -12238 2343 
COMT chr22:19949750-19951000 306 2361 
GATA2 chr3:128206519-128208069 79 2420 
PDLIM2 chr8:22429471-22430671 -6182 2494 
EFHD1 chr2:233488551-233489651 -9105 2519 
LIPG chr18:47123808-47124508 35732 2561 
FBXO11 chr2:48133301-48134201 -819 2565 
ARHGAP27 chr17:43502369-43503319 168 2578 
STRIP2 chr7:129073957-129074907 159 2595 
FURIN chr15:91414523-91415623 3189 2600 
ATG9B chr7:150721307-150722107 -121 2684 
PTEN chr10:89621974-89623524 -445 2742 
S100P chr4:6690600-6691150 -4690 2750 
DACT2 chr6:168719943-168720893 -16 2778 
SH3GLB1 chr1:87169871-87171321 344 2788 
CD164 chr6:109703343-109704543 -181 2840 
PPAP2B chr1:57035271-57036021 9611 2843 
CSRNP1 chr3:39194969-39195619 -192 2844 
PSMA6 chr14:35816381-35817331 55334 2881 
PRR5 chr22:45084950-45085600 12588 2903 
C10orf10 chr10:45474124-45475024 -244 2914 
C10orf95 chr10:104214324-104215124 -3424 2932 
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Supplementary Table 4.5. Intersection of GCM1-AP2A ChIP-seq peaks with Pr.synT gene-set  
Gene Peak Locus Dist to TSS LogFC (D6 vs D4) 
CGB5 chr19:49546516-49547316 -185 11.6 
CGB8 chr19:49552204-49553004 -236 9.2 
CGB chr19:49527466-49528266 -234 8.7 
INHA chr2:220436340-220437140 -213 6.9 
CGB2 chr19:49534104-49534904 -625 6.9 
CGB1 chr19:49540479-49541279 -688 6.9 
GSTA3 chr6:52787450-52788250 -13354 6.7 
CRIP2 chr14:105940062-105940862 -649 6.5 
CRIP2 chr14:105933362-105934162 -5512 6.5 
CRIP2 chr14:105921349-105922149 -17525 6.5 
MTSS1 chr8:125739594-125740394 754 6.3 
CGB7 chr19:49558916-49559716 -319 6.0 
RLBP1 chr15:89754767-89755567 9755 5.8 
SORBS1 chr10:97324393-97325193 -3622 5.5 
CSF2RB chr22:37324614-37325414 15340 5.3 
CSF2RB chr22:37308127-37308927 -1147 5.3 
SLC1A2 chr11:35439970-35440770 735 5.3 
DACT2 chr6:168719987-168720787 15 5.3 
DACT2 chr6:168758062-168758862 -38060 5.3 
FIBCD1 chr9:133811553-133812353 2286 5.2 
FIBCD1 chr9:133796040-133796840 17799 5.2 
FIBCD1 chr9:133814190-133814990 -351 5.2 
SLC38A3 chr3:50242886-50243686 595 5.2 
SLC38A3 chr3:50239023-50239823 -3268 5.2 
SYDE1 chr19:15217691-15218491 -122 5.1 
DHRS2 chr14:24107724-24108524 2552 5.0 
C10orf54 chr10:73524851-73525651 8086 4.9 
CGA chr6:87832000-87832800 -27535 4.9 
NR4A1 chr12:52430413-52431213 14198 4.6 
NR4A1 chr12:52435163-52435963 -9622 4.6 
CGREF1 chr2:27341044-27341844 551 4.6 
ATP2A3 chr17:3879256-3880056 -11898 4.6 
TWIST2 chr2:239757644-239758444 1372 4.6 
TWIST2 chr2:239772794-239773594 16522 4.6 
HTRA4 chr8:38831219-38832019 -48 4.5 
ABTB2 chr11:34296299-34297099 82856 4.5 
ABTB2 chr11:34379349-34380149 -194 4.5 
FAM25C chr10:49199564-49200364 7861 4.5 
FAM25C chr10:49195739-49196539 11686 4.5 
TGM2 chr20:36788465-36789265 4835 4.4 
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TGM2 chr20:36751178-36751978 42122 4.4 
TGM2 chr20:36797265-36798065 -3965 4.4 
TGM2 chr20:36824803-36825603 -31503 4.4 
TFPI chr2:188397131-188397931 21688 4.3 
SH3TC2 chr5:148442463-148443263 -126 4.3 
TREM1 chr6:41264862-41265662 -10805 4.3 
SESTD1 chr2:180141956-180142756 -13006 4.1 
SESTD1 chr2:180201606-180202406 -72656 4.1 
S100A9 chr1:153327999-153328799 -1930 4.1 
ADAMTS20 chr12:43876313-43877113 69011 4.1 
ADAMTS20 chr12:43992688-43993488 -47364 4.1 
PTPN21 chr14:89016237-89017037 4486 4.1 
C1QTNF1 chr17:77013237-77014037 -5378 4.0 
CALB2 chr16:71416650-71417450 24435 4.0 
IGSF5 chr21:41114235-41115035 -2698 4.0 
ERVV-1 chr19:53513179-53513979 -3764 3.9 
SERPINE1 chr7:100761480-100762280 -8489 3.9 
FAM83F chr22:40390814-40391614 262 3.8 
FAM83F chr22:40361539-40362339 -29013 3.8 
CDH5 chr16:66412500-66413300 12376 3.7 
CDH5 chr16:66388100-66388900 -12024 3.7 
CDH5 chr16:66332288-66333088 -67836 3.7 
SMAD7 chr18:46428084-46428884 40693 3.7 
SMAD7 chr18:46387471-46388271 81306 3.7 
SMAD7 chr18:46478721-46479521 -2040 3.7 
SMAD7 chr18:46519202-46520002 -42521 3.7 
ENDOU chr12:48131990-48132790 -13035 3.7 
FBXO32 chr8:124553519-124554319 -426 3.7 
FBXO32 chr8:124576007-124576807 -22914 3.7 
KIAA0040 chr1:175147167-175147967 14382 3.7 
KIAA0040 chr1:175338592-175339392 -176763 3.7 
CKMT1B chr15:43886129-43886929 1278 3.6 
HSD3B1 chr1:120012199-120012999 -37226 3.6 
TIMP3 chr22:33254364-33255164 57963 3.6 
TIMP3 chr22:33184827-33185627 -11574 3.6 
TIMP3 chr22:33129914-33130714 -66487 3.6 
ADAM19 chr5:157002413-157003213 18 3.6 
SLC22A11 chr11:64325003-64325803 2306 3.6 
TNFRSF1B chr1:12191967-12192767 -34692 3.5 
TIPARP chr3:156361486-156362286 -30318 3.5 
CKMT1A chr15:43985967-43986767 1284 3.5 
CKMT1A chr15:44002392-44003192 17709 3.5 
C10orf10 chr10:45474151-45474951 -221 3.5 
SLC2A12 chr6:134398787-134399587 -25398 3.5 
CYP11A1 chr15:74679128-74679928 -19447 3.4 
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HEY1 chr8:80695807-80696607 -16109 3.4 
TGFBR2 chr3:30591698-30592498 -55895 3.4 
APOBEC2 chr6:41026087-41026887 5548 3.4 
MICALL2 chr7:1494668-1495468 4041 3.4 
MICALL2 chr7:1508168-1508968 -9459 3.4 
MICALL2 chr7:1509680-1510480 -10971 3.4 
DAB2 chr5:39424488-39425288 447 3.4 
PRLR chr5:35229426-35230226 997 3.4 
PRLR chr5:35176638-35177438 53785 3.4 
KYNU chr2:143660944-143661744 26150 3.3 
FDX1 chr11:110349737-110350537 49477 3.3 
FDX1 chr11:110299499-110300299 -761 3.3 
ST3GAL1 chr8:134707494-134708294 -123711 3.3 
PAK3 chrX:110187938-110188738 826 3.3 
PAK3 chrX:110210001-110210801 22889 3.3 
COBLL1 chr2:165697781-165698581 497 3.3 
COBLL1 chr2:165697781-165698581 -253 3.3 
CD274 chr9:5451578-5452378 1476 3.3 
CD274 chr9:5446340-5447140 -3762 3.3 
BHLHA15 chr7:97840280-97841080 -885 3.2 
PDLIM3 chr4:186487424-186488224 -31112 3.2 
TRPV2 chr17:16301744-16302544 -16711 3.2 
ZNF703 chr8:37477694-37478494 -75206 3.2 
SDC1 chr2:20380606-20381406 43921 3.2 
SDC1 chr2:20338172-20338972 86355 3.2 
SDC1 chr2:20431831-20432631 -7037 3.2 
SDC1 chr2:20440981-20441781 -16187 3.2 
RHOBTB1 chr10:62755889-62756689 4447 3.2 
RHOBTB1 chr10:62835264-62836064 -74466 3.2 
EEPD1 chr7:36131893-36132693 -60542 3.2 
GALNT2 chr1:230290642-230291442 88087 3.2 
GALNT2 chr1:230193267-230194067 -9288 3.2 
EHD1 chr11:64644137-64644937 1703 3.2 
EHD1 chr11:64631662-64632462 14178 3.2 
PDE4DIP chr1:144932117-144932917 -152 3.2 
ERVFRD-1 chr6:11148017-11148817 -36346 3.1 
BTG1 chr12:92618413-92619213 -79140 3.1 
CPEB4 chr5:173307388-173308188 -7542 3.1 
CPEB4 chr5:173250101-173250901 -64829 3.1 
ANXA1 chr9:75702265-75703065 -64115 3.1 
HES1 chr3:193858900-193859700 5370 3.1 
HES1 chr3:193867973-193868773 14443 3.1 
HES1 chr3:193850584-193851384 -2946 3.1 
GDPD5 chr11:75209362-75210162 26837 3.1 
AFF1 chr4:87927962-87928762 210 3.0 
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SGK1 chr6:134495850-134496650 -216 3.0 
TGFBR3 chr1:92350917-92351717 519 3.0 
TGFBR3 chr1:92231021-92231821 120415 3.0 
SPCS3 chr4:177436274-177437074 195585 3.0 
SPCS3 chr4:177225474-177226274 -15215 3.0 
SNX27 chr1:151555229-151556029 -29032 3.0 
CYP19A1 chr15:51607301-51608101 23094 3.0 
ARID5B chr10:63866764-63867564 58195 3.0 
ARID5B chr10:63609843-63610643 -50769 3.0 
CDK19 chr6:111010085-111010885 125927 3.0 
CDK19 chr6:111140479-111141279 -4467 3.0 
PRKCZ chr1:2036317-2037117 563 2.9 
PRKCZ chr1:2066617-2067417 30863 2.9 
PRKCZ chr1:2021279-2022079 -14475 2.9 
SIAH1 chr16:48513688-48514488 -94859 2.9 
SLC2A1 chr1:43457717-43458517 -33270 2.9 
SLC2A1 chr1:43510362-43511162 -85915 2.9 
ENG chr9:130609778-130610578 -732 2.9 
ENG chr9:130612365-130613165 -3319 2.9 
 
 
 	  
 
 
